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 SUMMARY 
 
Diffuse gliomas are the most common and lethal brain tumors. Cell invasion into the 
surrounding brain tissue is a hallmark feature of glioma. Understanding the 
mechanism of glioma invasion could lead to the discovery of novel therapeutic 
strategies to treat affected patients. Earlier gene expression analyses on human 
glioma biopsies showed that SOX2 is associated with glioma invasiveness. The gene 
for transcription factor SOX2 localizes to 3q26.3 in the human genome amid 
oncogene PIK3CA and genes regulating mitochondrial fusion, MFN1 and OPA1. 
Increasing evidence points to a role for 3q26-29 genes in tumor invasion. We 
hypothesized that SOX2 regulates the 3q26-29 candidate genes as effectors of 
glioma cell invasion.  
We used SOX2 expressing human glioma cell lines, LN319 and U373 to test our 
hypothesis in vitro. Lentiviruses expressing shRNAs against PIK3CA, MFN1, OPA1 
or SOX2 were used for genetic knockdown. Engineered cells were assayed for 
invasion and migration using Boyden chamber and wound healing assays, 
respectively. Chromatin immuno-precipitation and luciferase assays were used to 
demonstrate protein-DNA interactions and trans-activation of 3q26-29 genes by 
SOX2. 
Our results show that cells downregulated for 3q26-29 genes exhibited enhanced 
invasion and migration, while shSOX2 and shPIK3CA cells exhibited reduced 
proliferation rates compared to sh scramble controls. Furthermore, we show that 
SOX2 knockdown reduced gene and protein expression of PIK3CA, MFN1 and 
OPA1 except for PIK3CA at the protein level. Chromatin immuno-precipitation 
assays suggested that SOX2 binds to the upstream region of 3q26-29 gene 
promoters in the glioma cells.  
Preliminary luciferase assays in HEK293 cells suggested that SOX2 trans-activates 
PIK3CA and OPA1. Preliminary immunofluorescence analysis showed that cells 
knocked-down for 3q26-29 genes demonstrated altered mitochondrial morphology 
compared to sh scramble controls. Overall, our results show that SOX2, PIK3CA, 
MFN1 and OPA1 contribute to glioma invasion and that SOX2 is a potential regulator 
of the 3q26-29 genes.  
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1. INTRODUCTION 
 
1.1. CANCER  
Cancer is a leading cause of death from disease in the world. Recent estimates, 
made in the time window of 2009-14 and published by World Health Organization 
(WHO), reveal that nearly 14.1 million people worldwide are diagnosed with cancer 
annually and that an estimated 8.2 million die of the disease per year (WHO, 2014). 
In Switzerland alone, 37,000 people are diagnosed with cancer and nearly 16,000 of 
them die every year (Krebsliga, 2014).  
 
Cancer incidence is growing exponentially and is predicted to increase by 70% in the 
next two decades. Such steep increase in cancer incidence, apart from demographic 
regional population and diet choice, is largely attributed to exposure to toxic 
environmental factors, and genetic susceptibility of an individual to the disease. 
Growing trends of cancer incidence and cancer-related morbidity dictates the need to 
focus on methods to improve cancer prevention and therapeutics. 
 
1.1.1. Causes of cancer 
 
Epidemiological studies show that many factors contribute to cancer development. 
Unhealthy diet, exposure to carcinogens such as high doses of ionizing radiation or 
UV, chemicals contained in tobacco smoke, and chronic infections caused by 
biological agents such as viruses or bacteria are well known inducers of cancer.  
 
Genetic association studies revealed that a portion of population carries damaged or 
mutated copy of genes, which increases the risk of developing cancer. For instance, 
Li-Fraumeni syndrome is a rare hereditary cancer pre-disposition syndrome that is 
linked to germline mutations of TP53, a tumor suppressor that regulates cell cycle 
progression and induces suicide of damaged cells.  
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1.1.2. Sustained proliferation  
 
Uncontrolled cellular proliferation is a fundamental process that contributes to tumor 
formation and progression (Feitelson et al., 2015; Hanahan D, 2011). Deregulated 
anti-proliferative signals and oncogenic mitotic stimuli promote sustained tumor cell 
proliferation. In neoplastic cells, constitutive proliferative signals can be activated by 
multiple ways: (i) unchecked constant activation of growth factor receptors through 
auto- and paracrine signaling in neoplastic cells, (ii) somatic mutations in mitogenic 
signaling determinants such as receptor tyrosine kinase (RTK), B-raf, and PIK3CA 
(iii) disruption of anti-proliferation signaling proteins such as Ras GTPases, PTEN 
phosphatases and mTOR kinases (iv) overexpression of telomerase (amplification of 
TERT and/or TERC, catalytic and RNA component of the reverse transcriptase 
enzyme respectively), that maintains sufficient telomere length for constant cell 
division and induce replicative immortality.   
 
1.1.3. Malignant transformation 
 
Stepwise accumulation of molecular changes eventually leads to cancer cell 
evolution towards a malignant state. Neoplastic molecular changes include loss of 
cell-to-cell contact inhibition resulting in increased cell proliferation and motility, 
enhanced production of growth factors that promote tumor vascularization (TGFβ 
and VEGF), loss of tumor suppressors (TP53 and RB), and deregulated apoptotic 
and autophagic pathways. Malignant transformation (MT) is hence characterized by 
tumor cell invasion that most often leads to the formation of secondary tumor at 
distant organs within the body (metastasis), tumor angiogenesis, and resistance to 
therapeutic agents.  
 
Excessive activation of proliferative signals in a hypoxic environment induces cell 
senescence and promotes necrosis (outbursts of bloated and enlarged neoplastic 
cells). Necrosis triggers pro-inflammatory responses, which in return enhances the 
secretion of pro-proliferative signals and growth factors in the tumor. Thus, necrosis 
and hypoxia contribute to the acceleration of tumor malignancy (Hanahan D, 2011). 
Moreover, enhanced secretion of immuno-suppressive proteins by tumor cells such 
as the growth factor TGFβ and immuno-suppressive acidic protein (IAP), disrupt the 
 5 
function of host immune cells. This is one of the strategies that neoplastic cells use to 
escape detection by host immune cells and evade host immune surveillance.   
 
Overall, genome instability and altered cellular metabolism contribute to neoplastic 
transformation. Thus, sustained cell proliferation, inflammation and evasion of host 
immunological responses, tumor cell invasion, angiogenesis, and resistance to 
therapy-induced apoptosis are features of tumor progression (Hanahan D, 2011).   
1.1.4. Cancer prevention 
 
Avoiding exposure to carcinogens including high-energy radiation, maintaining 
healthy diet, and early diagnosis are keys to cancer prevention. In some developed 
countries, cancer-related mortality rates have started to decline as a result of 
improved early cancer detection, existence of advanced cancer therapy centers, and 
reduced smoking (WHO, 2014).  
 
1.1.5. Detection 
 
Screening tests in patients without symptoms such as the pap smear test for cervical 
cancers and the mammography for breast cancers, allow early detection and greatly 
increase the success of cancer treatment. Preventive surgery in patients that are 
genetically susceptible to cancer for instance by prophylactic mastectomy in 
individuals with mutations in breast cancer-causing genes (BRCA1 and BRCA2) 
greatly reduces the risk of developing breast cancer.  
 
Magnetic resonance imaging (MRI) of body tissue is an effective means of tumor 
detection. Diagnostic surgery i.e. surgical resection of potential tumor tissue, followed 
by microscopic examination helps to detect the tumor and determine its malignancy 
index.  
 
1.1.6. Conventional therapies 
 
Currently, the majority of cancer therapies consist of surgical resection of tumor 
followed by adjuvant chemo- and radiotherapies. Chemotherapy uses chemical 
drugs while radiotherapy use high doses of ionizing radiation to kill proliferative cells. 
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Unfortunately, the primary cause of cancer-related morbidity in the patients is the 
relapse of therapy-resistant tumors.  
 
1.1.7. Novel therapies 
 
Growing knowledge on cancer progression shows that accumulation of genetic 
mutations triggers cancer. Identification of genetic mutations and gene signatures 
that define the cancer type has revolutionized the field of cancer research. These 
advances have led to the development of novel molecular therapies that target a 
specific molecular pathway. For instance, the kinase inhibitor erlotinib specifically 
targets epidermal growth factor receptor (EGFR) that shows a gain of function 
mutation and is highly expressed in many cancer types. Despite these efforts, most 
of the cancer types do not have a permanent cure. 
 
1.2. GLIOMA – CLINICAL FACTS  
1.2.1 The glial lineage 
 
The human brain is made up of neurons and glial cells. Cells of glial lineage 
represent more than 80% of the brain cells. Glial cells secrete myelin that surrounds 
and insulates neurons, and protects them from cytotoxic injury. In addition, glial cells 
maintain homeostasis and are scavengers for dead neurons.  
 
Three different types of glial cells are known in the central nervous system (CNS):  (i) 
Oligodendrocytes, cells that produce myelin; (ii) Astrocytes, which are a 
heterogeneous group of cells involved in blood brain barrier (BBB) formation; (iii) 
Ependymal cells, that are involved in the production of cerebrospinal fluid (CSF).  
 
Tumors that arise from cells of glial origin are called glioma. They comprise a broad 
group of tumors that represent almost 30% of all brain tumors including brain 
metastasis, and 80% of all malignant tumors of the central nervous system (CNS) 
(Alcantara Llaguno et al., 2009). Gliomas are among the most aggressive and the 
most lethal CNS tumors (Grier and Batchelor, 2006; Louis et al., 2007).   
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1.2.2. Histology 
 
Based on the cellular morphology of gliomas, the tumors can be classified into:  
(i) Oligodendrogliomas, tumors that primarily consist of neoplastic cells with 
oligodendroglial morphology; (ii) astrocytoma, tumors in which neoplastic cells show 
astrocytic morphology; (iii) mixed gliomas are those that display both above 
mentioned cellular morphologies; (iv) ependymomas that consist of neoplastic cells 
with ependymal morphology; (v) Glioblastoma multiforme (GBM) includes 
undifferentiated and a heterogenous population of neoplastic glial cells.   
 
1.2.3. Glioma grading  
 
WHO-based classification of glioma ranges from low grades (I and II) to high grades 
(III and IV) for the most malignant forms. Glial tumor grading is based on pathologic 
features such as mitotic index, necrosis, extent of differentiation, and vascular 
endothelial hyperplasia (Louis et al., 2007). Different grades of glioma are shown in 
Fig 1.  
 
Grade I is applied to tumors that show low proliferative potential, and are often 
curable by surgical resection. Pilocytic astrocytomas that develop in children and 
young adults belong to this category.  
 
Grade II is assigned to gliomas that are infiltrative in nature despite low proliferative 
capacity. They gradually progress to higher grades and tend to relapse after surgery. 
Diffuse astrocytomas, oligodendrogliomas, oligoastrocytomas belong to this grade.  
 
Grade III gliomas have histological evidence of malignancy such as abnormal nuclei 
and high mitotic index. Anaplastic or poorly differentiated astrocytomas, 
oligodendrogliomas and oligoastrocytomas belong to this category.  
 
Grade IV gliomas show high microvascular proliferative density, are mitotically active, 
necrosis-prone, and cytologically malignant with a high degree of cell heterogeneity. 
GBM is synonymous of grade IV glioma and is the most aggressive form of glioma.  
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Fig 1. Schematic representation of histology based WHO grade (II-IV) diffuse glioma 
classification. Grade II gliomas undergo slow progression to anaplastic grade III lesions that 
subsequently gives rise to secondary GBM. Shown are hallmark features of GBM such as 
microvasculature proliferation (marked V and indicated by black arrowhead) and pallisading necrosis 
(marked N).   
 
1.2.4. Incidence 
 
In Switzerland, with an annual incidence of 3.55 cases per 100,000 patients, high-
grade GBM are more frequent than low-grade glioma (LGG), with an incidence of 
0.63 per 100,000 patients (Ohgaki, 2005).  
 
In Switzerland, association studies of tumor histology with the sex of individual 
patients revealed that anaplastic oligoastrocytomas and GBM are more common in 
men: the male to female ratio being 3.3 and 1.34 respectively (Ohgaki, 2005). LGG is 
more common in younger patients between the age group of 20 and 40 years. GBM 
is common in individuals in the age group of 45 to 70 years.    
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 1.2.5. Major risk factors  
 
Exposure to high dose of ionizing radiation and inherited genetic associations are the 
only known risk factors for glioma (Braganza et al., 2012; Edick et al., 2005; Ohgaki, 
2005). Hereditary associations represent only a small percentage (5%) of gliomas. 
These genetic associations include neurofibramatosis syndrome (NF1-2 mutation), 
tuberous sclerosis, retinoblastoma (RB mutation), Li-Fraumeni syndrome (TP53 
mutation), Cowden syndrome (PTEN mutation), and Turcot’s syndrome (mutations in 
adenomatous polyposis coli (APC)) (El-Zein et al., 2002).  
 
1.2.6. Signs and symptoms  
 
Symptoms of a brain tumor depend on the location of the tumor in the brain. The 
most common symptoms associated with gliomas are seizures, neurological deficits 
– behavior and personality changes, and increased intracranial pressure.  
 
1.2.7. Etiology 
 
Gliomas arise from glial precursor and neural stem cells (Swartling et al., 2012). 
Growing evidence suggests that genetic transformation of glial and neural precursor 
cells lead to gliomagenesis (Ilkanizadeh et al., 2014; Lei and Canoll, 2011; Sugiarto 
et al., 2011; Zong et al., 2012). This will be further discussed in section 1.4.5. 
 
1.2.8. Patient survival  
 
In addition to the age at the time of diagnosis, survival time for patients with glioma is 
chiefly influenced by the histology and the extent of surgical resection of the tumor. 
Patients with grade I glioma are most often cured by surgical resection of the tumor. 
Patients with LGG (especially oligodendrogliomas and oligoastrocytomas) can 
survive up to ≈ 20 years. 
 
GBM that arise de novo are primary GBM, while those that arise due to progressive 
transformation of LGG are secondary GBM. Patients with primary GBM do not 
survive more than 24 months after diagnosis; however patients with secondary GBM 
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show longer median survival of over 4.7 months than primary GBM patients (Ohgaki 
et al., 2013).   
 
1.2.9. Current therapies and treatment  
 
Volume of tumor resected is of high prognostic value for patient survival (Barker et 
al., 1998; Hess, 1999; McGirt et al., 2008; Steiger et al., 2000). Therefore, surgical 
resection of the tumor followed by adjuvant chemo- and radiotherapy are opted to 
treat the disease (Stupp et al., 2005),    
1.3. GLIOMA – BIOLOGICAL FEATURES  
 
Somatic mutations found in glioma mostly target molecular pathways that govern cell 
proliferation, migration, invasion, angiogenesis, and survival. Consequently, the 
hallmarks of glioma are enhanced tumor proliferation, infiltrative behavior, tumor 
angiogenesis, and presence of therapy-resistant cells, along with altered cellular 
metabolism. The following sections of the thesis address each of these features in 
detail.   
1.4. PROLIFERATION  
1.4.1.  Molecular genetics of GBM proliferation  
1.4.1.1. Genes contributing to cell proliferation 
 
Extracellular ligands such as epidermal growth factor (EGF) and platelet derived 
growth factor (PDGF) play an important role in stimulating the growth and survival of 
neural and non-neural cells of the CNS. These growth factors bind to receptor 
tyrosine kinases (RTK) to transduce mitogenic signals in the cells. The genes for 
RTK such as EGFR and PDGFR are frequently altered in glioma. 
 
Gain of function amplification of EGF receptor (EGFR) with deletion of exons 2 to 
7, known as variant 3 (vIII EGFR) was first observed in glioma (Libermann et al., 
1985). Focal amplifications of EGFR (locus 7p12) have been frequently found in 
primary GBM (36-57%) and very rarely in secondary GBM (0-8%) (Quezado et al., 
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2005; Watanabe et al., 1996; Hegi et al., 2011; Ohgaki and Kleihues 2013). A gain of 
function mutation or amplification of EGFR leads to permanent activation of the 
PI3K/Akt pathway for continuous glioma cell proliferation (Ekstrand et al., 1992; 
Narita et al., 2002).  
 
Gain of function mutations of PDGF receptor alpha (PDGFRα) (locus 4q12) is 
found in over 10% of GBM samples (The Cancer Genome Atlas Research Network, 
2008). The deletion of exons 8 and 9 in PDGFRα gene are commonly observed 
events that result in constitutive activation of the receptor that induces tumor cell 
proliferation and survival (Clarke and Dirks, 2003).   
Loss of function mutation and deletions in Phosphatase and Tensin homolog 
(PTEN) are frequent events observed in over 41% of GBM samples (Brennan et al., 
2013). PTEN (locus 10q23.3) encodes for Ptdlns (4,5) P3 phosphatase, an antagonist 
of Phosphoinositide 3-kinase (PI3K) enzymes. The tyrosine phosphatase is a 
negative regulator of PI3K/AKT signaling pathway therefore acts as a tumor 
suppressor.  
 
Gain of function mutations in PIK3CA the gene encoding p110 catalytic subunit of 
PI3K enzyme, is observed in over 15% of GBM samples (Gallia et al., 2006; Samuels 
et al., 2004). The gene for PIK3CA (Phosphatidyl inositol 4,5 bisphosphate 3 kinase, 
catalytic subunit alpha) is located at 3q26 in the human genome. PI3K enzymes are 
heterodimeric lipid kinase that is composed of p110 catalytic and p85 regulatory sub 
units. PI3K enzymes are the mediators of the PI3K signaling pathway. The PI3K 
signaling pathway is activated by various RTK such as EGFR, PDGFR and MET. 
Once activated, the phosphatidylinositol 3,4,5 bisphosphate (PIP3) acts as a second 
messenger to transduce the signal downstream and activate AKT and mTOR thus 
regulating numerous cellular functions such as cell growth, survival, transformation, 
motility, and apoptosis (Cantley, 2002; Volinia et al., 1994). Gain of function mutation 
in PIK3CA and loss of PTEN, therefore leads to permanent activation of PI3K 
pathway in glioma cells (Knobbe and Reifenberger, 2003; Ohgaki et al., 2004). The 
PI3K signaling pathway is one of the most frequently altered pathway in glioma(Fig. 
2).  
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1.4.1.2. Genes regulating cell cycle progression  
 
The Retinoblastoma (RB) pathway largely transduces growth inhibitory signals from 
extra-cellular sources and governs cell cycle progression that prevents replication of 
cells with damaged DNA. Members of E2F family of transcription factors, regulate 
genes involved in cell cycle progression and DNA replication (Macaluso et al., 2005). 
Under un-stimulated conditions, hypo-phosphorylated protein RB binds to E2F 
factors and prevents them from trans-activating genes required for cell cycle 
progression. Mitogenic stimulation activates cyclin D1 and dependent kinases CDK4 
and CDK6, which in turn phosphorylates RB and relieves E2F factors. E2F factors 
then trans-activate genes required for early S phase entry and cell cycle progression 
(Aktas et al., 1997; Frolov and Dyson, 2004; Lavoie et al., 1996; Weinberg, 1995). 
Hence, RB acts as a checkpoint during G1-S transition of cell cycle. In gliomas, 
frequent mutations (7.6%) in Rb1 gene (located on chromosome 13q14), 
amplification of CDK4 located on chromosome 12q13-14, low-level amplifications 
CDK6 located at 7q21-22, and homozygous deletion of CDKN2A at the locus 9p21 is 
the most frequent alteration of this pathway These mutations favor cell cycle 
progression (Costello et al., 1997; James et al., 1988; Jen et al., 1994; Merlo et al., 
1995; Reifenberger et al., 1994; Schmidt et al., 1994).  
 
1.4.1.3. Genes regulating cell survival  
 
TP53 (tumor suppressor protein 53) encodes a transcription factor TP53 that trans-
activates >2500 target genes. TP53 is well characterized for its role in maintaining 
genome integrity and is known as “the guardian of the genome”. The TP53 pathway 
receives inputs from intra-cellular sources such as cellular stress and abnormal 
microenvironment (sub-optimal levels of nucleotide pools, growth promoting signals, 
or oxygenation) and induces apoptosis or cell cycle arrest in cells with unstable 
genome. Under normal conditions, TP53 remains inactive by binding to its negative 
repressor and TP53 ubiquitin ligase, mouse double minute homologue 2 (MDM2). 
During oncogenic stress the association between MDM2 and TP53 is disrupted by 
protein p14ARF, encoded by the gene CDKN2A. This leads to TP53-mediated 
transcriptional activation of downstream target genes involved in apoptosis, for 
instance members of Bcl2 family. Thus, TP53 acts as a tumor suppressor by 
regulating programmed cell death in cells with unstable genome (Miyashita et al., 
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1994; Pomerantz et al., 1998; Stott et al., 1998). In gliomas however, TP53 (located 
on chromosome 17p) is mutated or lost in over 60% of LGG and in 28% of GBM 
samples, which provides survival advantage to glioma cells (Ohgaki and Kleihues, 
2007; Brennan et al., 2013). Most of the cancer cells experience strong selective 
pressure to disable TP53 activity. In fact, TP53 mutation is considered as an early 
event during glioma progression (Fridman and Lowe, 2003; Louis, 1994; Meyer-
Puttlitz et al., 1997; Ohgaki and Kleihues, 2007). The chromosomal region 12q14-15 
and 1q32 harboring MDM2 and MDM4 (MDM2-related gene) are found to be 
amplified in 4-10% of GBM, which strengthens TP53 repression and thus supports 
cells to escape TP53-mediated apoptosis (Gu et al., 2002; Schmidt et al., 1994; 
Shvarts et al., 1996). 
 
1.4.1.4. Major signaling pathways altered in GBM 
 
GBM is the first cancer to be molecularly profiled by The Cancer Genome Atlas 
(TCGA) consortium. Most of the discovered genetic alterations hit 3 key signaling 
pathways. Deregulation of these three pathways is a core requirement for GBM 
pathogenesis (The Cancer Genome Atlas Research Network, 2008; Brennan et al., 
2013).  
 
(i) RTK/PI3K pathway – This pathway is altered in 90% of the GBM samples, and 
constitutive activation of PI3K/Akt pathway is triggered by loss of function mutation in 
PTEN and gain of function mutation in PIK3CA and RTKs such as in EGFR, PDGFR 
and MET. Constant activation of this pathway induces cancer cell proliferation and 
survival.   
 
(ii) RB signaling pathway – This pathway is altered in over 79% of the GBM samples. 
Loss of cell cycle control by this pathway supports uncontrolled cell division in glioma 
cells.  
 
(iii) TP53 pathway – This pathway is altered in 86% of GBM samples. Loss of TP53 
in glioma cells, promotes survival advantage by escape of senescence (The Cancer 
Genome Atlas Research Network, 2008). The schematic representation of targeted 
pathways is depicted in Fig. 2.  
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Fig 2. Schematic representation of major pathways targeted by genetic alterations in GBM. EGFR 
amplifications (57%), PTEN loss (41%), CDKN2A/2B deletions (61%), loss of TP53 (28%) are hallmark 
genetic alterations in GBM. These alterations target 3 major signaling pathways – PI3K (90%), RB 
pathway (79%) and TP53 pathway (86%). Frequencies of genetic alterations (glioma samples) are 
mentioned in percentage.    
 
  1.4.2. Gene expression profiles of GBM  
 
1.4.2.1. Signaling pathways that govern neural/glia development 
  
(i) Notch signaling pathway – Notch 1-4 belong to the family of trans-membrane 
receptor proteins. Notch signaling maintains tissue homeostasis and promotes neural 
stem cell growth and gliogenesis (Artavanis-Tsakonas, 1999; del Amo et al., 1993; 
Gridley, 1997; Scheer et al., 2001). Loss of Notch function induces differentiation of 
neural stem cells. Notch signaling pathway receives inputs from adjacent cells by 
membrane-bound ligands with DSL (Delta, Serrate and Lag2) domain such as Delta-
like 1,4, Jagged 1-2 (Henderson et al., 1994; Tax et al., 1994). Binding of the ligands 
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to Notch receptors exposes Notch intracellular domain (NICD) to proteolytic 
cleavage. This releases NICD into cytosol. Translocation of NICD into the nucleus, 
assisted by RBPJ-κ/ MAML complex, results in trans-activation of HES and HEY 
families of transcription factors. HES and HEY transcription factors in turn, activate 
the downstream target genes and promote glioma progression (Androutsellis-
Theotokis et al., 1996; Gaetani et al., 2010; Hulleman et al., 2009; Lino et al., 2010). 
Overexpression of Notch ligand Dll1 and Hash 1, a genetic regulator of Dll1, are 
commonly found in LGG and secondary GBM with an exception of LGG with 1p19q 
co-deletion (Alqudah et al., 2013).  
 
(ii) NF-kB pathway – NF-kB proteins are a family of transcription factors (RelA, RelB, 
c-Rel, NF-kB1 and NF-kB2). These are activated by pro-inflammatory cytokines such 
as tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1), and genotoxic stress 
factors such as oxidative stress and physical stress induced by exposure to UV or 
gamma irradiation. NF-kB pathway plays a central role in enabling cellular adaptation 
to environmental stress. It is well characterized for its role in neuro-protection and 
inducing inflammatory responses (Ghosh et al., 1994; Li and Verma 2002). NF-kB 
targets >150 genes in the genome and regulates cellular processes such as cell 
proliferation, angiogenesis, invasion, and apoptosis (Gastonguay et al., 2012, 
Brantley et al., 2001). Many mitogenic signaling pathways such as RAS/MAPK and 
PI3K pathways are known to activate NF-kB signaling (Fan et al., 2002; Mischel and 
Cloughesy, 2003). Under unstimulated conditions, NF-kB exists as dimers bound to 
IκB inhibitory proteins in the cytosol and remains inactive. Appropriate stimulus such 
as those afore mentioned, activates IKK complex (IκB kinase complex) that targets 
IκB proteins to phosphorylation induced proteosomal degradation. Nuclear 
translocation of NF-kB dimers, assisted by rapid degradation of IκB inhibitory 
proteins, allows trans-activation of downstream target genes involved in vital cellular 
processes. Gene expression of NF-kB is elevated in GBM (Ito et al., 1994, Wang et 
al., 2004). It has been shown that NF-kB activation correlates with poor response to 
radiation therapy and is associated with shorter survival in GBM patients (Bhat et al., 
2013). 
 
(iii) Sonic hedgehog (SHH) signaling pathway – SHH is a member of the hedgehog 
(HH) family of secreted proteins. HH proteins, produced in the cell undergo extensive 
post-translational modifications such as palmitoylation, are secreted into the 
extracellular space by neuronal cells via cellular filopodia. During neural 
development, gradient activity of SHH induces zonal polarization and contributes to 
 16 
neural patterning (Ericson et al., 1997). The mitogen SHH often elicits paracrine 
signaling in adjacent cells and propagates canonical HH signaling through a receptor 
complex that consists of G-protein coupled receptor smoothened (SMO) and the 
transmembrane receptor Patched (PTC1). Under unstimulated conditions, PTC1 
inhibits SMO action. In the presence of SHH, PTC1 binds to the ligand and relieves 
SMO. This results in SMO-mediated activation of Gli (Glioma- associated oncogene 
family members) family of transcription factors (Gli1, Gli2 and Gli3) that regulates the 
expression of multiple downstream target genes. Members of SHH pathway are 
known to contribute to various cellular processes through non canonical HH signaling 
for instance, activation of SHH inactivates the tumor suppressor RB1 and causes 
overexpression of the cell cycle regulator N-myc, and PTC1 directly regulates cell 
cycle through interaction with cyclin B1, which acts as a G2/M checkpoint. The Gli 
transcription factors are also known to be trans-activated by other signaling pathways 
such as RTK/ PI3K signaling pathways, independent of SHH pathway (Stecca and 
Ruiz, 2010). It was recently demonstrated that cross-talk between SHH and PI3K/Akt 
pathways promote GBM progression. Loss of SHH or mutations in PTC, the SHH 
receptor, results in enhanced susceptibility to cerebellar brain tumors 
(medulloblastoma). PTC mRNA levels correlate with grade II and grade III glioma, 
suggesting a potential role for the SHH pathway in glioma development (Abdouh et 
al., 2009; Ehtesham et al., 2007; Filbin et al., 2013).   
1.4.2.2. Molecular subtypes of GBM  
 
Gene expression analysis of GBM tumors reflects the tumor heterogeneity and 
biological state of malignancy more accurately than histopathological grading.  
Transcriptomic profiling based gene signatures can be effectively used to classify 
and study GBM tumors (Godard et al., 2003; Nutt et al., 2003; Rickman et al., 2001).  
 
Several reports classified GBM based on gene expression profiles. In 2003, Mischel 
et al. performed a global transcriptomic profiling of GBM and classified tumors into 
EGFR-positive, EGFR-negative, and a molecular subtype, which was predominantly 
characterized by overexpression of genes present in locus 12q13-15 and gene 
features of astrocytes and oligodendroglia (Mischel and Cloughesy, 2003). In 2010, 
Verhaak et al. integrated transcriptomic profiles together with gene copy number and 
mutation data, and globally classified GBM into 4 distinct transcriptional subclasses:  
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Classical subtype: Focal amplification of chromosome 7 (EGFR) paired with loss of 
chromosome 10 (PTEN) is the genetic signature of this subtype. These tumors show 
high-level amplification of EGFR and/or gain of function vIII EGFR mutation, and 
frequent homozygous deletion of CDKN2A. Tumors of this subtype show high gene 
expression for neural stem cell marker Nestin (NES), members of Notch (NOTCH3, 
JAG1) and SHH (SMO, GAS1 and Gli2) signaling pathways. 
 
Proneural subtype: Genetic alteration of 4q12 (PDGFRα) and point mutation in 
isocitrate dehydrogenase 1 (IDH1) that encodes a metabolic enzyme, and is the 
genetic signature that defines this subtype. Focal amplification of PDGFRα is the 
most frequently observed genetic alteration of 4q12 in this tumor subtype. Although 
rare, gain of function mutation and in frame deletion of PDGFRα is also documented 
in tumors of this subtype. Heterozygous loss (LOH) and loss of function mutation of 
TP53 are frequent in this subtype. Tumors of proneural subtype show high mRNA 
levels for genes associated with oligodendrocytic development - PDGFRα, NKX2-2 
and OLIG2 and developmental genes - DCX, TCF4, SOX members, and Notch 
members - DLL3, ASCL1. Most of the secondary GBM are part of this subtype.  
 
Neural subtype: These tumor subtypes do not show a specific genetic signature. 
However, they show high gene expression for neuronal and astrocytic markers like 
neurofilament (NEFL), gamma-aminobutyric acid A receptor alpha 1 (GABRA1), 
Synaptotagmin 1 (SYT1), and potassium/chloride transporter (SLC12A5).  
 
Mesenchymal subtype: The majority of mesenchymal GBM show focal hemizygous 
deletions of 17q11.2 (Neurofibromatosis 1-NF1) together with low mRNA levels of 
NF1. Loss of function co-mutation is frequently observed for TP53 and NF1 in this 
subtype. Mesenchymal GBM show high gene expression for astrocytic and 
mesenchymal markers such as MERTK, CHI3L1, MET, and CD44, members of TNF-
NF-kB pathway such as TRADD, RELB, and TNFRSF1α, and those involved in 
inflammation.  
1.4.3. Low-grade glioma  
 
Genetic alterations discovered in GBM provide information about glioma progression. 
However, alterations that describe glioma initiation are yet to be discovered. LGG 
gradually progresses to secondary GBM, by sequential accumulation of mutations. 
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Therefore, LGG represents a better candidate to study early gliomagenesis. Known 
genetic alterations in LGG are discussed in the following section.  
 
1.4.3.1. Genetic alterations in LGG   
 
Mutation in isocitrate dehydrogenase 1 (IDH1) is most commonly observed in 
LGG. IDH are homodimeric metabolic enzymes (IDH1-4) that localize in cell cytosol 
and peroxisomes (IDH1), and in mitochondria (IDH2-4). IDH enzymes catalyze the 
conversion of isocitrate to α-ketoglutarate (αKG) during Krebs cycle (TCA cycle) in 
mitochondria. In 2008, point mutations in isocitrate dehydrogenase 1 (IDH 1) were 
identified in GBM (Parsons et al., 2008). Further studies showed that over 80% of 
LGG and secondary GBM harbor IDH1 mutations compared to primary GBM (4-7%) 
(Ohgaki and Kleihues, 2013). Mutation in IDH (at Arg 132 for IDH1 and very rarely for 
Arg140 and 172 for IDH2) alter tumor cell metabolism and induce genome-wide 
changes in the epigenetic profile of tumor cell. Mutation in IDH 1 results in a novel 
enzyme function that catalyzes the conversion of α-KG to an oncometabolite 2-
hydroxy-glutarate (2HG). 2HG induces the genome-wide methylation of cytosine-
phosphate-guanine (CpG) islands found around promoter regions of genes (Zhu et 
al., 2011). In 2010, Noushmehr et al. performed promoter DNA methylation analysis 
and identified that a subset of proneural GBM showed hyper-methylation of a large 
number of loci, called glioma CpG island methylator phenotype (G-CIMP) 
(Christensen et al., 2011; Laffaire et al., 2011). Such epigenetic changes regulate 
mammalian gene expression primarily by gene silencing.  
 
Promoter methylation of O6- Methyl Guanine DNA Methyl Transferase (MGMT) 
is a common epigenetic alteration observed in 80% of LGG and 35-40% of malignant 
gliomas (Thon et al., 2012; Hegi et al., 2005). MGMT (locus 10q26) encodes for a 
DNA repair enzyme that removes alkyl adducts from O6-alkyl guanine (O6-Al-G). For 
example, the enzyme prevents methylation of CpG islands. Alkylated O6- Guanine 
leads to double-stranded DNA breakage and base mispairing. Loss of MGMT activity 
results in gene silencing and cell death due to genome instability. Unfortunately in 
glioma cells, presence of MGMT contributes to resistance against methylating 
chemotherapeutic agents such as temozolomide (TMZ), as MGMT repairs the 
lesions introduced by TMZ. Consequently, glioma patients with epigenetically 
silenced MGMT gene (MGMT promoter methylation) respond well to TMZ treatment 
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compared to glioma patients that do not have MGMT promoter methylation (Hegi et 
al., 2005).  
 
Point mutation in TP53 is a frequent event observed in over 60% of LGG and is 
most often found in astrocytoma (Ohgaki and Kleihues, 2007). Frequent point 
mutations in CpG sites from G:C to A:T results in loss of TP53 gene expression. 
TP53 is a tumor suppressor that maintains genome integrity (the cellular functions of 
TP53 is discussed in detail in section 1.4.1.3). Loss of function mutation in TP53 is 
associated with unfavorable outcome in LGG (Ohgaki and Kleihues, 2007; Ständer et 
al., 2004). TP53 mutations occur in over 65% of secondary GBM that arise from 
LGG, in contrast to primary GBM (28%) that arise de novo (Ohgaki et al., 2004).   
Codeletion of 1p and 19q arms is observed in over 80% of oligodendroglioma. 
Genes located in this region such as Notch 2 and CCNL2 (a regulator of cell cycle 
progression) are known to contribute to oligodendroglioma initiation and progression 
(Ferrer-Luna et al., 2009; Mukasa et al., 2002; Tews et al., 2006). In fact, combined 
heterozygous allelic loss of 1p and 19q is a good prognostic factor in patients with 
oligodendroglioma (Zhao et al., 2014). 
 
Point mutations in Telomerase reverse transcriptase (TERT) were found in over 
50% of gliomas and in 78% of oligodendrogliomas (Killela et al., 2013). The reverse 
transcriptase TERT is responsible for maintaining telomere length and thus regulate 
age and ability of a cell to divide (Masutomi et al., 2005). Frequent activating point 
mutations (C250T and C228T) in the promoter of TERT contribute to elevated levels 
of telomerase activity that contributes to gliomagenesis (Killela et al., 2013). 
Interestingly mutations in telomere binding proteins, that participates in maintaining 
telomere length such as alpha thalassemia/mental retardation syndrome X-linked 
(ATRX) and death-domain associated protein (DAXX) are mutually exclusive with 
TERT mutation (Killela et al., 2013).   
It has been demonstrated that gain of function mutation in IDH, TERT, loss of 
function mutation in TP53 contribute to gliomagenesis (Cohen et al., 2013; 
Labussière et al., 2014; Moriya et al., 2014). As IDH mutations are present in over 
80% of LGG irrespective of the histology of the tumor, it is postulated that IDH 
mutations occur early during gliomagenesis (Appin and Brat, 2015; Louis, 1994; 
Ohgaki and Kleihues, 2011; Watanabe et al., 2009; Yan et al., 2009).  
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1.4.3.2. Molecular subtypes of LGG 
 
LGG are broadly classified into 3 categories based on identified genetic aberrations 
(Eckel-Passow et al., 2015; TCGA, 2015; Leu et al., 2013; Suzuki et al., 2015):  
 
(i) IDHmut/1p19q LOH – LGG of this subtype show IDH mutation (IDHmut) and 
codeletion of 1p19q arms (1p19q LOH). In addition, this subtype harbors mutations 
that contribute to glioma proliferation such as in Capicua (CIC)- a modulator of ErbB 
signaling pathway (locus 1p), Far upstream element binding protein 1 (FUBP1)- an 
activator of myc (locus 19q), NOTCH1 and TERT. Patients with tumors of this 
subtype respond well to aggressive treatments and have high overall median survival 
of 8 years compared to other groups (TCGA 2015). Over 80% of IDH mut LGG also 
carry MGMT promoter methylation (MGMTmet). In fact, patients with IDH mut/1p19q 
LOH/MGMTmet LGG are also associated with higher overall survival time compared 
to IDH wt (Leu et al., 2013). 
 
 (ii) IDHmut – In addition to IDHmut, this LGG subtype also shows frequent 
coexistence of inactivating mutations in TP53 (TP53mut) and ATRX. Patients with 
this tumor subtype show median survival of 6.3 years (TCGA 2015). Consistently, 
IDHmut/TP53 mut LGG that also show MGMTmet (IDHmut/TP53/MGMTmet) is 
associated with reduced overall survival time compared to IDHmut/1p19q LOH/ 
MGMT met but higher compared to IDH wt (Leu et al., 2013). 
 
(iii) IDHwt – LGG of this subset express wild type IDH and harbor classical GBM 
subtype-like mutations and copy number variations (CNVs) for instance, gain of 
function mutation and amplification of EGFR and homozygous deletion of CDKN2A. 
The IDHwt subtype account for 20% of all the LGG and majority of the tumors are 
anaplastic astrocytomas. Patients with IDHwt LGG have the shortest survival with a 
median of 1.7 years compared to other afore mentioned LGG subtypes (TCGA 
2015).  
 
Overall, our current understanding of gliomagenesis is not yet sufficient to portray the 
complete picture of gliomagenesis. However, further understanding of sequential 
accumulation of mutations in glioma could give deeper insights into gliomagenesis. 
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1.4.4. Distinct pathways for glioma initiation 
 
In 1940, Hans-Joachim Scherer, a german neuropathologist was the first to suggest 
that based on biologic and clinical point of view, primary and secondary GBM can be 
distinguished. Although the view was clinically recognized, Scherrer’s distinction 
remained conceptual as the two lesions are histopathologically undistinguishable 
(Homma et al., 2006; Lee et al., 2013; Ohgaki and Kleihues, 2007; Ohgaki, 2005; 
Peiffer and Kleihues, 1999). 
 
In 1996, Ohgaki et al. reported that inactivating mutation in TP53 is more frequent in 
secondary GBM (65%) than in primary GBM (28%). Subsequent studies made 
similar observations, for instance focal amplifications in EGFR are more common in 
primary rather than in secondary GBM (Fujisawa et al., 2000; Ohgaki and Kleihues, 
2007;Ohgaki et al., 2004; Watanabe et al., 1996). In 2009, Nobusawa et al. identified 
point mutations in IDH1 as a molecular marker for secondary GBM (Nobusawa et al., 
2009). Subsequently, in 2010, Noushmehr et al. performed epigenetic profiling of all 
GBM samples and showed that over 93% of the proneural GBM harbored IDH1 
mutations and mostly are secondary GBM. The authors further showed that the IDH 
mutant secondary GBM showed a distinct glioma-CpG island methylator phenotype 
called G-CIMP (Noushmehr et al., 2010). Thus, all these observations show that 
primary and secondary GBM are genetically distinct. This led to postulate that two 
distinct pathways for gliomagenesis exist (Fig. 3).  
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Fig. 3. Schematic representation of glioma progression: Primary and secondary GBM are 
genetically distinct suggesting two pathways for gliomagenesis. The scheme represents the known 
genetic alterations in chronological order of disease progression. Primary GBM arise de novo and are 
characterized by alterations in PI3K pathway, p53, and RB pathways. Primary GBM occur in older 
individuals and have worse prognosis for survival (12-14 months). Secondary GBM occur by gradual 
progression of LGG to GBM. Secondary GBM are characterized by mutations in IDH, TP53. IDH 
mutations in secondary GBM and LGG are associated with a favorable patient outcome.    
 
 1.4.5. Cellular origin for gliomagenesis 
 
It is postulated that GBM contains a sub-population of cells that exhibit stem-like 
behavior (Altaner, 2008; Cho et al., 2013; Lathia et al., 2015; Persano et al., 2013). 
These so called glioma stem-like cells exhibit tumorigenic properties. Currently, 
these cells are identified using a cocktail of markers such as prominin 
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(CD133/PROM1), stage specific embryonic antigen 1(SSEA), integrin α6, CD44, and 
SOX2 (Suvà et al., 2014).   
 
Histologically, oligoastrogliomas offer deeper insight into the origin of gliomas. 
Gliomas of this subtype contain neoplastic cells with astrocytic and oligodendroglial 
morphology, suggesting that oligodendrocyte precursor cells (OPCs) and neural 
stem cells (NSCs) are potential candidates for gliomagenesis. In fact, using lineage-
tracing experiments such as mosaic analysis with double markers (MADM) on a 
syngenic glioma mouse model, Liu et al. showed that orthotopic implantation of 
OPCs genetically inactivated for tumor suppressor genes TP53 and NF1, results in 
sporadic GBM formation (Liu et al., 2011). Swartling et al. showed that orthotopic 
implantation of NSCs genetically altered to stably express high levels of N-myc, into 
the mouse forebrain results in formation of diffuse gliomas (Swartling et al., 2012).  
 
Overall, growing evidence supports that genetically altered NSC or OPC could be the 
cellular origin of glioma (Alderton, 2011; Lei and Canoll, 2011; Galvao et al., 2014; 
Lindberg et al., 2014; Monje et al., 2011).  
 
1.5. MALIGNANT TRANSFORMATION  
1.5.1. Glioma invasion 
 
Glioma cells invade deep into the brain tissue by the time of its detection and surgical 
resection (Matsukado, et al. 1961). This shows the extent of infiltrative behavior of 
glioma. Advanced stages of glioma present multifocal lesions with higher incidence 
of tumor relapse (Silbergeld et al 1999; Barnard and Geddes, 1987; Gaspar et al., 
1992; Giese et al., 2001). Over 90% of gliomas relapse within 2-3 cm from the site of 
surgical resection. Tumor relapse is the primary reason for tumor related morbidity in 
glioma patients (Burger et al., 1983; Gaspar et al., 1992). Extent of surgical tumor 
resection remains one of the strongest prognostic factors for glioma patient survival 
(Nitta and Sato, 1995).  
1.5.1.1. Gliomas invade but rarely metastasize  
 
Malignant tumors have one common denominator; they are highly invasive and often 
metastasize. Metastasis occurs in two steps: (i) Tumor cells migrate from their 
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primary site of origin in to distant organs that are capable of homing them through 
navigators such as blood vessel system (ii) Once reached, then proliferate and 
locally infiltrate the organ resulting in the formation of a secondary tumor at the new 
site – metastasis (Chambers et al., 2002).   
 
Unlike other solid tumors, gliomas very rarely (0.4%-2%) metastasize outside the 
brain. Many explanations have been proposed towards this behavior of gliomas.  
First, it is possible that individuals with GBM do not survive long enough for extra-
cranial metastasis to occur (Stupp et al., 2005 (radiotherapy), Stupp et al., 2005 
(chemotherapy)). Second, extra-cranial tissues may not contain the right 
microenvironment to support glioma cell survival. Third, glioma cells are unable to 
intravasate the BBB in order to enter into systemic circulation and metastasize 
outside the brain. There have been no clear demonstrations so far, to confirm these 
hypotheses (Beauchesne, 2011; Boelke et al., 2013). 
1.5.1.2. Modes of glioma invasion 
 
Glioma are known to invade along the long tracts of nerve fibers or white matter 
tracts (Bernstein et al., 1990; Giese et al., 1996; Yamada et al., 1994). Recently, it 
was shown that glioma participate in tumor angiogenesis and could migrate along the 
tumor vessels (Bao et al., 2006; El Hallani et al., 2014; Ricci-Vitiani et al., 2010). 
Brain parenchyma, perivascular structures, and blood vessel membranes are 
composed of diverse extracellular matrix (ECM) molecules and represent potential 
channels through which glioma cells can invade. The three known paths along which 
glioma cells invade and migrate are discussed below: 
1.5.1.2.1. Through brain parenchyma 
 
Glioma cells have long known to invade along the nerve fibers and white matter 
tracts. The extracellular matrix of brain parenchyma is made of proteoglycans such 
as lectican family members (eg. BEHAB/brevican, a known inducer of glioma cell 
motilty), and their binding partners hyaluronans, tenascins (TNC, TNW) (Bonneh-
Barkay and Wiley, 2009; Gary et al., 1998). Many of these ECM molecules are 
secreted by astrocytes and oligodendrocytes such as TNC. Cell bodies of astrocytes 
and oligodendrocytes among others, in the brain parenchyma contribute to enhanced 
physical resistance for glioma cell migration. The glioma cells in response to such 
stiff ECM secrete proteins and matrix-metallo-proteases (MMP) that help to digest 
and remodel ECM, thus facilitating their infiltration through the brain parenchyma.  
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1.5.1.2.2. Along the blood vessels 
 
BBB is composed of tight junctions between astrocytic end feet, endothelial cells and 
vascular pericytes called neurovascular units. These structures ensure proper flow of 
blood and availability of nutrients to brain tissues. Glioma cells are often found to 
crowd around the perivascular spaces in the tumor (Anand Cuddapah et al., 2014; 
Rutka et al., 1998). Close association of glioma cells to the vascular network helps 
them to derive maximum nutrition directly from the blood stream.  
 
Many research studies using xenograft mouse and rat models of glioma, 
demonstrated that majority of glioma cells migrate along the blood vessels by 
disrupting the BBB and invade the surrounding unaffected brain tissue (Farin et al., 
2006; Zagzag et al., 2000; Watkins et al., 2014). In 2014, Cudappah et al. postulated 
that invading glioma cells surround blood vessels and compete with astrocytic 
endfeet processes for physical interaction with vascular endothelial cells. In the 
process they lift up the astrocytic processes and degrade the underlying basement 
membrane by producing ECM proteins and proteases. In response, astrocytes 
become reactive and withdraw their end feet processes, thus disrupting the 
neurovascular unit (Anand Cuddapah et al., 2014). Glioma cells hence invade along 
the blood vessels by breaking the BBB (Fig. 4A).   
 
1.5.1.2.3. Along the subarachnoid-perivascular space 
 
Large blood vessels have considerably larger perivascular spaces called the Virchow 
Robin space, which is continuous with subarachnoid space. This space is separated 
from the brain parenchyma by the basement membrane, created by astrocytes along 
their end feet. Cerebrospinal fluid (CSF) is present in this space and this is regarded 
as the lymphatic system of the brain. This space consists of collagens type- I, III, and 
IV, fibronectin, laminins, and other proteoglycans. This perivascular space offers the 
path of least resistance for glioma migration (Giangaspero and Burger, 1983, Jones 
T G et al., 1981).  It is thought that the convection of CSF towards the brain surface 
and other subarachnoid space helps in directional glioma migration. (Jones et al., 
1981, Anand Cuddapah et al., 2014).  
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1.5.1.3.  Mechanistic overview of glioma invasion 
 
Glioma cells are highly sensitive to ECM stimulus that causes cell detachment and 
triggers cell migration. Cancer cells that disseminate from the primary site can exhibit 
mesenchymal or amoeboid migration (Friedl and Wolf, 2003). Gliomas exhibit 
mesenchymal invasion where the cells become polarized and secrete MMP and 
ECM molecules. Characteristic features of a migrating glioma cell are cell 
polarization, protrusion, and formation of focal adhesion complexes (explained in 
detail in the following section 1.5.1.4) at the leading edges that enable dynamic actin 
polymerization. 
 
The trans-differentiation of epithelial cells to motile mesenchymal cells, a process 
known as epithelial-mesenchymal transition (EMT), is commonly observed during 
embryogenesis, organogenesis, wound healing, and tissue remodeling. EMT is well 
described in many epithelial cancer types as an important mediator of cancer 
invasion and metastasis (Eckert et al., 2011; Huber et al., 2005; Thiery, 2002; Tsai et 
al., 2012).  
 
This phenomenon is characterized by transition of epithelial cells to polarized 
mesenchymal cells that leads to loss of adherent cell-cell junctions, gain of 
migratory/invasive phenotype, and elevated resistance to apoptosis. This trans-
differentiation is tightly controlled by key transcription factors such as SNAIL, Zinc-
finger E box (Zeb), and other basic helix loop helix factors such as myoD (Cannito et 
al., 2008; Nagaharu et al., 2011; Peinado et al., 2003). TGFβ directly regulates the 
expression of these transcription factors and plays an important role in inducing EMT 
(Peinado et al., 2003). 
 
Many reports have shown the existence of a EMT-like phenomenon in glioma (Anand 
Cuddapah et al., 2014; Soda et al., 2011; Zhao et al., 2010). Thus, hinting that EMT 
might be at play to during glioma invasion. Overall, glioma invasion can be described 
in 4 stages: 
 
a. Non-polarized epithelial-like cells detach from their primary site of origin. b. They 
undergo massive cytoskeletal reorganization, and develop new cell adhesion 
molecules and receptor repertoires that enable them to attach to the extracellular 
matrix (ECM). This results in cell polarization. c. The polarized cells then degrade 
and remodel the ECM with the help of proteases (MMP2, MMP 9) secreted into the 
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ECM, d. Glioma cells thus invade along the degraded ECM structures (Nakada et al., 
2007; Teodorczyk and Martin-Villalba, 2010; Wolf, 2003) (Fig. 4B). 
 
B 
 
Fig 4. Glioma invasion along the blood vessel structures: A. Top: Electron micrographs of intact 
blood vessel showing normal astrocytic (labeled A) end feet coverage and that of a disrupted blood 
vessel with glioma cells (green) covering most of the blood vessels (labeled V) in GBM patient derived 
cell lines. Bottom: Schematic representation of intact and disrupted BBB. Glioma cells displace 
astrocytic endfeet and migrate/invade along the blood vessels. B. Glioma invasion is effected in 3 steps. 
Step 1. Cells detach from their primary site of origin and undergo massive cytoskeletal reorganization. 
Step 2. They develop new repertoire of cell adhesion molecules and receptors and attach to ECM. 
During this phase cells become polarized. Step 3. They secrete various ECM ligands and proteases that 
degrade and remodel the ECM, and then effect invasion. 
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1.5.1.4. Molecular determinants of glioma invasion 
 
1.5.1.4.1. Rho GTPases 
 
Rho family members are small GTPases that belong to the Ras super family, and are 
known to play a crucial role in actin cytoskeletal remodeling. The small GTPases 
comprises more than 20 members. Among them, RhoA, Rac1, and Cdc42 have been 
well-studied for their role in cell invasion and migration (Bouzahzah et al., 2001; 
Keely et al., 1997). RhoA regulates the dynamic formation of stress fibers and 
adhesion complexes. Rac1 mediates the formation of lamellipodia at the leading 
edge of a migrating cell. Cdc42 promotes directional movement by regulating 
polarization and filipodia formation in the cell (Nobes and Hall, 1999). Interestingly, in 
glioma cells inhibition of RhoA results in Rac1 compensated cell migration (Salhia et 
al., 2005; Tran et al., 2006).  
 
1.5.1.4.2. Integrins and members of focal adhesion complex 
 
Integrins are trans-membrane heterodimer receptors consisting of an α- and a β 
subunit. Integrins primarily provide structural support to the cells by enabling them to 
attach to ECM molecules such as fibronectin and laminin. So far, over 18α and 8β 
subunits have been discovered and their heterodimeric combinations determine the 
ligand affinity. In addition to providing structural support, integrins also regulate 
anchorage-dependent cell growth by controlling ionic exchanges such as Ca++ influx 
and the Na+/K+ antiporter (Burridge and Chrzanowska-Wodnicka, 1996). Clustering 
of integrins on the leading edge of migrating cell results in the formation of focal 
adhesion contacts that serve as a link between ECM and cellular actin cytoskeleton. 
This serves as a docking site for focal adhesion kinases (FAK). Aggregated integrins, 
cytoskeletal proteins such as vinculin, and focal adhesion kinases (FAK) called focal 
adhesion complex facilitates dynamic cytoskeletal reorganization and establishes cell 
polarity. Formation of focal adhesion complex is required for glioma cell migration 
(D’Abaco and Kaye, 2007). The expression of αVβ1, αVβ5 integrins is shown to 
correlate with glioma invasiveness (Belot et al., 2001; Paulus et al., 1996).  
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1.5.1.4.3. ECM molecules and proteases 
 
Tenacin-C (TNC) is a glycoprotein secreted by glioma cells into their extracellular    
stroma. The ECM molecule is strongly linked to glioma malignancy and associated 
with poor prognosis in GBM patients (Bourdon et al., 1983; Leins et al., 2003). In 
fact, TNC is trans-activated by the Notch signaling pathway to induce glioma invasion 
(Sivasankaran et al., 2009). Laminin is a major component of the vascular basement 
membrane and a potent stimulator of glioma migration (Goldbrunner et al., 1996). 
Other ECM molecules such as vitronectin is an inhibitor of glioma cell migration when 
tested in vitro (Giese and Westphal, 1996). MMP belong to the family of 
Zn2+dependent proteases that are responsible for ECM degradation and 
maintenance. Glioma cells secrete MMPs such as MMP2, MMP9, whose expression 
correlate with glioma invasiveness and poor prognosis (Badiga et al., 2011; Lu et al., 
2012; Sun et al., 2013). 
 
1.5.1.4.4.Growth factor receptors 
 
The members of RTK family of growth factor receptors are important contributors to 
glioma cell proliferation, survival, invasion, and angiogenesis. For instance, the 
hepatocyte growth factor (HGF) receptor, MET (located at 7q) is frequently amplified 
and its expression correlates with tumor invasion and progression (Abounader and 
Laterra 2005; Koochekpour et al., 1997; Lamszus et al., 1998; Kong et al., 2009). 
Upon binding to HGF, the MET receptor undergoes phosphorylation and activates 
the Ras/MAPK and Akt signaling pathways. HGF/MET signaling is important for 
maintaining tissue homeostasis under normal physiological conditions. Similarly, 
VEGF is a chemotactic inducer of tumor cell invasion and mesenchymal transition 
and transduces signals through a complex system of RTK VEGF (VEGFR 1-4). It has 
been demonstrated that the pro-invasive ligand VEGF contributes to glioma invasion 
by activating downstream signals upon binding to MET/VEGFR2 complex (Nicola 
McCarthy 2012). Similarly, binding of EGF to EGFR promotes cell proliferation, 
invasion, and survival of glioma (Lund-Johansen et al., 1990). It was shown that 
EGFRvIII (one of the most common gain of function mutations in EGFR in GBM) 
promotes glioma cell invasion through protein kinase A (PKA) dependent activation 
of Rac1. Thus, contributing to cell cytoskeleton reorganization in addition to 
activating the PI3K pathway (Feng et al., 2014; Lund-Johansen et al., 1990; Micallef 
et al., 2009). 
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1.5.1.4.5. Epithelial-Mesenchymal Transition related markers 
 
Emerging literature supports the role of EMT inducers in glioma invasion. The 
transcription factor ZEB1 is an inducer of EMT and contributes to aggressive glioma 
behavior (invasion, migration and therapy resistance). Recently, markers associated 
with EMT such as Twist, Emx, and Snail have been shown to also contribute to 
glioma invasion (Bhat et al., 2011; Elias et al., 2005; Savary et al., 2013; Zhao et al., 
2012). 
1.5.2. Glioma angiogenesis 
 
Tumor angiogenesis is the principal source of nutrition for the growing tumor and is 
required to remove metabolic wastes and carbon dioxide from the tumor tissue. As 
gliomas progress to higher grades of malignancy, they become highly vascularized 
eventually forming abnormal leaky blood vessels, observed in GBM. Enhanced tumor 
vascularization is hence one of the biological features of GBM.  
   
Angiogenesis is the process of formation of new blood vessels from existing ones 
(Folkman, 1971; Kerbel, 2008). In adults, we commonly observe transient phases of 
angiogenesis for instance, during wound healing. These phases are tightly controlled 
by fine balance between pro- and antiangiogenic factors. Blood vessel formation 
from the pre-existing vessels is the primary mechanism of brain vascularization 
observed during both brain development and in brain cancer (Kurz et al., 2004, 2001; 
Plate et al., 1994; Risau, 1997).  
 
1.5.2.1. Types of tumor angiogenesis  
 
During embryonic development blood vessels initially arise from endothelial 
precursor cells called angioblasts. These cells are recruited and subjected to 
differentiation in response to cues from its local microenvironment. Followed by the 
de novo initiation of angiogenesis from precursor cells, activated endothelial cells 
respond to gradients of pro-angiogenic factors by sprouting.  
 
Although, tumor-associated angiogenesis classically involves endothelial sprouting, 
many different modes of angiogenesis have been documented during tumor 
angiogenesis. These modes of angiogenesis are listed below:  
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Vasculogenesis is the process where angioblasts from the host are recruited by pro-
angiogenic factors, such as VEGF. This process leads to de novo initiation of blood 
vessel formation, and is primarily observed during embryonic development. During 
tumor angiogenesis, tumor cells secrete VEGF to attract and recruit endothelial 
precursor cells from perivascular niches in to the tumor to form tube like structures 
(Patan, 2004).   
 
Sprouting angiogenesis is defined as the growth of a new blood vessel from a pre-
existing one, by means of endothelial proliferation (Hillen and Griffioen, 2007). This is 
the classical form of angiogenesis observed most commonly during embryonic 
development, wound healing, reproduction and tumor-associated angiogenesis. This 
process is also observed during tumor angiogenesis particularly in GBM (Ausprunk 
and Folkman, 1977). 
 
Intussusceptive angiogenesis is the process where a new vessel arises by splitting of 
pre-existing blood vessel. This type of angiogenesis is often considered to be fast 
and robust where microvascular growth can take place within hours because cell 
proliferation is not essential under these circumstances. This type of angiogenesis is 
observed during lung development (Djonov et al., 2000). 
 
Vessel co-option is the process where tumor cells invade through the normal 
vascular tissue and become part of the existing vasculature (Leenders et al., 2002). 
 
Vasculogenic mimicry is defined as the process where tumor cells replace 
endothelial cells and contribute to formation of vascular lumen. The consequence of 
such mimicry is the formation of abnormal and leaky blood vessels in the tumor 
(Folberg et al., 2000). 
 
Trans-differentiation is the process where cancer-stem like cells (CSCs) are recruited 
from tumor to form new blood vessels. CSCs differentiate towards mesenchymal 
phenotype in the presence of angiogenic factors and have been shown to participate 
in GBM neovascularization (Scully et al., 2012). 
 
Lymphangiogenesis is the form of angiogenesis that is observed in lymphatic 
system. Unlike the conventional vascular network formations, the lymphatic vascular 
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system collects and drains blood from each organ for downstream detoxification and 
then returns the blood into circuitry. In tumors, lymph angiogenesis is thought to be 
one of the primary gateways for cells to metastasize into different organs. Many of 
the vascular endothelial growth factor receptors (VEGFR) family members and 
PDGF have been associated with this type of angiogenesis (Stacker, 2009). 
 
1.5.2.2. Mechanistic overview  
 
Pro-angiogenic stimuli activate endothelial cells to form vascular sprout. Tip cells with 
numerous filopodia, showing enhanced migratory behavior are present in the leading 
front of a sprout. Tip cells are required to create new connections between different 
vascular sprouts. In the vascular sprout, beneath the tip cells are endothelial stalk 
cells that are characterized by fewer filopodia and high proliferative ability. Stalk cells 
are required to create adherent and tight junctions, and form the initial vascular 
lumen (Dejana et al., 2009; Gerhardt et al., 2003; Phng and Gerhardt, 2009) (Fig. 
5A,B).  
 
VEGF is secreted by tumor-associated endothelial cells and promotes GBM 
angiogenesis. The pro-angiogenic ligand present in ECM and vascular niches binds 
to endothelial VEGF receptor (VEGFR) and activates downstream signals that 
results in enhanced the migratory behavior of tip cells. Activation of VEGFR signaling 
cascade in tip cells induces the expression of notch ligand, Dll4. Secreted Dll4 
activates paracrine Notch signaling in adjacent cells leading to endothelial 
proliferation, the stalk cell phenotype (De Bock et al., 2013; Dejana et al., 2009; 
Gerhardt et al., 2003; Phng and Gerhardt, 2009; Harjes et al., 2012) (Fig. 5A,B).  
 
The work from 4 independent groups showed that glioma cells grow along the blood 
vessels by recruiting GSCs for tumor angiogenesis without triggering an angiogenic 
response. Trans-differentiation of GSCs to endothelial-like cells to participate in 
tumor angiogenesis, indicates the extent of GSC plasticity (Donnem et al., 2013; 
Folberg et al., 2000; Holash et al., 1999; Ricci-Vitiani et al., 2010)  (Fig. 5C). In 2010, 
Hallani et al. showed that glioma cells directly participate in blood vessel formation by 
the process of vasculogenic mimcry (El Hallani et al., 2010). This is schematically 
represented in Figure 5.   
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Fig. 5. Schematic representation of glioma angiogenesis processes observed. A. Representative 
image of an active sprout - during angiogenesis in response to pro-angiogenic stimulus (VEGF) 
endothelial cells are activated to form a sprout. Migrating tip cells are present at the leading front of a 
sprout, followed by proliferating stalk cells and quiescent endothelial cells. B. The process of sprouting 
angiogenesis in response to endothelial activation by pro-angiogenic factors is graphically shown. C. 
Glioma stem-like cells trans-differentiate towards endothelial-like cells during glioma angiogenesis. The 
process is known to contribute to the formation of abnormal leaky blood vessels.  
 
1.5.2.3. Molecular players  
 
Tumor cells respond to microenvironmental cues and recruit endothelial cells during 
angiogenesis. When pro-angiogenic factors like VEGF and angiopoietins (1-4), 
exceed the anti-angiogenic factors like endostatin and angiostatin, tumors 
experience an angiogenic switch that favors glioma angiogenesis (Bergers and 
Benjamin, 2003; Wicki and Christofori, 2008). In GBM, VEGF is highly upregulated 
and secreted by the tumor cells (Plate et al., 1994; Shweiki et al., 1992). During GBM 
growth, tumor proliferation exceeds the rate of tumor angiogenesis creating a 
hypoxic microenvironment inside the tumor. Hypoxia induces and enhances the 
secretion of VEGF, by activating the expression of hypoxia-inducible transcription 
factors (HIF1 and 2) (Heddlestone et al., 2010; Li et al., 2009).   
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Tie2, an endothelial tyrosine kinase receptor for angiopoietins, is constitutively 
expressed in adult vasculature and is important for homeostasis of mature 
vasculature and pericyte coverage. Homozygous deletion of Tie2 in mouse model 
results in severe vascular defects (Dumont et al., 1994). In GBM, Tie2/Angiopoietin 
signaling pathway is upregulated and is known to promote tumor angiogenesis 
(Stratmann et al., 1998). Endothelial cells also express the trans-membrane notch 
receptors 1 and 4. The ligand Dll4 plays an important role in inducing angiogenesis 
(Ribatti D and Crivellato E, 2012). Notch together with VEGF regulates stalk cell fate. 
High expression of Dll4 has been observed in glioma that support tumor 
vascularization (Jubb et al., 2012). Blocking Dll4-Notch signaling results in hyper-
nonfunctional vascularization that results in tumor regression (Kuhnert et al., 2011). 
 
1.5.3. Therapies and therapy resistance   
1.5.3.1. Current therapies 
 
Surgical resection coupled with ionizing radiation (radiation therapy) followed by 
chemotherapy with temozolomide (TMZ) is the current standard of care for glioma 
patients. TMZ is an alkylating agent that methylates DNA, most commonly at the N7 
and O6 positions of guanine and O3 position of adenine residues. Failure of DNA 
repair mechanisms to replace the methylated residues leads to DNA base mispairing 
induced breakage therefore cytotoxicity (Friedman et al., 2000b). Overall, treatment 
with TMZ improves median patient survival time by 2.5 months (Stupp et al., 2005).  
 
1.5.3.2. Therapy resistance  
Relapse of tumors that are insensitive to therapy-induced apoptosis, is the primary 
reason for morbidity among GBM patients (Wen, 2008). Infiltrative glioma cells and 
chemotherapy-resistant GSC are known to contribute to tumor relapse (Bao et al., 
2006; Bleau et al., 2009; Chen et al., 2012; Rich and Bao, 2007). In addition, the 
limited efficacy of chemotherapeutic drug (because of its low diffusion limit) also 
contributes to therapy resistance (Kesari et al., 2011; Reardon et al., 2011).  
 
Studies on molecular mechanisms of tumor resistance suggest that therapy 
resistance can be classified into intrinsic or innate and acquired or adaptive 
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resistance. Pre-existing evident genetic aberrations that could contribute to therapy 
resistance observed during the first course of treatment are called intrinsic or innate 
resistance, for instance, radio-resistance in GBM with TP53 loss (Shu et al., 1998). 
Development of resistance to therapy, observed during the course of treatment and 
relapse of therapy-resistant tumor are called acquired or adaptive resistance for 
instance, resistance to Bevacizumab in GBM (Piao et al., 2013). The field of therapy 
resistance is relatively new and molecular mechanisms for therapy resistance in 
GBM are currently being understood. Known mechanisms and molecular players in 
therapy resistance of GBM cells are detailed in following sections.  
 
1.5.3.2.1. MGMT mediated therapy resistance 
 
TMZ treatment introduces methyl groups on nucleotides including O6-Methyl Guanine 
(O6-Me-G). MGMT, a DNA repair enzyme, repairs this lesion by its DNA repair 
activity, thus reverting the effects of TMZ (Friedman et al., 2000a, 2000b; Park et al., 
2010). Subsequently, MGMT expression inversely correlates to sensitivity towards 
TMZ treatment. Thus, MGMT expressing GBM do not respond to TMZ treatment. In 
fact, MGMT promoter methylation observed in 80% of LGG and in 40% of GBM, 
which results in reduced MGMT expression, predicts favorable response towards 
TMZ treatment in glioma patients (Gerson, 2002; Hegi et al., 2004; Sato et al., 2012). 
Although, MGMT mediated therapy resistance could represent an innate mechanism, 
it is yet to be demonstrated. 
 
1.5.3.2.2. Resistance against Bevacizumab 
 
VEGF-A is a key proangiogenic factor for GBM angiogenesis and associated 
cerebral edema. Bevacizumab is a EU approved human monoclonal antibody 
against VEGF-A. Initial administration of Bevacizumab in GBM patients, improves 
progression-free survival by 6 months (Moen, 2010). Unfortunately, patients develop 
resistance to bevacizumab and experience tumor relapse (Lu et al., 2013; Iwamoto 
et al., 2009).  
 
At molecular level, it is proposed that Bevacizumab induces vessel normalization. 
Perivascular pericytes line the normal blood vessels, in contrast to tumor blood 
vessels with compromised BBB. Administration of Bevacizumab reduces the number 
of immature blood vessels found in tumor blood vessels and increases pericyte 
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coverage in the tumor vasculature, a process known as vessel normalization. This 
results in initial tumor regression. However, relapsed GBM with normalized 
vasculature do not respond to subsequent Bevacizumab administration (Arjaans et 
al., 2013).  
 
1.5.3.2.3. Known players in therapy resistance  
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that 
integrates growth signals and metabolic requirements in a cell. Therefore, the kinase 
is a master regulator of cell proliferation, survival, and metabolism. Over 90% of 
GBM samples show oncogenic PI3K signaling. Thus, mTOR emerged as a prime 
therapeutic target to treat GBM patients. However, patients experience relapse of 
mTOR-resistant GBM. Recently, Tanaka et al. using xenograft glioma mouse model 
and human GBM patient samples, showed that treatment with mTOR inhibitors alter 
cancer cell metabolism. The authors showed that compensatory glutamine 
metabolism contribute to GBM resistance to mTOR (Tanaka et al., 2015).  
 
Deregulated apoptotic pathways contribute to cancer development (Adams and 
Cory, 2007; Evan and Littlewood, 1998; Lowe et al., 2004; Ziegler et al.,2008). The 
process of programmed cell death (PCD) or apoptosis is vital for maintaining a pool 
of healthy cells, required for physiological growth and tissue homeostasis. PCD can 
be activated by extrinsic stimuli such as activation of TNFα receptors or by intrinsic 
factors such as cellular stress due to exposure of radiation or DNA damage induced 
by therapeutic targets, that trigger mitochondria mediated PCD. Both the intrinsic and 
extrinsic pathways for apoptosis trigger the caspase cascade to induce cell death.   
 
Bcl2 family of apoptotic proteins control and regulate mitochondria dependent cell 
death (intrinsic pathway). The family is composed of pro-apoptotic proteins (Bcl10, 
Bak, Bax, Bim, Bad, etc.) and anti-apoptotic proteins (Bcl2, Bcl-X, Bcl-w, etc.). Over 
25 genes for the Bcl2 family members have been identified. Activation of pro-
apoptotic proteins, Bax and Bak, located on the outer mitochondrial membrane 
(OMM), results in mitochondrial membrane permeabilization and subsequently 
releases cytochrome c (cyt c) from inner mitochondrial membrane (IMM). Release of 
cytochrome c activates the caspase cascade and induces cell death. In GBM, anti-
apoptotic proteins are upregulated while pro-apoptotic proteins are downregulated 
(Ruano et al., 2008; Stegh et al., 2007). Mitochondria mediated apoptotic pathway is 
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associated with acquired GBM resistance to RTK-targeted therapies (Ziegler et 
al.,2008). In fact, overexpression of OPA1, a regulator of cytochrome c release, 
blocks caspase induced apoptosis in gliomas and contributes to tumor resistance in 
many cancers (Arnoult et al., 2005; H.-Y. Fang et al., 2011; Frezza et al., 2006; X. 
Zhao et al., 2013).  
 
The transcription factor SOX2 is a regulator of stemness in embryonic and neural 
stem cells. Recent studies on breast cancer and medulloblastoma cells show that 
SOX2 expressing CSCs are able to resist anti-mitotic drugs and repopulate the 
tumor, contributing to tumor relapse (Piva et al., 2014; Vanner et al., 2014). 
Molecular mechanisms regulating the contribution of SOX2 towards therapy 
resistance is yet to be elucidated.  
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1.6. METABOLIC PERSPECTIVE ON GLIOMA CELLS 
 
Otto Warburg received the Nobel Prize in 1931, for his seminal observations that 
cancer cells exhibit altered cell metabolism. He noted that cancer cells show high 
consumption of glucose, the majority of which was converted into lactate even in the 
presence of oxygen, compared to normal cells (Koppenol et al., 2011). This 
phenomenon is known as the “Warburg effect”. Warburg hypothesized that this 
altered metabolism was specific to cancer cells due to mitochondrial defects.  
However in recent times, it has become clear that not only cancer cells, but also 
healthy proliferating cells (cells with high energy and metabolic demand) reprogram 
their metabolism to undergo aerobic glycolysis, the reason for which, is still debated 
(Lunt and Vander Heiden, 2011). 
 
1.6.1. Cellular respiration 
     
1.6.1.1. Glycolysis and oxidative phosphorylation 
 
Generating cellular energy in the form of ATP through mitochondria, in the presence 
of oxygen is termed as aerobic respiration. Cellular glucose is metabolized to 
pyruvate by the process of glycolysis in the cell cytosol. In the presence of oxygen, 
pyruvate enters mitochondria and undergoes further oxidation via the tri-carboxylic 
acid cycle (TCA), also known as the Krebs cycle. In mitochondria, NADH, the by-
product of TCA cycle further undergoes oxidation via electron transport chain (ETC) 
and adenosine tri-phosphate (ATP) is synthesized as the final outcome. This process 
is known as oxidative phosphorylation (OXPHOS). Glucose metabolism in the 
presence of oxygen is highly efficient and generates 36 mol of ATP per mol of 
glucose consumed (Fig. 6A Left) (Berg et al., 2006; Porter and Brand, 1995).  
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    1.6.1.2. Aerobic glycolysis 
 
Glucose metabolism can occur both in the presence and in the absence of oxygen. 
Cancer or proliferating cells with high metabolic demand undergo an inefficient 
glucose metabolism known as aerobic glycolysis, even in the presence of oxygen. 
Glucose is metabolized to pyruvate via glycolysis and during reduced oxygen levels 
and increased metabolic needs, pyruvate is then converted to lactate in the cell 
cytosol, releasing 4 mol of ATP per mol of glucose (Fig. 6A Right) (Postovit et al., 
2002; Zu and Guppy, 2004).  
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Heiden et al., 2009 
Fig 6. Cellular respiration: A. Schematic representation of the differences in cellular respiration 
between nonproliferating (differentiated) and proliferating tissue including tumor cells: Glucose 
consumed by the cell is metabolized to pyruvate in the cell cytosol via glycolysis. Left: In the presence of 
oxygen, pyruvate is oxidized to CO2 during OXPHOS in mitochondria. Because oxygen is the final 
electron acceptor in the ETC, presence of oxygen is crucial for mitochondrial respiration. Oxidative 
phosphorylation results in the generation of 36 mol of ATP per mol of glucose consumed. Right: Low 
levels of oxygen or increased metabolic demand in the cell results in the reduction of pyruvate to lactate 
in the cytosol. Cancer cells convert over 85% of the pyruvate into lactate even in the presence of 
oxygen, (aerobic glycolysis). Aerobic glycolysis results in minimal generation of ATP compared to 
oxidative phosphorylation. B. Global overview of active metabolic pathways in a proliferating cell: 
Glycolytic intermediates are precursor substrates for the biosynthesis of nucleotide via the pentose 
phosphate pathway (PPP) and amino acid biosynthesis. Increased production of lactate in the cells 
creates an acidic environment that alters the glutaminolysis pathway, thus contributes to lipid synthesis. 
Enhanced glycolysis thus can cater cellular metabolic demand. These metabolic pathways are directly 
under the control of growth factor signaling pathways, tumor suppressors and oncogenes. The 
activation of mitogenic PI3K signaling enhances glycolytic influx by directly controls key enzymes 
involved in glycolysis pathway such as Glucose transporter, Hexokinase and Phosphofructokinase. The 
tyrosine kinase activation inhibits the enzyme pyruvate kinase M2, thus making the glycolytic 
intermdiates available for biosynthesis of macromolecules. Presence of TP53, a tumor suppressor 
decreases the influx of glycolytic intermediates into PPP pathway, thus reduces proliferation in response 
to stress. The tumor suppressors are shown in red, and oncogenes are in green and key metabolic 
enzymes are shown in blue.  
B 
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Enhanced glycolysis and lipid biosynthesis is characteristic feature of cells with high 
metabolic demand. Studies show that intermediates of glycolysis and TCA cycle are 
precursors for many macromolecular biosynthetic pathways (Fig. 6B). For instance, 
glucose along with many other amino acids are the precursors for pentose 
phosphate pathway (PPP), the metabolic pathway that generates nucleic acids; 
glycolytic intermediates are precursor substrates for fatty acids and non-essential 
amino acids biosynthesis (Bauer et al., 2005; Deberardinis et al., 2008.; 
Hatzivassiliou et al., 2005; Kuhajda et al., 1994; Pizer et al., 1996). Thus, suggesting 
that enhanced aerobic glycolysis in cancer or proliferating cells cater to metabolic 
needs of the cell. 
 
Metabolic reprogramming in cancer cells is caused by activation of certain 
oncogenes such as PIK3CA, inactivation of tumor suppressors such as TP53, and 
sustained aerobic glycolysis (Ward and Thompson 2012; Babbar and Sheikh, 2013; 
Dang, 2012; Hanahan and Weinberg, 2011; Maroon et al., 2015; Seyfried et al., 
2011; Solaini et al., 2010). Known inducers of metabolic reprograming in glioma are 
briefly discussed below:  
 
(i) Cancer cells adapt to hypoxic conditions by stabilizing hypoxia-inducing factors 
(HIF1 and HIF2). Stabilization of HIF factors occurs not only during hypoxic 
conditions but also during inactivating mutations in tumor suppressors. The HIF 
factors regulate numerous genes involved in glycolytic pathways (Kucharzewska et 
al., 2015; Lu et al., 2002; Xiang et al., 2011; Zhou et al., 2011). Stabilization of HIF 
factors thereby triggers the glycolytic switch.  
 
(ii) Mutations in IDH1, key metabolic enzyme involved in the conversion of isocitrate 
to α Ketoglutarate (α-KG) in TCA cycle, causes gain of a novel enzyme function that 
converts isocitrate into 2 hydroxy glutarate (2HG). This alters mitochondrial 
respiration in the cells. Over 80% of the LGGs are mutated for IDH1, which results in 
dysfunctional oxidative phosphorylation in gliomas (Mustafa et al., 2014; Wolf et al., 
2010 ; Zhang et al., 2013).  
(iii) Constitutively active RTK receptor genes EGFR, PDGFR or amplification of 
PIK3CA, induce tumor proliferation. Activation of PI3K/Akt pathway targets mTOR, a 
major downstream cell metabolism regulator that regulates key genes involved in 
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glycolysis. Activation of mTOR, a cell metabolism regulator, triggers the glycolytic 
switch (Beckner et al., 2005; Elstrom et al., 2004; Tanaka et al., 2015).   
(iv) Myc is an important regulator of growth factors that controls cell proliferation. Myc 
directly regulates metabolic enzymes involved in glutamine uptake. Myc is 
overexpressed in GBM thereby contributes to Warburg effect in glioma cells (Annibali 
et al., 2014). 
 
(iv) TP53, also known as the guardian of the genome, is an important negative 
regulator of cell proliferation. During cellular stress, TP53 decreases the influx of 
glycolytic intermediates into metabolic pathways such as in PPP thereby reducing 
cells ability to proliferate. Thus, loss of TP53 results in constant influx of glycolytic 
intermediates that are precursor substrates to many macro-molecular biosynthesis. 
Loss of function mutation in TP53 is a frequent event in GBM (Annibali et al., 2014).  
1.7. MITOCHONDRIA    
Mitochondria are small, semi-autonomous double membrane organelles that cater to 
bioenergetic needs in the cell. Therefore, they are also known as the powerhouse of 
cell. These organelles are hub to many biosynthetic pathways and play a crucial role 
in regulating cell metabolism (Harbauer et al., 2014; Kornmann and Walter, 2010; 
Scheffler, 2007). The functional importance of mitochondrial membranes and the 
matrix within are detailed below:  
 
The outer mitochondrial membrane (OMM) is lipid bilayer similar to cellular plasma 
membrane. It contains large number of integral membrane proteins called porins that 
allow the transport of molecules between cellular cytosol and mitochondria. In 
addition, the OMM hosts a range of enzymes including monoamine oxidase, NADH-
cytochrome c reductase that participate in fatty acid biosynthesis, oxidation of 
epinephrine (neurotransmitter), and degradation of tryptophan. The OMM can attach 
to the endoplasmic reticulum (ER). This helps in maintaining mitochondria-ER 
calcium signaling, as well as in lipid transfer between the two organelles. The inner 
mitochondrial membrane (IMM) is compartmentalized into folded junctions called the 
cristae. The IMM hosts a range of enzymes including the respiratory super 
complexes (RSC) (I-IV) and the ATP synthase. Therefore, IMM is the primary site for 
mitochondrial respiration (OXPHOS). Mitochondrial matrix enclosed by IMM contains 
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mitochondrial genome and hosts TCA or Krebs cycle. In addition, the matrix often 
remains filled with enzymes that are required for TCA cycle and fatty acid oxidation. 
Because of their key role in regulating cell metabolism and survival, they control 
major cellular functions including cell growth, invasion, differentiation, and death 
(Agorreta et al., 2014; Ahn and Metallo, 2015; Antico Arciuch et al., 2013).     
  
1.7.1. Mitochondrial dynamics 
 
Mitochondrial organelles are highly dynamic in nature. They undergo permanent 
cycles of fusion and fission. Fission serves to generate new mitochondria, through a 
process called mitochondrial biogenesis, and to eliminate dysfunctional mitochondria 
by the process termed mitophagy (Chen and Chan, 2009; Twig et al., 2008).  
 
Mitochondria contain their own genome that is highly susceptible to mutations. 
Mitochondrial fusion and fission cycles allow efficient mixing of mitochondrial DNA 
content, and are required for quality control of the organelles in order to maintain 
mitochondrial genome integrity (Ni et al., 2015). Mitochondrial dynamics are tightly 
regulated by fusion-fission machinery. Disruption of fission-fusion balance alters cell 
metabolism (Babbar and Sheikh, 2013; Boland et al., 2013). 
 
1.7.1.1. Molecular machinery  
 
The subtle balance between fission and fusion cycles is tightly controlled by large 
GTPases in the dynamin family that are evolutionarily conserved. The fission and 
fusion processes involve the division and fusion of mitochondrial membranes. 
GTPases mitofusins (MFN1 and MFN2) and optic atrophy 1 (OPA1) are principle 
regulators of mitochondrial fusion. Mitofusins help the organelles to tether and fuse 
their OMM while OPA1 regulates the fusion of IMM. In addition, OPA1 governs 
mitochondrial cristae remodeling and helps to maintain the membrane potential 
gradient required to carry out the mitochondrial respiration in the organelles (Frezza 
et al., 2006; Olichon et al., 2003). In the cristae junctions, OPA1 holds cytochrome c, 
an important initiator of mitochondrial apoptotic pathway. The release of cytochrome 
c triggers the caspase cascade causing cell death (Cipolat et al., 2006.; Olichon et 
al., 2003; Patten et al., 2014).  
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Stimuli like decreased energy status; cellular stress and apoptosis activate 
mitochondrial fission. A number of fission factors such as Mid 49, 51 and Mitofusin 
fission factor (MFF) together with Fission factor 1 (Fis1) recruit Dynamin-related 
protein 1 (DRP1) or Dynamin like protein 1 (Dnm1) from the cytosol to sites on ER 
that are in contact with OMM (Frank et al., 2001; Smirnova et al., 2001; Youle et al., 
2012). Recruited DRP1 then forms ring like clusters around the mitochondrial 
membranes and helps to pinch off the fused organelles by constriction resulting in 
mitochondrial fission (Fig. 7) (Westermann, 2012).  
 
 
                                                                                                           Mandemakers et al., 2007 
Fig 7. Simple schematic overview of mitochondrial fusion-fission components: A. Mitochondrial 
fusion – the Mitofusins (MFN1 and MFN2) regulate the fusion of OMM. The Optic Atrophy 1 (OPA1) 
located on the IMM and regulates the fusion of IMM. B. Mitochondrial fission – Dynamin related Protein 
(DRP1) or Dnm1l is recruited to ER, that interacts directly or indirectly with Fission factor 1 (FIS1). The 
DRP1 forms a coating surrounding the elongated mitochondria and helps to constrict and pinch off the 
organelles. Core proteins involved in the mitochondrial involved in fission-fusion process are shown in 
the schematic diagram. 
 
1.7.2. Mitochondrial dynamics and cell invasion 
 
Mitochondrial fission and fusion play important roles in cellular processes such as 
maintaining calcium homeostasis, generation and distribution of ATP, generation of 
ROS, and cell metabolism. Thus, mitochondria represent the central metabolic 
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organelle, as they coordinate cellular metabolism and cell response to a given stimuli 
(Muliyil and Narasimha, 2014; Park et al., 2012; Xie et al., 2015).  
 
1.7.2.1. Increased levels of ROS contribute to tumor cell invasion   
During OXPHOS, electrons are delivered through mitochondrial respiration super 
complexes (RSC) that establish a proton gradient, which facilitates ATP synthesis. 
However, during ETC, electrons escape from the RSC, especially from complex I 
and III and reacts with oxygen to form superoxide radicals (ROS). Under 
physiological conditions appropriate levels of ROS are required to ensure redox 
balance and proliferation signals in the cell (Pelicano et al., 2003). Enhanced ROS 
production primarily from the mitochondria is one of the key features observed in 
cancer cells (Boland et al., 2013). This is mainly attributed to inefficient electron 
transport during the mitochondrial respiration, enhanced metabolic demand in the 
cells, reduced ROS scavenging and altered mitochondrial dynamics (Schumacker 
2006; Hamanaka and Chandel 2010; Sena and Chandel 2012). The accumulation of 
ROS causes intracellular damages like DNA damage due to oxidation, inactivation of 
enzymes such as PTEN, protein oxidation. In fact, increased accumulation of ROS 
promotes mitochondrial fission and triggers the release of cytochrome c from IMM 
(Yu et al., 2005). Several studies suggest that enhanced ROS production in Hela, 
glioma, mouse embryonic fibroblasts, cortical neuronal cultures promotes cell 
invasion, while beyond the tolerable limits induces autophagy in the cell (De Vos et 
al., 2005; Liot et al., 2009; Pletjushkina et al., 2006; Westermann, 2012; Kolli-
Bouhafs et al., 2014). In fact, in 2014, using multiple breast cancer cell lines such as 
4T1,B16F10 and MDA-MB231, and xenograft mouse model, LeBleu et al. 
demonstrated that mitochondrial ATP is required for breast cancer cell invasion 
(LeBleu et al., 2014). Overall, these observations suggest that accumulation of ROS 
due to imbalance of mitochondrial dynamics or defects in mitochondrial respiration 
contributes to cancer cell invasion (Boland et al., 2013).  
 
1.7.2.2. Metabolic enzymes contribute to glioma invasion  
 
In 2005, Yu et al. demonstrated in vitro using rat liver cells and myoblasts that high 
glycolytic influx in these cells resulted in enhanced ROS production and promoted 
mitochondrial fission in the cells (Yu et al., 2005). In fact, Glucose-6-phosphate 
(G6P), a key enzyme of glycolysis pathway that is over-expressed in GBM, 
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contributes to glioma invasion (Abbadi et al., 2014). Lactate dehydrogenase A (LDH-
A) converts pyruvate to lactate during aerobic glycolysis. Baumann et al. showed that 
lactate induces glioma cells to secrete TGFβ2 that enhances glioma migration. 
Phoshoglycerate dehydrogenase (PHGDH) is a key enzyme that utilizes the 
intermediates from glycolysis pathway for serine biosynthesis, and is highly 
expressed in astrocytic tumors and more aggressive cancer types (Liu et al., 2013). 
Inhibition of this enzyme down-regulates expression of VEGF, MMP2 and reduces 
overall aggressiveness of glioma cells by reducing proliferation and invasion. Thus, 
increased expressions of metabolic enzymes contribute to glioma invasion 
(Baumann et al., 2009, Abbadi et al., 2014, Liu et al., 2013). 
 
1.8. PRELIMINARY OBSERVATIONS  
Astrocytomas, oligoastrocytomas, GBM, and to some extent oligodendrogliomas 
show diffused infiltration irrespective of their WHO grade (Louis et al., 2007). In order 
to study the infiltrative behavior and identify genes involved in glioma invasion, 
glioma biopsies were classified based on their invasive ability and subjected to 
transcriptomic analysis.  
Measuring thickness of the infiltration zone (IZ) surrounding the tumor mass, 
visualized using magnetic resonance imaging (MRI) can help assess the infiltrative 
nature of glioma. Gliomas were classified based on their infiltration grade (IG): IG-1 
(0-3 mm), IG-2 (3-10 mm), and IG-3 (>10 mm). Transcriptomic analyses on glioma 
biopsies (n=20), showed that mRNA levels of BEHAB, a known inducer of glioma 
invasion, SOX2 and HEY1 correlate with increasing IG (unpublished data). This 
association suggested a potential role for SOX2 and HEY1 in glioma invasion (Fig. 
8).  
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Fig 8. Glioma classification based on their infiltration grades (IG): Top: MRI allows classification of 
tumors based on the thickness of their infiltration zone (IZ). Based on the IZ (the distance between 
tumor periphery and core) gliomas were classified into IG I (0-3 mm), IG II (3-10mm) and IG III (10mm). 
Bottom: Gene expression analyses on glioma biopsies suggest that BEHAB, SOX2 and HEY1 mRNA 
levels correlate with high infiltration grades. BEHAB/Brevican is an ECM molecule and a known inducer 
of glioma invasion and is used as a positive control to validate the analyses. Gene expression analysis 
was performed on 20 glioma samples in total and is an unpublished work of Prof Dr med Luigi Mariani.    
 
1.9. SOX2  
 
SOX2 (Sex determining region of Y chromosome- related High Mobility Group (HMG) 
box 2) is a transcription factor that regulates cell fate determination and 
differentiation. SOX2 is expressed in the embryo and is required to maintain 
embryonic cell stemness. In neural progenitors, expression of SOX2 prevents 
neuronal differentiation and maintains neural cell stemness (Graham et al., 2003; 
Heavner et al., 2014). The 32 KDa transcription factor has numerous effector genes 
and is a master regulator of many vital cellular functions such as cell survival and cell 
differentiation (Agathocleous et al., 2009; Ding et al., 2012; Hawkins et al., 2014).  
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In developmental mouse model, genetic ablation of SOX2 is embryonic lethal. 
Conditional knockout of SOX2 at various developmental stages results in defective 
stem cell proliferation, neural crest cell migration, failed wound healing, and brain 
abnormalities (Ferri et al., 2004; Pevny and Nicolis, 2010; Que et al., 2009; Zenteno 
et al. 2005). Aberrant SOX2 expression is associated with many developmental 
disorders like progressive hearing loss, developmental malformations of the eye, and 
is also observed during cancer development (Hever et al., 2006; Rodriguez-Pinilla et 
al., 2007).  
 1.9.1. Oncogenic role of SOX2  
 
Gain of SOX2 function is oncogenic in many epithelial cancer types (Bass et al., 
2009; Justilien et al., 2014; Watanabe et al., 2014). Focal amplification of SOX2 
locus (3q26.3) is frequently observed in GBM and in many other solid cancers such 
as squamous and small cell lung carcinoma (23-27%), esophagus (15%), and breast 
cancer (8-10%). Consistent with its crucial role in stem cell proliferation, SOX2 gene 
amplification is strongly associated to tumorigenesis (Chen et al., 2014).  
 
Recently, it was shown that SOX2 expressing cancer stem-like cells are the founding 
population of tumor relapse after treatment with anti-mitotic drugs and contributes to 
therapy-induced chemoresistance in breast cancer, medulloblastoma, and squamous 
cell carcinoma (Boumahdi et al., 2014; Piva et al., 2014; Vanner et al., 2014).  
 
1.9.2. SOX2 contributes to tumor cell invasion 
 
Literature suggests conflicting roles for SOX2 in cancer cell migration, including in 
the field of glioma, as evidence support overexpression as well as reduced SOX2 
mRNA levels, contribute to cancer cell invasion and migration (Annovazzi et al., 
2011; Feng et al., 2013; Stolzenburg et al., 2012). Overall, SOX2 expression is 
correlated with tumor cell motility (Girouard et al., 2011). Although the involvement of 
SOX2 is clearly depicted in cancer invasion, the molecular mechanism remains 
elusive.  
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1.10.  HEY1 
 
HEY1 (Hairy/Enhancer of Split Related with YRPW motif 1) belongs to basic-helix-
loop-helix-orange (bHLH) family of transcription factors. Members of the family of 
Hairy/Enhancer of split (HES 1-7 and HEY-1,2 and L) are transcriptional repressors. 
The HES and HEY family of bHLH transcription factors are direct transcriptional 
targets of Notch signaling pathway. HEY1 is overexpressed in GBM and its 
expression in GBM correlates with tumor grade and progression.  
 
The role of HEY1 and its contribution to glioma invasion is discussed in detail in 
Chapter II of this thesis.  
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1.11. AIM OF THE THESIS  
 My PhD project has been devoted to understand the molecular mechanisms 
involved in glioma invasion. Our preliminary observations on human glioma biopsies 
showed that SOX2 and HEY1 mRNA levels correlate with glioma invasiveness. 
Thus the aims of my project have been:  
1. Chapter I: The gene for SOX2 localizes to 3q26.3 in the human genome, a 
region frequently amplified in glioma. The locus 3q26-29 contains key glioma 
oncogene PIK3CA, and mitochondrial dynamics regulators MFN1 and OPA1. 
Therefore, our aim was to investigate (i) whether 3q26-29 genes participate 
in glioma invasion and (ii) whether SOX2 is a regulator of this gene cluster. 
 
2. Chapter II: To explore the role of HEY1, an effector of notch signaling 
pathway, in glioma invasion. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 53 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
  
Contribution of 3q26-29 gene cluster to 
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2. CHAPTER I - STRATEGIC LOCALIZATION OF SOX2   
2.1. 3q26-29 gene cluster     
 
The gene for SOX2 localizes to 3q26.3 in the human genome, in close proximity to 
the glioma oncogene PIK3CA (2.1Mb upstream of SOX2 gene), and the genes that 
regulate mitochondrial fusion MFN1 (2Mb upstream) and OPA1 (12Mb downstream) 
(Fig. 9).   
 
 
Fig 9. Schematic representation of strategic localization of SOX2: SOX2 colocalizes with PIK3CA, 
gene for key signaling component of RTK/PI3K pathway, MFN1 and OPA1, regulators of the 
mitochondrial fusion process.   
  
  
  
 56 
 
2.2. PIK3CA     
2.2.1. PIK3CA during development 
 
During glial cell development, PI3K signaling pathway is activated by brain derived 
neurotrophic factors (BDNF), glial cell derived neurotrophic factor (GDNF), and 
insulin-like growth factors (IGF). The PI3K signaling pathway promotes the 
production of myelin in oligodendrocytes and schwann cells (Kristjan et al., 2005). 
The PI3K-Akt signaling pathway mediates cell proliferation and survival by regulating 
glucose metabolism in the cells (Danielsen et al., 2014). 
 
2.2.2. Oncogenic role of PIK3CA 
 
PIK3CA is a well-characterized oncogene that is amplified in many cancer types 
(Katso et al., 2001; Shayesteh et al., 1999). In gliomas, PIK3CA is mutated and 
amplified in over 14-17% of the samples (The Cancer Genome Atlas Research 
Network, 2008). PIK3CA often harbors somatic missense activating mutations that 
lead to permanent activation of the PI3K signaling pathway (Gallia et al., 2006; 
Samuels et al., 2004). Loss of PIK3CA reduces glioma cell proliferation (Weber et al., 
2011).  Activating PIK3CA mutation via the Akt – mTOR signaling pathway induces 
cell proliferation and is associated with colorectal cancer cell invasion (Samuels 
2005).  
 
2.2.3. PIK3CA contributes to tumor cell invasion 
 
PIK3CA, like SOX2, is associated with cancer cell invasion. However, the role of 
PIK3CA is not well elucidated. In 2005, Samuels et al. showed that in colorectal 
cancers, permanent PIK3CA activation leads to enhanced cancer cell motility which 
was inhibited by LY294002, a general PI3K inhibitor. However in 2015, Caino et al. 
showed that, glioma cells and prostate cancer cells treated with GDC-0941, PIK3CA 
inhibitor, became highly invasive. The mechanism behind such activation or inhibition 
of cell motility is yet to be explored (Caino et al., 2015; Samuels et al., 2005).  
 57 
2.3. MFN1 AND OPA1   
MFN1 and OPA1 are core regulators of mitochondrial fusion (detailed in section 
1.7.1). Therefore, they govern mitochondrial dynamics. In migrating lymphocytes, 
mitochondria localize between the nucleus and the trailing edge of the migrating 
cells. Disrupting the functions of MFN1 and OPA1 alters the migrating capacity of the 
cells (Campello et al., 2006). In epithelial cells, down-regulation of OPA1 resulted in 
increased mitochondrial fission and increased cell migration velocities during 
chemokine-induced epithelial cell migration. As a consequence of knockdown 
mitochondrial morphology is permanently altered and random cell motility is induced 
(Fig. 10) (Campello et al., 2006; Desai et al., 2013). Many studies show that the 
fission-fusion balance is frequently disturbed in cancer cells. This perturbation is 
associated with tumor cell motility (Lebleu et al., 2014; J. Zhao et al., 2013).  
 
 
                                                                                           Adapted from Campello et al., 2006  
Fig 10. Mitochondrial fusion abolishes lymphocyte migration: A. Upon chemotactic stimulation with 
chemokine, CXCL12, DRP1 overexpression (OE) mediated mitochondrial fission promotes cell 
polarization in Jurkat T cells, whereas OPA1-OE mediated mitochondrial fusion abolishes cell 
polarization ability in the cells B. Summary of migration assay showing enhanced mitochondrial fission 
(DRP1 OE) in Jurkat T cell promotes cell migration which was abolished in cells exhibiting enhanced 
mitochondrial fusion (OPA1 OE).     
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2.4. GENOMIC ALTERATIONS AT 3q26-29 LOCUS IN GLIOMA 
 
2.4.1. Glioma samples from TCGA repository 
 
Comprehensive analysis of the GBM genome, based on copy number analyses 
(CNA) on 543 GBM samples, reveal significant focal amplification at 3q26 and 
deletion at the 3q29 locus (Brennan et al., 2013). Similar patterns are observed in 
LGG (upon CNA on 717 LGG samples). Although the focal amplification at 3q26 and 
deletion at 3q29 were significant, they are less pronounced as compared to GBM 
(Suzuki et al., 2015) (Fig. 11). 
 
 
Fig 11. 3q26-29 genetic alterations in glioma: Somatic landscapes showing genetic alterations in 
gliomas, highlighted are 3q26 (amplification), 3q29 (deletion), EGFR (amplification), and CDKN2A/2B 
(deletion). A. Schematic representation of recurrent copy number aberrations in 543 samples in GBM B. 
Schematic representation of recurrent copy number aberrations in 717 samples in LGG (Grade II-III). 
Statistically significant focally amplified (red) and deleted (blue) regions are shown in the plot.  
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2.4.2. Glioma biopsies from BTB tumor bank 
 
A total of 68 GBM and 32 LGG are used for copy number analysis (CNA) of 3q26-29 
genes from BTB-Lab tumor bank. CNA show that focal amplification of SOX2 
(3q26.3) is observed in 35% of GBM and in 17% of LGG samples. Both GBM and 
LGG show homozygous deletion of OPA1 (29% in GBM and 36% in LGG). A small 
population of 2-8% shows amplification of PIK3CA, MFN1 or OPA1, while none was 
observed in LGG. In GBM and LGG, over 7% and 17% samples harbor SOX2 
deletion. These copy number variations (CNVs) in 3q26-29 genes are significant 
compared to well characterized somatic alterations such as EGFR amplifications 
(53%) and CDKN2A (33%) deletions in GBM (Fig. 12). In summary, glioma samples 
show significant genetic alterations at 3q26-29 loci. Focal amplification of SOX2 
(3q26.3) and homozygous deletion of OPA1 (3q29) are the most frequent genetic 
aberrations observed in this region.  
 
 
 
Fig 12. 3q26-29 genetic alterations in glioma samples (BTB tumor bank): Red bars indicate 
amplifications and blue bars indicate deletions. Left. Copy number analysis on GBM samples (n=68). 
The significance of these alterations in 3q26-29 genes can be estimated compared to frequency of 
EGFR amplifications and CDKN2A deletions (major somatic alterations known in GBM) in our samples. 
Right. Copy number analysis on LGG samples (n=32) significant alterations in 3q26-29 genes. 
(Experiment was performed by Cristobal Tostado and data analysis by PD Dr Jean-Louis Boulay). 
Copy number alterations in GBM  Copy number alterations in LGG  
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2.5. CHAPTER I – WORKING HYPOTHESIS 
 
Given that the hallmark feature of gliomas is their infiltrative nature, which results in 
tumor malignancy (inducing angiogenesis, therapy resistance and tumor relapse), 
understanding the molecular mechanisms governing glioma invasion will help in the 
development of novel strategies targeting glioma progression. Invasive gliomas 
display high mRNA levels of the gene for the transcription factor SOX2. SOX2 
localizes to 3q26 in the human genome along with PIK3CA, MFN1 and OPA1, a 
region that is significantly altered in gliomas. These genes (are known to) contribute 
to cancer cell invasion.  
 
Therefore we hypothesized that:  
 
1. 3q26-29 genes participate in glioma invasion   
2. SOX2 regulates the 3q26-29 gene cluster and contributes to the invasive 
phenotype of the cells   
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3. CHAPTER I - RESULTS   
 
3.1. Selection of SOX2-expressing cell lines  
3.1.1. SOX2 expression and localization in glioma cell lines 
 
Our preliminary observations suggested that SOX2 was overexpressed in invasive 
gliomas (Fig. 13). In order to investigate the role of SOX2 in glioma invasion, we 
selected glioma cell lines based on SOX2 expression levels. We first analyzed SOX2 
mRNA levels in seven glioma cell lines by qRT-PCR. Results showed that LN405 cell 
line had the lowest SOX2 mRNA levels; hence, data from other cell lines were 
normalized using LN405 levels as a baseline. U373, LN319, LN215 and LN401 
expressed over 5-, 7- and 11- fold higher SOX2 mRNA levels compared to LN405, 
respectively (Fig. 13A). We next performed Western blot analysis in order to estimate 
SOX2 protein levels. U373 and LN319 were the only SOX2 protein expressors 
among the cell lines studied (Western blot was performed by Alexandra Gerber) (Fig. 
13B).  
 
Nuclear localization of SOX2 indicates that the transcription factor is functionally 
active (Baltus et al., 2009). Immunofluorescence staining of glioma cells for SOX2 
and examination by confocal microscopy revealed that LN319 cells had a higher 
number of cells exhibiting nuclear localization rather than cytoplasmic. U373 cells 
showed both nuclear and cytoplasmic SOX2 localization, whereas in LN215 cells 
SOX2 was predominantly in the cytosol (Fig. 13C).  
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3.1.2. Expression of mitochondrial fusion proteins in   
          glioma cell lines 
 
We next performed Western blot analysis to study the expression of mitochondrial 
fusion proteins in glioma cells. Mitofusins (MFN1, MFN2) and Optic Atrophy 1 
(OPA1) are regulators of mitochondrial fusion. Our results showed that glioma cell 
lines have variable expression levels of mitochondrial fusion proteins compared to 
gray matter (GM) and white matter (WM) controls (Fig. 14). This Western blot was 
performed at the Institute of Pathology at the University Hospital of Basel, 
Switzerland under the guidance of Dr Donato D’Alonso. 
 
 
 
Based on SOX2 expression (mRNA and protein) and protein levels of MFN1 and 
OPA1, we selected LN319 and U373 glioma cell lines for further experiments. 
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3.2. Genetic inactivation of 3q26-29 genes  
 
In order to study the function of these genes in both selected cell lines, 3q26-29 
genes were individually knocked-down (KD) using lentiviruses expressing short 
hairpin RNA (shRNA) against SOX2, MFN1, OPA1 and PIK3CA, respectively. We 
used 5X104 infectious units (IFU) of virus. Glioma cells transduced with lentiviruses 
expressing GFP were used to measure transduction efficiency. The percentage of 
GFP positive cells was estimated by fluorescent activated cell sorting (FACS) in both 
cell lines to be over 80% in LN319 and 60% in U373, respectively (Fig. 15 and 16). 
Puromycin was used for long-term selection of KD cells. 
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In LN319 cells, we achieved over 6-, 8-, 23- and 5-fold decrease in mRNA levels of 
SOX2, MFN1, OPA1 and PIK3CA, respectively (Fig. 17A Top) and in U373 cells, 
decrease of 11-, 6-, 1.5- and 2-fold, respectively (Fig. 17B Top). KD of 3q26-29 
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genes were confirmed at the protein level using Western blot (Fig. 17A and 17B 
Bottom). The cells KD for the 3q26-29 genes will henceforth be designated as sh 
SOX2, sh MFN1, sh OPA1 and sh PIK3CA.  
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3.3. 3q26-29 gene inactivation alters cell motility  
 
 
To assess the invasive potential of KD cells we performed matrigel-coated Boyden 
chamber invasion assay over 16 hours. Invasive cells were stained and counted.  
 
Overall, we observed that LN319 were less invasive compared to U373 cells. The 
shSOX2 cells exhibited enhanced invasive phenotype compared to the sh scrambled 
control cells in the two cell lines. We observed over 2.5-fold and 3-fold increase in 
invasive cell numbers for LN319 and U373 respectively, compared to sh scrambled 
control cells (Fig. 18 Top).  
 
Similarly, gene inactivation of the other three 3q26-29 genes (MFN1, OPA1 and 
PIK3CA) resulted in over 2-fold increase in invasive cell numbers in LN319 cells 
compared to sh scramble controls (Fig. 18 Bottom). On the other hand, while 
shMFN1 cells in U373 displayed increased relative invasiveness, shOPA1 cells in 
U373 did not result in a significant increase in invasion (Fig. 18 Bottom).  
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In order to assess the migratory phenotype in KD cells, we performed wound-healing 
assays. Cells were allowed to migrate into scratch wounds created using 200μl 
pipette tips. The assays were carried out over 24 hours on a Cell IQ analyzer. The 
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percentage of wounded area closed at 24 hours was used as the final readout for the 
assay. 
 
We observed that LN319 cells migrated slower than U373 cells. KD of SOX2 resulted 
in an enhanced migratory phenotype in the two cell lines. We observed that shSOX2 
cells covered 1.5-fold more area during the assay compared to sh scrambled control 
LN319 and U373 cells (Fig.19 Top.).  
 
Similarly, gene inactivation of MFN1, OPA1 resulted in an enhanced migratory 
phenotype in the two cell lines (Fig. 19 Bottom). We observed that KD of these genes 
in LN319 cells resulted in 1.5-fold more area coverage compared to sh scrambled 
control cells. Although we observed that shPIK3CA cells covered over 1.5-fold more 
wound area, the results were not statistically significant.  While, in U373, consistent 
with our previous observations, we found that shOPA1 cells showed over 1.5-fold 
more wound area coverage compared to sh control cells. The wound closure by 
shMFN1 cells was however, not significantly different compared to sh scrambled 
control cells.  
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3.4. SOX2 and PIK3CA KDs reduce glioma proliferation  
 
 
Although SOX2 and PIK3CA are oncogenes and are known inducers of tumor 
proliferation, the KD effect of MFN1 and OPA1 on cell proliferation remains to be 
determined in glioma cells (Santini et al., 2014, Meyer et al., 2013, Hagey and Muhr 
2014, Samuels et al., 2005). We therefore investigated the effect of MFN1 and OPA1 
KD in our glioma cell lines using proliferation assays. Cells were seeded with sparse 
density and imaged over 6 days using the Cell IQ image analyzer. Relative 
proliferative index was calculated with respective to time (t=0) for each condition. 
These assays were performed in the laboratory of Prof Dr Primo Schär at DBM 
Mattenstrasse, University of Basel. 
 
We observed that LN319 cells proliferated slower compared to U373 cells. In LN319 
and U373 cell lines, shSOX2 and shPIK3CA cells showed strong reduction in 
proliferation, compared to the respective sh scramble controls (Fig. 20 Top).  
 
Consistent with the expected role of OPA1, shOPA1 cells in LN319 showed reduced 
proliferation rate. In contrast shOPA1 and shMFN1 cells, in U373 showed 
significantly enhanced glioma proliferation (Fig. 20 Bottom).  
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3.5. KDs of 3q26-29 genes induce mitochondrial fragmentation  
 
 
KD of mitochondrial fusion genes (MFN1, MFN2, OPA1) induces mitochondrial 
fragmentation, which is a prerequisite for cancer cell invasion (Campello et al., 2006, 
Chen et al., 2003, Zhang et al., 2011). We therefore investigated mitochondrial 
morphology in the KD cells. To study live mitochondrial dynamics, cells were stained 
with mito-tracker green that labels mitochondria and Hoechst that labels the nucleus. 
 
This analysis reveals that sh scrambled control cells in both cell lines as estimated by 
eye, exhibited elongated mitochondria. In contrast, shOPA1 cells exhibited 100% 
mitochondrial fission (mitochondria existed as small and round organelles), whereas 
KD of MFN1 resulted in partial mitochondrial fission (around 60% of mitochondria 
existed as individual organelles, while the rest remained fused). KD of PIK3CA and 
SOX2 had a phenotype reminiscent of mitochondrial fission, as they appeared to be 
similar to shMFN1 cells in LN319 and U373 cells (Fig. 21).  We are currently 
quantifying our results to determine the extent of fission in shSOX2 and sh PIK3CA 
cells.  
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3.6. SOX2 is a potential activator of 3q26-29 gene promoter  
 
3.6.1. KD of SOX2 reduces expression of 3q26-29 genes 
 
 
Since SOX2 is a transcription factor, we hypothesized that SOX2 could trans-activate 
the 3q26-29 genes through regional regulation. It has been observed in many cases 
that genes co-localized together could regulate each other. 
 
qRT-PCR analysis on up to 10 individual colonies of shSOX2 cells in LN319 and 
U373 glioma cells were performed. KD of SOX2 reduced mRNA levels for MFN1, 
OPA1 and PIK3CA between 1.5- to 3- fold in both cell lines (Fig. 22A). Protein levels 
quantified using Western blot, were consistent with corresponding mRNA levels for 
OPA1 and MFN1 in both cell lines (Fig. 22B). However, reduction in PIK3CA protein 
level was inconclusive (data not shown). 
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3.6.2. Potential SOX2 binding sites on upstream region of   
          3q26-29 genes  
 
Since KD of SOX2 reduced expression of PIK3CA, MFN1 and OPA1 in the two cell 
lines, we therefore looked for potential SOX2 binding sites on the upstream region of 
3q26-29 genes. Fig. 23A. is a schematic representation of the candidate genes co-
localized on 3q26-29 locus in the human genome.  
 
The SOX2 binding motif was obtained from JASPAR database (Fig. 23B). Conserved 
SOX2 binding motifs between mouse and human on up to 2000 bp upstream of 
3q26-29 genes were searched for. Potential SOX2 binding sites were found in the 
promoters of SOX2 (8 sites), PIK3CA (1 site), MFN1 (1 site) and OPA1 (2 sites) (Fig. 
23C). The panel on the right in Fig. 23C is a schematic representation of the 
identified binding sites with respect to distance from the transcription start site and 
orientation of the binding.  
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3.6.3. SOX2 binds upstream of 3q26-29 genes in glioma cells  
 
 
In order to test whether SOX2 binds to the upstream region of 3q26-29 genes 
(detailed in section 3.6.1), we performed chromatin immuno-precipitation (ChIP) 
assays on genomic DNA fragments containing the potential binding sites. Immuno-
precipitations (IP) were performed on sh scramble control and shSOX2 cells using 
anti-SOX2 and goat anti-IgG antibodies (to estimate nonspecific binding of DNA to 
beads).  
 
In LN319, we observed the IP of 4-chromatin fragments containing the predicted 
binding sites. This IP was reduced in shSOX2 cells. IP of chromatin fragments in 
LN319 shSOX2 cells, showed 4-fold decrease in amount of fragments containing 
MFN1, a 2-fold decrease in the amount of fragments containing OPA1 (site 2 or 3),  
and a 2-fold decrease in chromatin fragments PIK3CA upstream regions carrying the 
potential binding sites compared to LN319 sh scrambled control cells (Fig. 24A Top). 
As we observed qRT-PCR signal (with IP’d chromatin fragments) only for SOX2 
binding sites 2 and 3 found in the upstream region of OPA1, these two sites have 
been analyzed with this assay. 
 
In U373 shSOX2 cells, we observed a 2.6-fold decrease in the amount of DNA 
precipitated when analyzed for the predicted MFN1 promoter site. Although we 
observed a decrease in the chromatin DNA IP of sh SOX2 when analyzed for the two 
regions containing the potential binding sites in OPA1, the observed results were not 
statistically significant, similar to that observed for PIK3CA (Fig. 24A Bottom).  
 
Thus our results show physical binding of SOX2 upstream of 3q26-29 genes in 
LN319. Although not statistically significant, ChIP data from U373 cells supports the 
observations made in LN319 cells.  
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We also predicted multiple SOX2 binding sites on the SOX2 promoter. In order to 
evaluate whether SOX2 binds to its own promoter, we performed the ChIP analysis 
with chromatin DNA IP samples in sh control and sh SOX2 cells in both cell lines. 
Primers were designed to amplify five regions upstream of SOX2, containing 
potential SOX2 binding sites, as indicated in Fig. 24B.  
 
In LN319 shSOX2 cells, we observed over 200-fold decrease in chromatin DNA IP 
when analyzed for region 5 (which contained most of the predicted binding sites) 
compared to sh control cells; whereas in U373 shSOX2 cells, we observed over 1.5-
fold and 2.5-fold decrease in chromatin DNA IP when analyzed for region 1 and 2 
(Fig. 24B). Although these results suggested that SOX2 could bind to its own 
promoter, these results were not statistically significant.  
 
3.6.4. SOX2 trans-activates 3q26-29 genes – preliminary 
results 
 
To test whether the association of SOX2 to genetic elements in the 3q26-29 
promoter region results in gene transcription activation, we are using a quantitative 
reporter gene assay based on luciferase activity. We constructed luciferase plasmids 
containing the putative promoter region of the 3q26-29 genes in front of the 
luciferase reporter gene. Since glioma cells are transfected with low efficiency, we 
used human embryonic kidney cells, HEK293.  
3.6.4.1. Experimental settings 
 
To maximize SOX2 expression, we transfected HEK293 cells with increasing 
amounts of flag-tagged SOX2 expression vector pMSCV-SOX2  (1,10,100 ng). After 
48 hours post transfection, proteins were extracted from the cells and Western blot 
analysis was performed on the lysates. SOX2 protein levels were higher in pMSCV-
SOX2 treated cells compared to mock transfected or parental control cells (Fig. 25A). 
We observed that transfection of HEK293 cells with over 10ng of pMSCV-SOX2 
vector did not show further increase in SOX2 expression. Therefore, these conditions 
were used for further transfection experiments. These experiments were performed 
under the guidance of Dr. Lionel Tintignac (from the lab of Prof. Michael Sinnreich, 
DBM, University of Basel). 
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3.6.4.2. Activation of PIK3CA promoter by SOX2 
 
In order to optimize the PIK3CA-Luc (PIK3CA promoter with Luc reporter gene) 
concentration for further experiments, we transfected increasing amounts of PIK3CA-
Luc (1,10,100 ng) in mock-treated as well as in SOX2 over-expressing HEK293 cells 
(10 ng pMSCV-SOX2). In this experiment, we observed that SOX2 overexpression 
resulted in 2-fold higher PIK3CA promoter activity compared to mock-treated (Fig. 
25B Left).  
 
To test whether SOX2 overexpression can increase PIK3CA promoter activity, we 
transfected increasing amounts of pMSCV-SOX2 (1,10,100 ng) while keeping the 
PIK3CA-Luc vector concentration constant (10ng). Consistent with previous 
observations, a 2-fold increase in the PIK3CA promoter activity was observed (Fig. 
25B Right).  
 
Thus, these experiments support the observation of a functional-physical association 
of SOX2 on PIK3CA upstream of that transcription initiation site (Fig. 25B Right). 
Whether the SOX2 binding site we suspect is indeed a cis-acting element of the 
PIK3CA promoter will be further tested using promoter constructs mutated at 
potential SOX2 binding sites. 
 
3.6.4.3. SOX2 trans-activates OPA1 promoter 
 
 
In order to optimize the OPA1-Luc (OPA1 promoter vector with Luc promoter gene) 
concentration for further assays, we transfected increasing amounts of OPA1-Luc 
(1,10,100 ng) in HEK293 cells in mock-treated as well as SOX2 over-expressing 
HEK293 cells (10 ng pMSCV-SOX2). SOX2 overexpression resulted in 7-fold higher 
OPA1 promoter activity compared to mock-treated (Fig. 25C Top).  
 
We next transfected HEK293 cells with increasing amounts of pMSCV-SOX2 
(1,10,100 ng) while keeping OPA1-Luc constant (10ng). Unfortunately, we did not 
observe differences in OPA1 promoter activity between mock-treated and SOX2 
overexpressing HEK293 cells. However quantification of OPA1 protein in HEK293 
cell lysates using Western blot of cell lysates suggested that OPA1 protein 
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expression was 2 fold higher compared to the mock-treaed controls (Fig. 25C 
Bottom).  
 
Hence, overall preliminary results from luciferase assay suggest that the physical 
association of SOX2 on PIK3CA and OPA1 promoters could potentially result in 
functional activation of these promoters (Fig. 25B Right).  
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4. CHAPTER I - DISCUSSION 
 
Invasiveness of gliomas contributes to the notorious nature of the tumor. The 
infiltrative nature of glioma cells is one of the primary causes of tumor relapse after 
surgery (Gaspar et al., 1992; Giangaspero and Burger, 1983). Thus, understanding 
molecular mechanisms that govern glioma cell invasion will help in the development 
of novel therapeutics for glioma treatment.  
Earlier gene expression analyses on glioma biopsies suggested that SOX2 mRNA 
was overexpressed in invasive gliomas. SOX2 is an oncogene, and an inducer of 
glioma proliferation (X. Fang et al., 2011; Gangemi et al., 2009). SOX2 mRNA 
expression levels correlate with tumor malignancy (Berezovsky et al., 2014; Li et al., 
2014; Neumann et al., 2011). The gene for SOX2 co-localizes with the oncogene 
PIK3CA and the mitochondrial fusion regulators MFN1 and OPA1, at 3q26-29 in the 
human genome. The region 3q26-29 is subjected to frequent genetic alterations in 
GBM and LGG (The Cancer Genome Atlas Research Network, 2008; TCGA, 2015;). 
Mitochondria are dynamic organelles that undergo constant fission-fusion cycles, a 
process that regulate cell proliferation, invasion and survival. Mitochondrial fission is 
required to establish cell polarity (Campello et al., 2006; Desai et al., 2013). Based 
on our observations and the importance of mitochondrial dynamics, we hypothesized 
that 3q26-29 genes contribute to glioma invasion. We used two human glioma cell 
lines to test this hypothesis.  
Our results show that the 3q26-29 genes contribute to glioma invasion. Further, we 
have accumulated arguments suggesting that SOX2 regionally regulates OPA1, 
MFN1 and PIK3CA to induce glioma invasion.  
 
4.1. The use of glioma cell lines 
 
Although qRT-PCR analysis showed that most glioma cell lines exhibit high SOX2 
mRNA levels, Western blot analysis revealed that expression of SOX2 protein was 
observed only in LN319 and U373 cells, showing that there is not necessarily a 
correlation between mRNA and protein levels of SOX2. Nuclear localization, 
indicative of functionally active SOX2, was observed in LN319 and U373 cells. 
Therefore, LN319 and U373 were chosen as appropriate glioma cell lines for further 
investigation (Table 1). 
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Overall, cellular assays revealed that U373 cells exhibited higher invasive (2.5-fold), 
migratory (≈2-fold) and proliferative (≈3-fold) behavior compared to LN319 cells. 
During migration assays, we observed that U373 cells exhibited polarized phenotype 
i.e. individual cells were migrating alone, as opposed to LN319 cells that displayed 
collective amoeboid migration. Thus, U373 cells were more aggressive than LN319 
cells. 
 
Despite quantitative differences in migratory, invasive and proliferative abilities 
between the two cell lines, our results from all experiments consistently show that KD 
of 3q26-29 genes in both cell lines resulted in a similar phenotype (Tables 2 and 3). 
We found that KD of 3q26-29 genes (SOX2, MFN1, OPA1 and PIK3CA) resulted in 
enhanced invasive and migratory behavior in both cell lines. In LN319 cells, KD of 
3q26-29 genes resulted in a 2 to 2.5-fold increase in cell invasiveness. Similarly in 
U373 cells we observed 3.5-fold increase in invasiveness of shSOX2 cells, and 1.5-
fold increase in case of the shOPA1 cells compared to sh scramble controls. A 
similar trend in migratory behavior was observed in both cell lines. We found that in 
LN319 and U373 cells KD of 3q26-29 genes resulted in over 1.5 times increased 
wound area closure compared to sh scramble controls. 
 
 In U373 cells, KD of MFN1 did not induce a significant increase in migration. It could 
be possible that MFN2 compensated for the KD.  In U373 cells, although KD of 
OPA1 resulted in 2-fold enhanced invasiveness, and KD of PIK3CA resulted in 
enhanced migratory phenotype, we found that these observations were not 
statistically significant. As LN319 cells were slower in cell migration and invasion 
compared to U373, it could be possible that altered cellular dynamics contribute to 
such variations. It is also possible that 24 hours were not sufficient to assess their 
motility in LN319, as their proliferation rate was observed to be over 3 days. Hence 
experiments could be performed over 48 or more hours to reduce such variations.  
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 LN319 U373 
SOX2 MFN1 OPA1 PIK3CA SOX2 MFN1 OPA1 PIK3CA 
Gene/protein 
Expression in 
the cell lines 
+++ + +  
To do 
++ ++ ++  
To do 
Table 1. Expression of 3q26-29-genes between LN319 and U373 glioma cell lines 
 KD of LN319 KD of U373 
sh SOX2 sh MFN1 sh OPA1 sh PIK3CA sh SOX2 sh MFN1 sh OPA1 sh PIK3CA 
Invasion 
vs sh control  
++ ++ ++ ++ +++ ++ 
 
+ 
ns 
 
To do 
Migration  
vs sh control 
+ + + + 
ns 
+  
ns 
+  
To do 
Proliferation 
vs sh control 
---  
To do 
--- --- --- ++ ++ --- 
Mitochondrial 
fragmentation 
vs sh control 
++ ++ +++ ++ ++ + +++ ++ 
Table 2. Comparison of KD effect of 3q26-29 genes between LN319 and U373 
 LN319 sh SOX2 U373 sh SOX2 
Gene 
expression 
SOX2 MFN1 OPA1 PIK3CA SOX2 MFN1 OPA1 PIK3CA 
mRNA levels in 
sh SOX2 cells ---   - -- -- --- - -- -- 
protein  levels in 
sh SOX2 cells 
NA   - -- To do NA -- -- To do 
ChIP assay (IP) 
of DNA region 
containing 
putative 
binding sites 
for 3q26-29 
genes 
NA -- 
 
-- 
 
-- 
 
NA - 
 
- 
ns 
 
ns 
 
Table 3. Comparison of KD effect of shSOX2 on 3q26-29 genes between LN319 and U373: The 
tables above represent differences in expression levels of 3q26-29 genes between two cell lines (+++ 
very high; ++ high; + slight increase. --- very low, -- low, - slight decrease, ns, non significant; NA not 
applicable, all symbol representations are compared to respective controls). 
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In order to evaluate the proliferative ability of the glioma cells, we imaged cells over 6 
days and counted the cells. As expected, given the role of SOX2 and PIK3CA in cell 
proliferation, KD of these genes consistently displayed reduced proliferation rates 
compared to sh scrambled control cells. In addition, based on the expected role of 
mitochondrial fusion genes in inducing cell proliferation, we expected that shMFN1 
and shOPA1 cells would display reduced proliferation rates compared to sh 
scrambled control cells. Consistently, we found that in LN319 cells, shMFN1 and 
shOPA1 cells displayed reduced proliferative abilities. In contrast, in U373 cells 
shMFN1 and shOPA1 cells exhibited significantly higher proliferative rates.  
 
It could be possible that U373 cells display metabolic adaptation in response to loss 
of OPA1 and MFN1 and switch to mitochondria-independent cellular growth. This 
hypothesis could be explored by testing active metabolic pathways and for the state 
of glycolysis in the cells (discussed in detail in section 4 of this chapter). In addition, 
other proliferation assays such as EdU (E-Ethynyl-2-deoxyuridine) incorporation 
could be performed to confirm the observed results and to evaluate whether cell 
cycle progression is indeed altered. 
 
In LN319 cells, physical association studies reveal that SOX2 binds to the predicted 
region upstream of 3q26-29 gene promoters. Although data from U373 cells were not 
statistically significant, they support the observations made in LN319 cells. 
Subsequently, preliminary reporter gene assays performed so far suggest that SOX2 
trans-activates PIK3CA and OPA1 gene promoters in HEK293 cells.  
 
4.2. Immediate perspectives of the project  
 
4.2.1. Completion of invasion and proliferation assays  
 
In order to further understand the role of 3q26-29 genes in glioma invasion, 
migration, and proliferation, Boyden chamber and wound healing assays on 
shPIK3CA cells in U373, and proliferation assays on shMFN1 cells in LN319 need to 
be performed.  
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4.2.2. Completion of luciferase assays in HEK293 cells 
 
We observed that SOX2 binds to the predicted region upstream of 3q26-29 genes. 
To further show that the physical association of SOX2 results in functional activation 
of 3q26-29 genes, reporter gene assays need to be performed.  
 
We have recently set up dual luciferase reporter assay in our laboratory. This assay 
system relies on two reporter genes Renilla and firefly luciferase, to quantify 
promoter activity. In the presence of substrate, enzymes such as Renilla and firefly 
luciferase oxidize the substrate to release energy in the form of photons, which can 
be captured by a luminometer. The assay will assess the activity of PIK3CA, MFN1, 
SOX2, and OPA1 promoters in response to SOX2 overexpression in HEK293 cells. 
Promoter regions up to 2000 bp upstream of transcription start site of 3q26-29 genes 
have been cloned into the pGCL4.1 basic luciferase vector (for vector map and 
strategy refer to Materials and Methods). Loss of luciferase gene activation 
compared to WT promoter sequence would demonstrate that suspected SOX2 
binding sites are indeed used for gene promoter activation. Therefore, promoter 
constructs mutated at predicted SOX2 binding sites are currently being generated by 
site directed mutagenesis. 
 
4.2.3. Mitochondrial morphology   
 
Mitochondrial morphology 
 
Ablation of mitochondrial fusion proteins (MFN1, MFN2 or OPA1) enhances 
mitochondria fission (Campello et al., 2006; Chen et al., 2003; Suen et al., 2008). 
Mitochondrial fission enhances cell motility. Therefore, genetic regulation of MFN1 
and OPA1 by SOX2 could induce mitochondrial fragmentation. In order to reproduce 
the KD phenotype of MFN1 and OPA1 and to study mitochondrial morphology of KD 
of SOX2 in live glioma cells, 3D-time lapse imaging of cells stained for mitochondria 
was opted for (Marín-García et al., 2013; Mitra and Lippincott-Schwartz, 2010). Mito-
tracker green, a membrane potential insensitive dye was used to stain mitochondria. 
Mitochondrial morphology of cells KD for MFN1 and OPA1 are being used as 
phenotype controls to estimate the extent of mitochondrial fragmentation in shSOX2 
cells. We plan to image at least 20 cells per condition. So far, we have analyzed over 
4 cells per condition. We are currently quantifying our results.  
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We are collaborating with the electron microscope (EM) facility (at the Biocenter 
imaging facility of University of Basel) to image the mitochondria. Although this 
approach enables us to study of mitochondrial shape, it is biased by altered cell 
shape due to suspension in culture medium before the fixation, as opposed to 
studying live cell dynamics. 
 
Caino et al. recently showed that infiltration of mitochondria to the lamellipodia at the 
leading front in an actively migrating cell could be visualized by staining mitochondria 
(Caino et al., 2015). Thus, tracking dynamic infiltration of migrating mitochondrial 
organelles towards the lamellipodia in shSOX2 cells compared to sh controls could 
help determine altered mitochondrial dynamics in SOX2 depleted cells. To do so, we 
will use mito-tracker green to stain the mitochondria in living cells and perform 
wound-healing assays using the Cell-IQ imaging system.  
 
Apoptosis and membrane potential 
 
Flow cytometry could be used to quantify independent apoptosis-associated events 
in KD cells for LN319 and U373 glioma cells. To determine the alterations in 
membrane potential and apoptosis in the cells, we could use two established cell 
death assays: DiOC6(3) to measure alterations of the mitochondrial membrane 
potential ∆ym (Kluck et al., 1997; Kroemer et al., 1998; Scaffidi et al., 1998), and 
terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick-end labeling 
(TUNEL), to quantify apoptotic DNA fragmentation (Gorczyca et al., 1993).  
 
4.2.4. Mitochondrial respiration  
 
Mitochondrial respiration involves the oxidation of NADH (a reduced form of 
nicotinamide adenine dinucleotide), which is a byproduct of Krebs cycle (TCA cycle) 
that finally generates energy in the form of ATP. During mitochondrial respiration, the 
respiratory super complexes (RSC) (I-IV) are assembled in the cristae at the 
mitochondrial inner membrane (IMM) to establish a proton gradient that further 
oxidizes NADH to generate ATP through the electron transport chain (ETC). This 
process is also described as oxidative phosphorylation (OXPHOS) (Fig. 26.Top).  
 94 
 
Recent evidence suggests that reduced mitochondrial respiration and bioenergetics 
affects cell invasion (Caino et al., 2015; Kastl et al., 2014; J. Zhao et al., 2013; Zhou 
et al., 2014). Indeed, increased levels of reactive oxygen species (ROS), a byproduct 
of OXPHOS is observed in cancer cells and promotes migration and invasion 
(Ishikawa et al., 2008; Luanpitpong et al., 2010; Pelicano et al., 2009). 
 
 In fact, loss of mitochondrial ATP generation reduces cancer cell migration (Hao et 
al., 2010; J. Zhao et al., 2013). In 2014, LeBleu et al. used orthotopic breast cancer 
mouse model and cell lines to show that invasive cancer cells favored mitochondrial 
respiration and increased ATP generation to invade and metastasize (LeBleu et al., 
2014). Thus, cancer cell invasion depends on ATP generated during mitochondrial 
respiration. 
 
OPA1 regulates cristae remodeling, the site where respiratory super complexes (I-IV) 
assemble (Fig. 26.Bottom). Thus, short-term loss of OPA1 reduces the mitochondrial 
respiration rate (Cogliati et al., 2013; Kushnareva et al., 2013). If SOX2 plays a role 
in glioma invasion by genetically activating OPA1, mitochondrial respiration rate 
could be altered.  
 
In order to confirm the source of energy for invasion and migration in KD cells, we 
will evaluate functional mitochondrial measurements such as basal respiration and 
ATP production using a Seahorse bioanalyzer.  
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                                   Adapted from website of Stockholm University, and Cogliati et al., 2013 
 
Fig 26. OPA1 regulated cristae shape controls respiratory chain super complex assembly and 
stability: Top. Respiratory chain super complex (RCS) I-IV and ATP synthase machinery. The RCS 
complex oxidizes NADH, a byproduct of Krebs cycle, to ultimately generate ATP by establishing a 
proton gradient across these complexes, also known as electron transport chain. The process of 
oxidation of NADH and synthesis of ATP from the energy generated is OXPHOS. Bottom. RCS 
complexes are found to be present on mitochondrial inner membrane called cristae. The cristae shape 
determines the assembly and stability of the complex, thus regulates mitochondrial respiration. OPA1 is 
the regulator of cristae shape depletion of OPA1 thus reduces mitochondrial respiration.  
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4.2.5. SOX2 overexpression in glioma cells 
 
Our observations have shown that KD of SOX2 enhances glioma invasion. SOX2 
rescue experiments could be performed in order to show that the observed 
phenotype is KD specific. Ectopic expression of SOX2 can be performed by transient 
transfection of SOX2 expression vector (plasmid DNA) or by transducing viral 
particles for efficient and long-term expression. It has been noted that glioma cells 
are difficult to transfected with plasmid DNAs, hence, we chose to prepare viruses 
that overexpressed SOX2 to reach maximum transduction efficiency.  
 
We generated lentiviruses that could overexpress SOX2 in glioma cells. However, 
qRT-PCR analysis on transduced cells showed that SOX2 overexpression could not 
be achieved upon transduction of produced viruses in HEK293 cells (Fig. 27A). We 
tested lentiviral particles custom made by a biotech company (Genecoepia). Similar 
to the previously observed results, qRT-PCR analysis on treated glioma cells 
compared to control scramble treated cells showed that SOX2 could not be 
overexpressed in glioma cells (Fig. 27B). Glioma cells are high expressors of SOX2 
(Annovazzi L, Mellai M, Caldera V, Valente G, 2011). Hence, it could be possible that 
beyond the threshold limits for SOX2 expression in glioma cells, we might saturate 
the system.  
 97 
 
 98 
4.3. Suppression of mitochondrial fusion increases glioma 
invasion   
Mitochondrial fission and fusion cycles are maintained by subtle balance between the 
two processes (Chen et al., 2003, Stojanovski et al., 2004, Ishihara et al., 2009, 
Wakabayashi et al., 2009, Waterham et al., 2007). KD of mitochondrial fusion genes 
MFN1 and OPA1 enhances mitochondrial fission in cells (Chen et al., 2003, 
Campello et al., 2006, Desai et al., 2013). Mitochondrial fission regulates cell 
invasion, as mitochondria are required to establish polarity in the cells, a prerequisite 
for cell migration (refer to introduction section 1.7.2). We showed that KD of MFN1 
and OPA1 in LN319 and U373 glioma cells resulted in enhanced invasion and 
migration and mitochondrial fission.  
 
4.4. MFN1 and OPA1 contribute to cell proliferation  
 
During the process of cell division, cells enter the M (mitotic) phase during which 
cells actively undergo mitosis and division of cytoplasm (cytokinesis). G1 (Gap1) 
phase is when cells are metabolically active and grow without replicating their DNA, 
and in S (synthesis) phase, DNA replication occurs. Following the phase of DNA 
synthesis, cells enter G2 (Gap2) phase during when cells double their masses and 
protein synthesis takes place as the cells prepare to re-enter into the M phase to 
form new daughter cells, unless stopped by cell cycle regulators (Cooper and 
Hausman, 2007). Mitochondrial morphology coordinates with cell cycle progression. 
It has been observed that mitochondria fuse and become elongated during G1-S 
transition to support the metabolic requirements of the cycling cell (Mishra and Chan, 
2014). Mitochondria remain fragmented as individual organelles through G2-M phase 
and equally split among the daughter cells (Antico Arciuch et al., 2013; Mishra and 
Chan, 2014). The schematic representation of the coordination of mitochondrial 
dynamics with cell cycle progression is depicted in the Figure 28. 
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                                                                                                             Mishra and Chan, 2014 
 
Fig 28. Mitochondrial dynamics during cell cycle progression: Mitochondrial dynamics coordinate 
with cell cycle and promote equal segregation of mitochondria during cell division. At G1 stage 
mitochondria show various shapes, during the G1/S transition, mitochondria fuse and become 
elongated presumably to support the metabolic need of the cell. In contrast, at G2 and M phases, 
mitochondria undergo fission and form numerous individual organelles that are spatially distributed 
throughout the cell soma thus promoting equal segregation of the mitochondria to newly formed 
daughter cells at M phase.    
 
Cell proliferation is regulated by mitochondrial cristae remodeling, which allows 
cellular adaptations to meet the metabolic need (Merkwirth and Langer, 2009; Patten 
et al., 2014). OPA1, chief regulator of cristae shape, plays an important role in cell 
proliferation (Cogliati et al., 2013; Frezza et al., 2006; Garedew et al., 2010; Patten et 
al., 2014; Scorrano, 2007). Consistent with the proposed role for OPA1, we observed 
that in LN319 shOPA1 cells, proliferation was reduced.  
 
Interestingly in U373 cells, depletion of OPA1 and MFN1 resulted in a significant 
increase of proliferation rate. Two plausible arguments could be put forth for the 
differences observed between the two cell lines. First, the two human glioma cell 
lines exhibit different degrees of invasiveness and cell proliferation rates. Hence, 
their responses towards depletion of 3q26-29 genes could be different (Discussion 
section: Table 1).  Second, short-term OPA1 depletion affects the cristae shape and 
remodeling dynamics, and therefore reduces cell proliferation (Cogliati et al., 2013). 
However, long-term depletion of OPA1 and MFN1 also reduces mitochondrial 
biogenesis. Hence, it could be possible that long-term depletion of OPA1 in U373 
cells could favor mitochondria-independent cell growth potentially supported by 
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enhanced glycolysis. Metabolic assays could be performed to investigate whether 
long term OPA1 depletion could result in increased rates of macromolecular 
biosynthesis in U373 cells.  
 
4.5. SOX2 and PIK3CA induce glioma proliferation  
 
SOX2 and PIK3CA are oncogenic in glioma and many other solid cancers including 
breast, pancreatic cancers, small cell lung adenocarcinomas or squamous cell 
carcinomas (Boumahdi et al., 2014; Chou et al., 2013; Samuels et al., 2005; Bader et 
al., 2006). Supporting the known role and functions of SOX2 and PIK3CA in inducing 
tumor cell proliferation, our results show that KD cells consistently reduced glioma 
proliferation. 
 
4.6. Increased glioma cell motility upon KD of SOX2 and PIK3CA 
 
Our initial observations based on gene expression analysis on human glioma 
biopsies showed that SOX2 mRNA was highly expressed in invasive gliomas. Thus, 
we hypothesized that SOX2 contributes to glioma invasion. PIK3CA is a component 
required for a functional PI3K/Akt signaling pathway, which is associated with tumor 
malignancy (Samuels et al., 2005). In fact, constitutively active PI3K-Akt-mTOR 
pathway also promotes cancer cell invasion (Shukla et al., 2007). Hence these 
evidences suggested that SOX2 and PIK3CA overexpression induce cancer cell 
invasion. 
 
Surprisingly, we observed that KD of SOX2 and PIK3CA resulted in enhanced 
invasive and migratory phenotype in LN319 and U373 cells. Similar observations 
reported by Caino et al. showed that in vitro treatment of prostate cancer (PC3), 
adenocarcinoma (A549), and glioblastoma (LN229) cell lines with PI3K inhibitors 
(AZD6482, GCD0941 and BKM120) targeting PI3K/Akt signaling pathway, enhanced 
cancer cell invasion by mitochondrial relocalization to cortical cytoskeleton 
(cytoplasmic cytoskeleton beneath the plasma membrane) (Caino et al., 2015). 
 
In 2011, Oppel et al. demonstrated that KD of SOX2 in U343 glioma cells in a 
xenografted mouse model resulted in invasive tumors (Oppel et al., 2011). Molecular 
mechanisms that contribute to the enhanced invasiveness in SOX2 KD cells remain 
elusive. However, based on our results and literature evidence, we propose that the 
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molecular mechanism involving SOX2-OPA1 signaling pathway could provide 
arguments towards the documented counterintuitive observations (For further 
discussion refer to 4.9.1 of this chapter).  
 
In addition, higher SOX2 mRNA levels observed during gene expression analysis on 
invasive glioma biopsies could be due to contamination of proliferating neoplastic 
cells present in tumor core rather than infiltrative neoplastic cells at the tumor 
periphery.  
 
Overall, to test the hypothesis that SOX2 and OPA1 overexpression can influence 
glioma invasion and migration, we could ectopically induce SOX2 expression or use 
a glioma mouse model that can conditionally overexpress SOX2 and OPA1, and 
assay the tumor cells for invasion, migration and proliferation phenotype.   
 
4.7. SOX2 is a potential genetic regulator of 3q26-29 genes  
 
Since SOX2 is a transcription factor, we hypothesized that SOX2 could regulate 
transcription of the 3q26-29 genes. As predicted, we observed decreased mRNA and 
protein levels of 3q26-29 genes, except for PIK3CA at the protein level. PIK3CA 
expression is regulated by many factors such as transcription factors NFκB and 
TP53. Hence, reduction of mRNA levels by SOX2 could have triggered 
compensatory mechanism to maintain PIK3CA expression levels (Astanehe et al., 
2008; Yang et al., 2008).  
 
In order to further study the genetic regulation of 3q26-29 genes by SOX2, we 
identified conserved potential SOX2 binding sites on upstream regions of the 3q26-
29 genes. Physical association studies by ChIP showed that in LN319 cells, SOX2 
binds to the predicted region on the promoters of PIK3CA, MFN1 and OPA1. 
Although in U373 cells we did observed similar trends in U373 cells, statistical 
significance could not be determined. Depending on their sequences, the predicted 
SOX2 binding sites may have distinct affinities for SOX2, and are therefore sensitive 
to differences in SOX2 levels. Consistent with association studies, preliminary 
luciferase assays indicate that SOX2 trans-activates PIK3CA and OPA1 genes. 
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4.8. Correlation between clinical data and in vitro observations  
 
4.8.1. Clinical data  
 
4.8.1.1. Glioma samples from TCGA  
 
In 2013, Verhaak et al. from the TCGA consortium performed copy number analysis 
on 543 human GBM samples and showed that the region 3q26 is subjected to 
frequent amplification while 3q29 is frequently deleted. Following this observation, in 
2015, Suzuki et al. showed similar patterns of 3q26 amplification and 3q29 deletion 
in LGG.  
 
4.8.1.2. Copy number analysis of glioma biopsies from BTB tumor bank 
 
Copy number analysis (CNA) for 3q26-29 genes on 68 freshly resected human GBM 
samples from BTB tumor bank showed that SOX2 (3q26.3) is the most frequently 
amplified gene (35%) while OPA1 (3q29) is frequently deleted (29%). The frequency 
of these events can be compared to EGFR amplification (53%) and CDKN2A 
deletion (33%), which are well-characterized genetic alterations in GBM. 
Amplifications of MFN1, PIK3CA, and OPA1 were observed only in 2%, 8%, and 8% 
of the GBM samples, respectively, while deletions of MFN1 and SOX2 were also 
observed in 6% and 7% of samples respectively.  
 
CNA on 32 LGG samples showed that SOX2 was amplified (17%) and frequently 
deleted (17%) while OPA1 deletions were most frequent (36%). We also observed 
that PIK3CA and MFN1 were deleted in 6% and 10% of the LGG samples.  
 
Our observations are consistent with the CNA from TCGA data that 3q26 is amplified 
and 3q29 is deleted. We found that SOX2, located on 3q26.3 is frequently amplified 
and OPA1, located on 3q29, is frequently deleted in gliomas.  
  
 103 
 
4.8.1.3. Mutual exclusivity 
 
Key genetic alterations in GBM are mutually exclusive when they target a common 
signaling pathway (The Cancer Genome Atlas Research Network, 2008). Our 
observations show that frequent SOX2 amplifications and OPA1 deletions appear to 
be mutually exclusive.  
 
4.8.2. Correlation with in vitro experiments  
 
4.8.2.1. OPA1 deletions 
 
Based on CNA from BTB samples, we found that OPA1 deletion is one of the 
frequent events observed in GBM (29%) and in LGG (36%). Consistently, our in vitro 
experiments show that KD of OPA1 results in enhanced glioma invasion.  Thus, we 
provide initial arguments that OPA1 deletion could contribute to tumor 
aggressiveness. MRI data of glioma patients with OPA1 deletion could be used to 
analyze tumor volume and assess the infiltration grade of glioma. These data 
together with our in vitro observations could help us understand whether OPA1 
deletion affect tumor progression in glioma patients.  
 
4.8.2.2. SOX2 amplifications  
 
SOX2 amplification is one of the major events (35%) observed in GBM samples. Our 
in vitro results provide arguments that SOX2 is a potential genetic regulator of OPA1.  
It has been shown that, in glioma genetic alterations in genes targeting the same 
pathway are often mutually exclusive (TCGA 2008). Indeed our copy number 
analysis (CNA) suggests that SOX2 amplification and OPA1 deletion appear to be 
mutually exclusive. Gene signature analysis could be performed on glioma samples 
with focal SOX2 amplification and homozygous OPA1 deletion to study the 
correlation with tumor malignancy/aggressiveness. Although the phenotype (cell 
motility) of SOX2 overexpressing glioma cells is yet to be determined experimentally, 
evidence from literature show that SOX2 overexpression is capable of inducing 
invasive phenotype in glioma cells (Berezovsky et al., 2014; Alonso et al., 2011).   
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Also, our in vitro observations show that loss of SOX2 enhances glioma invasion. 
MRI data of glioma patients with SOX2 deletion (7% of GBM and 17% of LGG 
samples) could be used to analyze tumor volume and assess the infiltration grade of 
these glioma. These data together with our in vitro observations could help us 
understand whether SOX2 deletion alters infiltrative capacity of human glioma cells 
during tumor progression.  
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Fig 29. Correlation of clinical data with observed in vitro results: Clinical observations show that 
SOX2 is frequently amplified whereas OPA1 is deleted in glioma. Based on clinical observations we 
expected that SOX2 overexpression and OPA1 deletion could contribute to glioma invasion. 
Surprisingly, we observed that SOX2 down regulation enhanced, while OPA1 depletion as expected 
contributed to glioma invasion. Based on the metabolic perspective, we provide arguments that support 
the notion that proliferation and invasion need not be mutually exclusive and hence hypothesize that in 
glioma cells SOX2 amplification and deletion both contribute to invasion. However, studies on glioma 
cells overexpressing SOX2 and OPA1 should to be done in order to assess the invasive potential of the 
cells and to confirm the above hypothesis. Red box indicates amplification/overexpression and blue box 
indicates deletion/ downregulation. 
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4. 9. GLOBAL PROJECT OUTLOOK 
 
4.9.1. SOX2-OPA1 signaling pathway  
 
4.9.1.1. Invasion and proliferation are not always mutually exclusive  
 
Cell proliferation is a phase during which cells experience greater energy and 
metabolic needs. During periods of high metabolic needs mitochondria fuse and 
forms elongated tube-like structures (Escobar-Henriques and Anton, 2013). 
Elongated mitochondrial structures increase membrane potential, thus maintaining it 
across the entire cell (Westermann, 2012). This helps to maintain ATP supply 
throughout the cell and also triggers glycolysis that helps in the biosynthesis of many 
macromolecules (Mitra, 2013; Rehman et al., 2012).  
 
In contrast to proliferation, cell invasion and migration are events with low metabolic 
demands (Chernoivanenko et al., 2014; Deberardinis et al., 2008; Desai et al., 2013; 
Schulze and Harris, 2012; Vander Heiden et al., 2009). Many studies have shown 
that blocking the local energy supply by inhibiting mitochondrial OXPHOS using 
oligomycin A inhibits cancer cell invasion. This indicates that ATP production through 
mitochondrial respiration is an important source of local energy (Hao, 2010, Ma, 
2013, Zhao, 2014). Mitochondria fission facilitates improved mitochondrial respiration 
and dynamic re-localization of the organelles and thus caters to local energy needs 
(Campello et al., 2006; Desai et al., 2013; Hollenbeck and Saxton, 2005).  
 
Invasion and proliferation are both manifestations of a tumor growing towards 
malignancy. In fact, it has been observed that cells at any given time point can switch 
between proliferative and invasive phenotype, while also displaying the two 
phenotypes simultaneously (Fortin Ensign et al., 2013; Gao et al., 2005; Liu et al., 
2013; Liuq et al., 2014). Such studies have provided evidence that suggest that cell 
proliferation and invasion are not necessarily mutually exclusive. 
 107 
 
4.9.1.2. Proliferation and therapy resistance  
 
SOX2 overexpression is associated with tumor malignancy. SOX2 expression 
induces tumor proliferation in breast, colorectal, gastric, GBM, hepatocellular 
carcinoma and ovarian cancer cells (Weina and Utikal, 2014).  
 
In 2014, Piva et al. demonstrated using in vitro as well as in vivo experiments that 
SOX2 overexpressing breast cancer cells were resistant to tamoxifen, an oestrogen 
receptor antagonist. Vanner et al., using a syngenic mouse model of 
medulloblastoma showed that SOX2 positive quiescent cells resisted antimitotic 
drugs (cytarabine and vismodegib). And Boumahdi et al., using a syngenic mouse 
model of skin-squamous cell carcinoma (SCC), showed that SOX2 positive stem-
cells exhibited higher mRNA levels of genes involved in therapy resistance and cell 
survival (Chek 2, Itga3, Aurka/b, mgmt, Abcb1). In addition, Rothenberg et al. 
showed in vitro and in vivo using a xenograft mouse model for lung cancer, that 
treatment of cells with erlotinib, a kinase inhibitor of EGFR, induced SOX2 
expression. Recent reports showed that SOX2 positive cancer stem cells are 
required for tumor relapse and that SOX2 regulates mitochondria induced apoptosis 
and contribute to therapy resistance in cancer stem cells (Boumahdi et al., 2014; 
Piva et al., 2014; Vanner et al., 2014).  
 
Similarly, in 2012, Fang et al. demonstrated in vitro using lung adenocarcinoma cells 
that OPA1 overexpression induces therapeutic resistance against cisplatin. In 2013, 
Zhang et al. showed that treatment of hepatocellular carcinoma (HCC) in vivo with 
sorafenib, a kinase inhibitor of VEGFR and PDGFR, induced apoptosis by blocking 
OPA1, thereby targeting mitochondria-induced autophagy. Unfortunately, HCC 
patients treated with sorafenib, developed resistance against this drug over time. The 
potential molecular mechanism behind the development of therapy resistance is yet 
to be elucidated (H.-Y. Fang et al., 2011; Rudalska et al., 2014; Viscomi et al., 2015; 
Zhai and Sun, 2013; X. Zhao et al., 2013). In SCC and pulmonary carcinoid tumors, 
chemotherapy resistance is shown to be dependent on loss of mitochondria 
mediated apoptosis (Gandhi et al., 2009; Thomas and Gustafsson, 2013).  
 
Little literature evidence is currently available that could demonstrate the role of 
OPA1 in inducing tumor proliferation. However, given the role of OPA1 in promoting 
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therapy resistance, it is not difficult to conceive that overexpression of OPA1 might 
contribute to enhanced tumor proliferation.  
 
4.9.1.3. Cancer cell invasion and migration  
 
In HeLa a cervical cancer cells overexpression of OPA1 beyond threshold limits of 
the cell induces mitochondrial fragmentation and perinuclear clustering of 
mitochondrial organelles promoting cancer cell invasion (Cipolat et al., 2006; Griparic 
et al., 2004; Olichon et al., 2002). Concurrently, many reports show that SOX2 
overexpression induces cancer cell invasion and migration. Lou et al. demonstrated, 
using ovarian cancer cell lines in vitro, that SOX2 genetically targets Fibronectin 1 
(FN1) to promote cancer cell invasion (Lou et al., 2013). Sun et al. showed using a 
xenograft mouse model of HCC, that SOX2 overexpression correlated with enhanced 
metastatic ability in the tumors (Zhai and Sun, 2013). Alonso et al. demonstrated 
using in vitro experiments in brain tumor stem cells and glioma cell lines, that SOX2 
overexpression resulted in enhanced invasive and migratory properties (Alonso, 
2011).  
 
These observations demonstrate that overexpression of SOX2 or OPA1 could 
potentially contribute to cancer cell invasion. Although the role for overexpression of 
SOX2 and OPA1 in cancer cell invasion is demonstrated, molecular mechanisms 
behind such observations remain to be explored (Fig. 29). 
 
4.9.1.4. Potential perspective   
 
Together with our observations and evidence from literature, it can be proposed that 
SOX2-OPA1 overexpression could promote tumor invasion as well as therapy 
resistance, thus contributing to tumor aggressiveness. Therefore, we could 
hypothesize that enhanced SOX2-OPA1 signaling contributes to glioma invasion. 
Invasion, migration, proliferation, and apoptosis assays could be performed on SOX2 
overexpressing human glioma cell lines or on mouse glioma cells, to test the above 
hypothesis.   
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4.9.2. Mitochondrial biogenesis and mitophagy  
 
Mitochondrial biogenesis is the process of formation of new mitochondria in the cells. 
The process includes replication of the mitochondrial genome and serves to maintain 
mitochondrial mass in the cells. Mitochondrial biogenesis is very tightly associated 
with mitochondrial fission and fusion cycles. Given such close associations between 
the two processes it would be essential to understand if KD of SOX2 in glioma cells 
alters mitochondrial biogenesis. qRT-PCR experiments using primers targeting 
mtDNA could be performed in order to estimate alterations in mitochondrial 
biogenesis.  
 
Mitophagy is the process of removing of defective mitochondria from the 
mitochondrial pool in a cell, thus helps to maintain the mitochondrial genome 
integrity. Several studies show that loss of mitochondrial membrane potential induces 
autophagic machinery (Tolkovsky, 2009). Mitochondrial fission plays an important 
role in depolarizing the mitochondrial membrane, thus fission is known to promote 
mitophagy (Dagda et al., 2009; Martínez-Fábregas et al., 2014). In response to 
membrane depolarization, PTEN induced kinase 1 (PINK1) accumulates at the Outer 
mitochondrial membrane and phosphorylates MFN2, which in turn acts as receptor 
for the E3 ubiquitin ligase, Parkin. Parkin, ubiquitinylates the dysfunctional 
mitochondria. These ubiquitinylated mitochondria are further recognized by 
autophagosome-specific proteins such as microtubule-associated protein 1 light 
chain 3 (LC3) and delivered to lysosome for degradation. In addition to the 
PINK/PARKIN pathway, hypoxia inducible genes BNIP3 and NIX have also been 
implicated in mitophagy by associating with apoptotic proteins Bcl-2 and Bcl-XL 
(Zhang et al., 2008). 
 
Since OPA1 is a key mediator of apoptosis, it would be worth investigating whether 
sh SOX2 and shOPA1 glioma cells affect mitophagy. Western blot analysis mediated 
estimation of LC3 II/I ratio could be performed to estimate autophagy/ mitophagy in 
the system.  
 
4.9.3. Orthotopic glioma mouse model 
 
In vitro assays on 2D cell culture model represent a simple system to visualize and 
study a phenotype and to dissect a genetic mechanism. However, because of the 
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simplicity of the system, the model does not take into account the complex biological 
interactions during tumor progression. Critical aspects of tumor growth including 
tumor proliferation and primary metabolic responses are shown to be altered in in 
vitro culture conditions compared to in vivo tumor progression (Gillet et al., 2011; 
Lukk et al., 2010). In addition, our experiments to overexpress SOX2 have not been 
successful in glioma cell lines. Using a mouse model of glioma, conditional SOX2 
overexpression and deletion experiments can be performed. Thus, mouse models 
could provide insights into tumor progression during SOX2 overexpression or 
depletion conditions, and the associated metabolic changes.  
  
The xenograft mouse model, in which human glioma cell lines are orthotopically 
introduced into the mouse’s brain, is the most commonly studied model system, is 
the most common mouse model. However, recent evidence shows that because of 
the difference in host micro-environment (in species variation), the infiltrative ability of 
cells is altered (Stylli et al., 2015). Another well-characterized genetic mouse model 
is the TP53-/-PDGF+/+ model (Weiss, 2003). In addition to insights into tumor growth 
in vivo conditions, mouse models can provide further insights into the behavior of 
3q26-29 genes upon treatment with chemotherapeutic agents.  
 
5.  CHAPTER I - CONCLUSION AND SIGNIFICANCE  
 
The aim of this work was to uncover a novel molecular mechanism that regulates 
glioma invasion. Oncogenes SOX2 and PIK3CA, and mitochondrial fusion genes 
MFN1 and OPA1 co-localize to 3q26-29 in the human genome, a region subjected to 
frequent genetic alterations in gliomas. Our study explored the role of 3q26-29 genes 
in glioma invasion in vitro.  
 
We showed that individual genetic inactivation of 3q26-29 genes lead to alteration of 
invasion, migration and proliferation. Given their respective function in cell 
physiology, we suspected a cascade that regulates glioma progression.  
 
Our work provides arguments to support a molecular model that SOX2 contributes to 
glioma invasion and proliferation by regional trans-activation. This model proposes 
that SOX2 could act as a potential sensor that regulates both glioma cell invasion 
and proliferation as shown in the model depicted in Fig. 30.  
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Thus, we provide novel insights into the molecular mechanism of SOX2-driven 
mitochondria-dependent glioma invasion, through regional regulation of OPA1 and 
MFN1 by SOX2. This work highlights that therapeutic targeting of SOX2 and PIK3CA 
(oncogenes) in glioma should be carefully addressed, as we show that KD of the 
genes induces glioma cell invasion. Altogether, the finding of a novel oncogenic 
molecular pathway provides tool for developing future target therapies to control 
glioma progression.  
 
  
Fig 30. Molecular model based on our observations in glioma cells: Schematic summary of our 
observations in glioma cell lines LN319 and U373. KD of SOX2, MFN1, OPA1 or PIK3CA in glioma cells 
results in enhanced invasiveness and migratory behavior. Glioma cells KD for SOX2 or PIK3CA reduce 
tumor cell proliferation. Our results suggest that SOX2 exerts regional trans-activation of 3q26-29 genes 
in order to contribute to glioma invasion. Filled-solid black arrows represent completed experiments, 
whereas dotted arrows and exclamatory mark inside the box show preliminary observations currently 
under validation. 
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6. CHAPTER II – INTRODUCTION – SOX2-HEY1 SIGNALING 
 
The notch signaling pathway is an evolutionarily conserved pathway that plays a 
central embryonic role in development and organogenesis by regulating cell fate, 
survival, and apoptosis. Notch effectors HEY1 and HEY2 are involved in embryonic 
vascular development and promote neural stem cell proliferation (Fischer et al., 
2004).  
 
6.1. Notch signaling pathway in glioma invasion  
 
The notch signaling pathway allows cell-to-cell communication by juxtacrine signaling 
between neighboring cells. Binding of Notch ligands to their receptors result in 
cleavage of the cytosolic part of trans-membrane Notch receptors to release the 
Notch intracellular domain (NICD) into the cytoplasm. NICD binds to RBPJ-κ/MAML 
complex and is translocated into the nucleus, where it induces expression of Notch 
target genes such as members of hairy/enhancer of split (HES and HEY) in humans.  
 
Malignant gliomas express high levels of HEY1 mRNA and the expression levels 
correlate with poor prognosis (Gaetani et al., 2010; Hulleman et al., 2009). In a 
xenograft model, the notch signaling pathway contributes to mammary breast cancer 
cells invasion, osteosarcoma invasion, and metastasis. Activation of Notch signaling 
pathway in vitro induced the expression of Snail and subsequent-induction of 
epithelial-mesenchymal transition (EMT) (Zavadil et al., 2009; Leong et al., 2007). In 
2009, Sivasankaran et al. demonstrated that TNC, an ECM component and a 
diagnostic marker for glioma progression, is regulated by Notch signaling to facilitate 
glioma invasion (Sivasankaran et al., 2009). 
 
6.2. Notch regulates expression of SOX2  
 
SRY-related HMG box 2 (SOX2) is transcription factor that is primarily known for its 
role in regulating cell stemness. SOX2 targets many genes involved in cell fate 
determination, growth, survival and apoptosis. Hence, it is considered to be a master 
regulator of cellular processes. In neural progenitor cells SOX2 is expressed at 
different stages of CNS development. SOX2 transcription is promoted by Notch 
signaling pathway (Dabdoub, 2008.; Neves et al., 2012; Pan et al., 2013). Members 
of SOX transcription factors are thought to inhibit bHLH-mediated neuronal 
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differentiation, thus maintaining neural precursor cells in the progenitor state, while 
bHLH proteins inhibit the expression and activation of SOX members in order to 
induce cellular differentiation (Dabdoub et al., 2008). Although it is known that SOX2 
is regulated by Notch signaling pathway during development, such regulations are 
yet to be demonstrated in cancer cells.  
6.3. Aim of the project  
 
Based on our observations that invasive cells show higher levels of mRNA 
expression for HEY1 and SOX2, we aimed to understand the role SOX2 and HEY1 
in glioma invasion.  
 
7. CHAPTER II - RESULTS 
 
7.1. Expression of SOX2 and HEY1 in glioma biopsies   
Our preliminary results suggested that HEY1 is highly expressed in invasive gliomas. 
In order to investigate whether HEY1 also correlated with tumor progression and to 
select glioma cell lines for further experiments, we studied the mRNA expression 
patterns in glioma cells lines and WHO-classified glioma biopsies.  
 
qRT-PCR mediated mRNA expression analysis of over 30 glioma biopsies classified 
according to WHO grade, showed that SOX2 and HEY1 expression indeed 
correlated with tumor progression. We also observed that NOTCH1 mRNA 
expression levels also correlated with increasing glioma malignancy. Our results 
support the observations made by others that SOX2 and HEY1 gene expression 
correlates with tumor progression (Fig. 31A).  
 
7.2. Selection of SOX2 and HEY1 expressing glioma cell lines  
 
To investigate the role of SOX2 and HEY1 in glioma invasion, we selected glioma 
cell lines based on mRNA levels for both SOX2 and HEY1 and SOX2 protein 
expression in the glioma cells. LN405 showed least mRNA levels for SOX2 and 
HEY1 among the cells, hence data from other cell lines were normalized using 
LN405 as a baseline. Most of the cell lines analyzed, showed over 20 fold higher 
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HEY1 expression levels compared to LN405, except LN71 and LN319 which showed 
over 5 fold increase in HEY1 expression compared to LN405. SOX2 mRNA levels 
were higher in LN319 and U373 cells (Fig. 31B). We thus selected LN319 and U373 
cells for further experiments. 
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7.3. Genetic inactivation of SOX2 and HEY1 alter glioma invasion 
 
SOX2 and HEY1 genes were KD using lentiviruses expressing shRNAs again SOX2 
and HEY1 in LN319 and U373 cells. We confirmed the KD for SOX2 using qRT-PCR 
as well as western blot (refer to thesis part 1 result section Fig.13). KD of HEY1 was 
confirmed using qRT-PCR in U373 and LN319 (Fig. 32A).  
 
In order to study if KD of SOX2 and HEY1 could alter invasive ability in glioma cells, 
we performed Boyden chamber assays over 16 hours. Invasive cells were stained 
and counted as a read out for the experiment. We observed that KD of SOX2 
resulted in enhanced glioma invasion in both cell lines (refer Fig 18. Chapter 1 
results for detailed analysis). Consistent with the known role for HEY1, in LN319 and 
U373 we observed that shHEY1 cells showed 40% and 50% reduction in glioma 
invasion compared to sh controls, respectively. The results thus show that KD of 
SOX2 and HEY1 had opposite effects on glioma invasion (Fig. 32B).  
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7.4. Gene expression analysis of SOX2 and HEY1 in KD cells  
 
To define possible downstream targets of SOX2 and HEY1, we performed genome-
wide expression analysis on shSOX2 and shHEY1 compared to sh control cells in 
U373. Microarray analyses show that in U373 cells, KD of SOX2 enhances gene 
expression of members of TGF β signaling pathway and EMT, while KD of HEY1 
reduces the expression of members involved in Notch signaling pathway but 
increases the expression of members of the TGF β signaling pathway. It should be 
noted that the experiments were performed on shSOX2 cells that had decrease of 
1.4-fold for SOX2 mRNA levels, while shHEY1 had over 3.4-fold decreased HEY1 
mRNA levels compared to sh scramble controls respectively (Fig. 33). Data that had 
p<0.05 were considered for the analysis. 
 
In order to achieve better KD efficiency for SOX2 and HEY1, we tested new shSOX2 
and shHEY1 cells (from aliquots of frozen transduced cells, refer materials and 
methods for detailed explanation) for U373 that had better downregulation for SOX2 
using qRT-PCR analysis. We found that in shSOX2 and shHEY1 cells with KD of 
over 4-fold and 5-fold, respectively (KD efficiency shown Fig. 34), gene expressions 
for SOX2 and HEY1 were altered in both KD cells. We observed that shSOX2 cells 
had reduced mRNA levels for HEY1 by over 6-8 folds, whereas, shHEY1 cells 
showed enhanced mRNA levels for SOX2 by over 20 folds in U373 cells.  
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8. CHAPTER II - DISCUSSION 
 
Overall our mRNA expression analysis shows that HEY1 mRNA levels correlate with 
glioma malignancy particularly with tumor invasiveness. We confirmed the KD for the 
genes using qRT-PCR. In contrast to SOX2, we show that shHEY1 cells display 
reduced invasion phenotype in glioma. Gene expression analysis on shSOX2 and sh 
HEY1 cells in U373 suggested that members of TGFβ signaling pathway and EMT 
were upregulated in shSOX2 cells and members of Notch and EMT were 
downregulated in the sh HEY1 cells. Although these are preliminary data from one 
cell line (U373), these observations should be validated using qRT-PCR and 
confirmed in another cell line or glioma model. 
 
 8.1. SOX2-HEY1 signaling loop in U373 cells 
 
Our results suggested that KD of SOX2 reduced HEY1, while KD of HEY1 enhanced 
SOX2 mRNA expression levels. This suggested that SOX2 and HEY1 could act in a 
loop in which HEY1 could potentially repress SOX transcription factors and SOX2 
could induce HEY1 expression (Dabdoub et al., 2008). The genetic regulation of 
SOX2 and HEY1 on each other should be explored using chromatin immuno-
precipitation and reporter gene assays. 
 
8.2. Notch – TGFβ pathway interplay in EMT 
 
EMT is a process that plays an important role during cancer cell invasion. EMT is 
characterized by loss of cell adhesion contacts, dynamic reorganization of the 
cytoskeleton, gain of cell polarity, and cell spreading. TGFβ signaling pathway is a 
well-known inducer of EMT in cancer cells. Zavadil et al. using in vitro kinetic 
experiments and primary cultures from wild type and smad 3 (activator of TGF β 
signaling pathway) knockout mice, showed that HEY1 is under transcriptional control 
of TGFβ signaling pathway, thus showing that HEY1 mediates the crosstalk between 
Notch and TGFβ signaling pathway during EMT (Zavadil et al., 2004).  
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9. CHAPTER II - CONCLUSION AND OUTLOOK  
 
Overall, our results provide arguments that HEY1 contributes to glioma invasion.  
Preliminary results suggest that SOX2 and HEY1 could act in a loop to contribute to 
glioma invasion. Although these results should be validated with another model 
system, our data provide molecular basis to explore novel molecular mechanisms 
involved in glioma invasion. 
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MATERIALS AND METHODS 
 
Cell culture and reagents  
 
Human glioma cell lines U373, LN319, LN18, LN71, LN215, LN229, LN319, LN401, 
LN405, U87 and Human embryonic kidney 293 (HEK293) cells were obtained from 
either University Hospital of Lausanne or ATCC. U373 and LN319 cells were cultured 
in Dulbecco’s Modified Eagle Medium with high glucose (DMEM, D6429, Sigma- 
Aldrich) with 5% heat inactivated fetal bovine serum (non USA origin, F7524, Sigma-
Aldrich), 1% Pen-Strep (P4333, Sigma-Aldrich). HEK293 was cultured in DMEM 
Glutamax (GIBCO) supplemented with 1% Sodium pyruvate solution (S8636, Sigma-
Aldrich) and 10% heat inactivated fetal bovine serum (non USA origin, F7524, 
Sigma-Aldrich). Cells were incubated at 37°C in 5% CO2 in a humidified atmosphere.  
 
Invasion assay 
Boyden chamber assays were carried out using the matrigel coated CytoSelect TM 
24-well cell invasion assay kits (Cat No. CBA-100-C,Cell Biolabs, Inc.), according to 
the manufacturers’s instructions with minor modifications. Cells were serum starved 
overnight and 5X104cells were seeded on the upper chamber. The cells were 
allowed to invade over 24 hours at 370C. The medium was then removed from the 
chambers and non-invading cells were scraped off the top of the membrane using 
Phosphate buffer saline (PBS) soaked cotton swab. The invaded cells (in the bottom 
side of the membrane) were fixed with 4% Para Formaldehyde (PFA). The cell nuclei 
were then stained with 4’,6- diamidino-2 phenylindole (DAPI) and counted over five 
microscopic fields per well (at 10X magnification). Assays were in done in triplicates.  
Migration assay 
 
Wound healing assays were carried on 24 well plates. 5X104cells were seeded 
overnight prior to the experiment. Scratches (~120-140 μm) were made using the 
100μl pipette tips. The cells were imaged using the Cell-IQ machine (Chipman 
Technologies) with 30-minute interval over 24 hours. The cell-free area was analyzed 
as a measure of cell migration, using automated Cell AnalyzerTM software. Assays 
were in done in triplicates. The assays were performed in Prof. Primo Schär’s 
laboratory at Mattenstrasse, Department of Biomedicine, University of Basel. For 
quantification purposes, we used the following meta-data (provided by the Cell IQ 
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manufacturer) spatial resolution in X (μm/pixel) = 0.702 and the spatial resolution in 
Y (μm/pixel) = 0.702. 
 
Cell proliferation assay  
 
Cell proliferation assays were performed in 24 well plates. 3000 cells per well were 
seeded and imaged over a period of 6 days with 6 hours interval between successive 
images, using the Cell-IQ machine (Chipman Technologies). Cells were counted 
using the software Cell Analyzer TM (Chipman Technologies). Assays were done in 
triplicates and statistical significance was estimated. The assays were performed in 
Prof. Primo Schär’s laboratory at Mattenstrasse, Department of Biomedicine, 
University of Basel.  
 
Lentivirus mediated stable KD  
 
For stable transductions recombinant lenti-virus particles expressing short hairpin 
(sh) RNA against SOX2 (sc-38408-V, Santa Cruz Biotechnology, Inc.), HEY1 (sc-
37914-V, Santa Cruz Biotechnology, Inc.), MFN1 (sc-43927-V, Santa Cruz 
Biotechnology, Inc), OPA1 (sc-106808-V, Santa Cruz Biotechnology, Inc.) and 
PIK3CA (sc-39127-V, Santa Cruz Biotechnology, Inc.) were used according to 
manufacturer’s instructions to stably KD of genes in U373 and LN319 glioma cell 
lines. Transduced cells were maintained in DMEM (D6429, Sigma-Aldrich) with the 
supplements mentioned in the previous section (cell culture and reagents). Long-
term selection was applied to KD cells with 5μg/ml of puromycin (P8833, Sigma-
Aldrich). After 1 day of selection, cells were used for experiments. Many aliquots 
were made and frozen for future experiments. RT-qPCR and Western blots were 
performed to validate cells for KD of candidate genes in the cell lines.  
 
Lentiviral transduction efficiency was measured using FACS sorting for GFP upon 
transduction of GFP expressing lentiviruses in glioma cells. The experimental setting 
for FACS sorting is displayed in Fig 35. 
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Chromatin immunoprecipitation (ChIP assay) 
 
General chromatin immunoprecipitation (ChIP) method described by Carey et al 
2013, was followed with minor modifications. 50-100 million cells were used per 
experimental condition. Cells were treated with 1% formaldehyde for 15 mn for DNA 
cross-link at room temperature and then quenched with 0.125 M glycine for 5 mn. 
After wash with PBS, samples were homogenized in lysis buffer (5mM PIPES (pH 
8.0), 0.5% NP40, 85mM KCl) containing protease inhibitors (Sigma-Aldrich) at 4°C. 
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Isolated chromatin was sheared with pulse sonicator for 8 cycles of 15 s ON/15 s 
OFF on ice. Average DNA fragment size in the range of 300–400 bp was confirmed 
by agarose gel electrophoresis. For immuno-precipitation (IP), 100 μg of chromatin 
was diluted to 750 μl with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 
mM EDTA, 16.7 mM Tris-HCl, 167 mM NaCl, pH 8.1). ∼1% of the diluted sample was 
saved to serve as input controls. Before sample sonication, dyna beads protein A/G 
(Cat No. 10001D, Life Technologies) were incubated with anti-SOX2 antibody 
(ab59776, Abcam), anti-H3 antibody (ab1791, Abcam) or IgG (12-170, Millipore), at a 
concentration of 10μg antibody per 100μg chromatin. Chromatin-antibody mix was 
incubated overnight at 4°C under constant rotation in blocking solution (0.5% BSA in 
PBS). Following wash and re suspension of the antibody-bead conjugates, chromatin 
samples were added in antibody-bead mixtures and incubated for 16 h under 
constant rotation at 4°C. After immuno-precipitation, the beads were washed at least 
four times (10 mn each) with high salt wash buffer (50 mM HEPES-KOH, pH 7.6, 500 
mM NaCl, 1 mM EDTA, 0.1% SDS, 0.1% deoxycholate, 1% Triton X-100), one time 
with TE buffer (10 mM Tris-HCl, pH 8.1, 1 mM EDTA), and then eluted with 200 μl 
elution buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS). The eluate was 
incubated at 65°C overnight (o/n) to reverse the cross-link. The input DNA was 
diluted in elution buffer to a final volume of 200 μl and processed for cross-link 
reversal. Samples were then digested sequentially with 0.2 μg/ml RNase A for 2 h at 
37°C and with 20 μg of proteinase K for 30 mn at 55°C. DNA was extracted by 
phenol/chloroform/isoamyl alcohol and subjected to quantitative PCR (IQTM Green 
Supermix, Cat No. 1708880, Bio-Rad) with primers specific to the predicted SOX2 
binding sites on promoter region of PIK3CA, SOX2, MFN1 and OPA1 gene.   
The quantitative real-time PCR data were analyzed by comparative Ct method. To 
control for variation between ChIP fractions, a ΔCt value was calculated according to 
the following formula: ΔCt (Normalized ChIP) = Ct (ChIP) − (Ct Input − Log2 (fraction of the input 
saved)-1). Further, to estimate signal vs background, ΔΔCt = ΔCt (Normalized ChIP) / Ct (IgG). 
Data are presented as fold enrichment above background for each IP sample: fold 
change = 2− (ΔΔCt).  
Primer pairs (PP) used for ChIP assay  
 PP1   SOX2 FP: GACAGTAACAGGCTAGGGAG 
       SOX2 RP: GTATCTACCAGCCACGTTCC 
 PP2   SOX2 FP: TTATAAAAAAGAAATGGCATCAGG 
       SOX2 RP: TAGAGGAGGATGAGATGGG  
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   PP3   SOX2 FP:  CACAATGGAAATCTACGGG 
         SOX2 RP:  CGGCACTGTATGGAGGTG 
    PP4  SOX2 FP:  TCGGGACTGTGAGAAGG 
         SOX2 RP:  TGGAAACAGCCAGTGCAG 
    PP5  SOX2 FP:  TCATTTAAGTACCCTGCACC 
         SOX2 RP:  AGCCTGCCAGCCACTGAG 
    MFN1_ChIP_FW:  TACTTGGACACTTTGAGGGG 
    MFN1_ChIP_RP:  CGCCATTTTCCTTAAGGG 
   OPA1_ChIP_FP_1: TATTTTCTAAAATAACAAGG 
   OPA1_ChIP_RP_1: GCAGGTCCAGAGAGCAAT 
   OPA1_ChIP_FP_2: ATTGCTCTCTGGACCTGC 
   OPA1_ChIP_RP_2: GTCAGAATCATAAGTCTGGACC 
   OPA1_ChIP_FP_3: GTAGTTGAAGGAGTGCTC 
   OPA1_ChIP_RP_3: GTTGAAATGGTCCTCGTC 
   PIK3CA_ChIP_FP: CCTCCTCAGCTCTTACCC 
   PIK3CA_ChIP_RP: GGTCTCTTTTTCCGCTCACA 
 
Affymetrix Gene Chip analysis 
Microarray experiment was performed at the Life Sciences Training Facility (LSTF), 
Biozentrum, University of Basel. Total RNAs (200 ng) were used to synthesize target 
cRNA using the WT expression kit (Ambion). cRNAs (10 μg) were used to generate 
~8.0 μg (±0.1 μg) of cDNAs. The WT Terminal Labelling Kit (Affymetrix) was used to 
fragment the cDNAs. The hybridization cocktail (85 μl) containing fragmented and 
biotin-labelled cDNAs (25 ng/μl) was transferred into Affymetrix GeneChip MoGene-
1_0-st-v1 cassettes, which were incubated at 45°C inside a hybridization oven by 
rotating them at 60 rpm for 17 hours. Then the GeneChip arrays were washed and 
developed using the Hybridization Wash and Stain Kit in a Fluidics Station 450. The 
GeneChip arrays were read using the GeneChip Scanner 3000 7G and DAT image 
files were generated using the GeneChip Command Console (Affymetrix).  
The Partek Genomic Suite 6.5 was employed to further validate the GeneChip 
results. Three completely independent samples for the cell line U373 (sh control, sh 
SOX2 and sh HEY1) were used to determine significant differences in expression 
levels. All Affymetrix CEL files were normalized using the RMA method and all data 
were log2 transformed. To identify differentially expressed genes, two-way ANOVA 
analysis based on the ‘method of moments’ was used. Differentially expressed genes 
were further filtered using a P-value threshold of 0.05 or less.  
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Generation of promoter constructs and cloning into expression vector 
 
Genomic DNA was isolated from HEK293 cells using the Qiagen DNeasy Blood and 
Tissue kit (Cat No. 69504, Qiagen) according to manufacturer’s instructions. The 
promoters of SOX2, MFN1, OPA1 and PIK3CA were amplified from genomic DNA 
isolated from HEK293 cells. MFN1, SOX2, PIK3CA promoter fragments were 
amplified by generating BglII-HindIII over hangs. OPA1 promoter fragments were 
generated with BamHI-NotI overhangs. All the promoter fragments were amplified 
using Expand long template dNTP pack 175U (Cat. No. 04829034001, Roche) and 
PCRs were performed according to manufacturer’s instructions. Amplified promoter 
fragments were then cloned into pGCL4.1 basic expression plasmid (Promega) 
(kindly provided by Prof. G Christofori). PGCL4.1-Luc-SOX2, pGCL4.1-LucMFN1, 
pGCL4.1-Luc PIK3CA were constructed by inserting the respective BglII-HindIII 
promoter fragments into the BglII-HindIII site of the pGCL4.1 expression vector. 
pGCL4.1-Luc OPA1 vector was constructed by inserting the BamHI-NotI promoter 
fragment into BamHI-NotI site of the pGCL4.1 expression vector. Restriction 
enzymes BamHI (Cat No. R3136, NEB), NotI (Cat No. R3189, NEB), BglII (Cat No. 
10348767001, Sigma-Aldrich) and HindIII (Cat No. 10656321001, Sigma-Aldrich) 
were used for cloning. Site directed mutagenesis is currently being performed. 
Primers used to amplify promoter regions and site directed mutagenesis are 
mentioned below.  
1. Primers used for cloning promoter region 
SOX2   FP: GGAAGATCTACGTGGCTGGTAGATACTATT 
       RP: GCGGAAGCTTTCCATATGTGACGGGGGCTGT 
- Promoter was cloned into pGCL4.1 basic Luciferase expression vector by creating 
BglII- HindIII  
MFN1 FP: GGAAGATCTGGAAGATCTCATGATCCAAACTGCTGG  
     RP: GGGAAGCTTGCCTCATCTTCCCGAG  
- Promoter was cloned into pGCL4.1 basic Luciferase expression vector by creating 
BglII- HindIII 
    OPA1 FP: CGGCGCTAGCAGTAGAGACAGGGTTTCACC 
               RP: GGCTCGAGGGCGCATGGACTTCCGCAAG  
- Promoter was cloned into pGCL4.1 basic Luciferase expression vector by 
creating NheI- XhoI 
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PIK3CA FP: GGCAGATCTCCTAGCACTCTGGGAAGTCG 
              RP: CGCAAGCTTACTTCTCGCTCCCTCTCCTC 
Promoter was cloned into pGCL4.1 basic Luciferase expression vector by 
creating BglII- HindIII 2. Cloning strategy for 3q26-29 promoter regions 
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3. Primers used for site directed mutagenesis 
 
Primer pairs were generated around the predicted SOX2 binding sites in 
promoter region of 3q26-29 genes. Mutated nucleotides are highlighted in 
red. Restriction enzyme sites formed on sdm constructs are underlined.  
 
SOX2 site 1_FW: GCGAGAGGGGAACGTTAGGTTTCTCAGTGG 
          1_RP: CCACTGAGAAACCTAACGTTCCCCTCTCGC 
SOX2 site 2_FW: GATGAGCGGGAAACGTTTGACACACCAACTC 
          2_RP: GAGTTGGTGTGTCAAAGTTCTCCCGCTCATC 
SOX2 site 3_FW: GCGTGGGAGGGAGTAACGTTCTGCGGCCCA 
          3_RP: TGGGCCGCAGAACGTTACTCCCTCCCACGC 
 
OPA1 site 1FW: GGAAGTAACGATTACTTAGACACTTTTTGTAC 
               1RP: GTACAAAAAGTGTCTAAGTAATCGTTACTTCC 
     OPA1 site 2FW: TACTCTTGGTGGTAAAGTGAGTGCATGGGTC 
               2RP: GACCCATGCACTCACTTTACCACCAAGAGTAG 
     OPA1 site 3FW: AGGCTCACTGGCCACTTACAATAGGGAGCTGG 
               3RP: CCAGCTCCCTATTGTAAGTGGCCAGTGAGCCT 
    PIK3CA site FW: GAAGAGTTCGTTGTAAGCTTACACGATGTG 
                RP: CACATCGTGTAAGCTTACAACGAACTCTTC 
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4. Cloning strategy for sdm of predicted binding sites in 3q26-29 promoters 
 
 
Luciferase assays 
Human Embryonic Kidney (HEK) 293 cells were used for Dual luciferase assay. 
75,000 cells per well were seeded in 12 well plates. JET PEITM transfection reagent 
(Cat No. 101-01N*, Polypus-transfection) was used to transfect HEK293 cells with 
luciferase reporter vector along with Renilla vector (0.1μg) for estimation of 
background. Cell lysates were extracted after 48 hours of incubation and analyzed 
using the Promega Dual Luciferase Assay kit (DLRTM Cat No. E1980, Promega) and 
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luciferase activity was measured using TECANTM (TECAN Infinite 1000, Tecan 
group). 
 
Generation of SOX2 overexpressing Lentiviruses  
 
1. Cloning 
The cDNA of SOX2 was amplified from mRNA that was isolated from HEK293 cells 
using the Qiagen RNeasy kit (Cat No. 74104, Qiagen). The cDNA was amplified by 
generating BamHI-HindIII over hangs using Expand long template dNTP pack 175U 
(Cat. No. 04829034001, Roche) and PCRs was performed according to 
manufacturer’s instructions. Amplified cDNA fragment were then cloned into pHAGE-
Lentivirus vector system (Invitrogen, and was kindly provided by Prof. Yves Barde). 
Restriction enzymes BamHI (Cat No. R3136, NEB), NotI (Cat No. R3189, NEB), 
were used for cloning. 
Primers used for SOX2 cDNA amplification: 
FW: 
GCGGCCGCGCCACCATGGAACAAAAACTTATTTCTGAAGAAGATCTGTACAACATGATGGAGACGGAG 
RW: GGATCCTCACATGTGTGAGAGGGGCAG 
2. Lentiviral packaging and transduction 
 
HEK-293T cells were seeded at 40% density on 10 cm culture dishes. After 24 
hours, the packaging plasmid (psPAX2), the plasmid coding for the envelope 
proteins (pMD2-VSV-G) and Lentivirus vector (pHAGE-PGK-MCS-IRES-ZsGreen-W-
scrambled, pHAGE-PGK-MCS-IRES-ZsGreen-W containing cDNA insert of SOX2 
and pHAGE-PGK-MCS-IRES-ZsGreen-W containing cDNA insert of HEY1) that 
carries the gene of interest were transfected on HEK-293 cells using Pei 
transfection reagent (Cat No. 115-010, Polypus Transfection). The transfection mix 
contained a total of 8.2 μg of pHAGE- Lentivirus vector system/ 10-cm dish – 4 μg 
Lenti- SOX2/ Lenti-HEY1 vector, 3 μg PAX2, 1.2-μg pMD2-VSV-G.  
 
After 48 hours of the transfection the supernatant was collected and centrifuged at 
3000 rpm for 15 minutes. The supernatant was passed through a 0.45µm 
PVDF membrane filter. The viral supernatant was spun 3000 rpm for 90 min. The 
pellet was suspended in 100μl DMEM and were stored in -80°C. The supernatant 
was titrated on HEK293 cells to estimate the viral transduction efficiency.  
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RT-qPCR 
 
Total cellular RNA was extracted from subconfluent cells using Trizol reagent (Cat 
No. 15596-026, Thermo Fischer scientific) and RNeasy Qiagen kit (Cat No. 74104, 
Qiagen). RT-qPCR was performed with 300ng of RNA using iScript cDNA synthesis 
kit (Cat No. 170-8890, Bio-Rad) according to manufacturer’s instructions. The qPCR 
from the cDNA was performed using Ssofast Evagreen supermix kit (Cat No. 172-
5200, Bio-Rad) using the CFX90 qPCR thermocycler (Bio-Rad). The data obtained 
were quantified using ΔΔCt method and results were expressed as fold change (2-
ΔΔCt) compared to control samples and GAPDH (housekeeping gene).  
 
Primers for cDNA synthesis were purchased from Qiagen 
 
Hs_GAPDH_1_SG QuantiTect Primer Assay (QT00079247) 
Hs_SOX2_1_SG QuantiTect Primer Assay (QT00237601) 
Hs_MFN1_1_SG QuantiTect Primer Assay (QT00077966) 
Hs_OPA1_1_SG QuantiTect Primer Assay (QT00085519) 
Hs_PIK3CA_1_SG QuantiTect Primer Assay (QT00014861) 
Hs_HEY1_1_SG QuantiTect Primer Assay (QT00035644) 
 
Western blot analysis and antibodies  
 
Total cellular lysates were obtained using the NE-PER nuclear and cytoplasmic 
extraction kit (Cat No. 78833, Thermofischer Scientific). Protein concentration was 
measured using Bicinchoninic acid (BCA) assay (Cat No. 23225, PierceTM Protein 
assay kit, Thermofischer Scientific). Proteins were denatured in Laemmli sample 
buffer (1:1) and were resolved on 4-20% and 8-16% bis-tris gels (Novex Page, 
Invitrogen). Western blots were performed using anti-SOX2 (MAB4343, Millipore), 
anti-MFN1 (sc50330, Santa Cruz), anti-OPA1 (BD Bioscience), anti-actin (sc1615, 
Santa Cruz), anti-PIK3CA (Proteintech) antibody at 1:1000 dilution. All the blots were 
blocked in 3% Top-block solution and Li-cor Odyssey secondary antibodies were 
used to detect the bands in the Li-cor Odyssey machine.  
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Immunofluorescence imaging  
 
In order to study mitochondrial dynamics, cells were co-stained with 12nM mito-
tracker green and 1mM Hoechst dye for 30 minutes and were washed with PBS. 
Spinning disk confocal microscope (Perkin Elmer), available at the Imaging core 
facility (IMCF), in Biocenter, University of Basel, was used for mitochondrial imaging. 
In order to study mitochondrial dynamics, 5000 cells were seeded on borosilicate 
1.5mm glass chambers (Cat No. 155411,Lab-Tek II 8 well, Thermofischer Scientific). 
Cells were stained with mito-tracker green and Hoechst. Live cell imaging was 
performed at 37oC and 5% CO2 conditions. Cells were imaged up to 7 minutes and 
12 images per minute were recorded. All confocal images were subjected to 
standard data processing tools and were done according to the guidelines provided 
by the IMCF.  
 
Immunocytochemical stainings were performed using anti-SOX2 antibody and 
DAPI. The cultured cells were fixed with PFA for 20 minutes and then were 
permeabilized with PBS containing 0.01% triton X-100. The permeabilized cells were 
incubated with primary antibody overnight and over 1.5 hours with secondary 
antibody. Cells were washed and stained for DAPI. The stained cells were then 
mounted on a glass slide for imaging. Laser scanning confocal microscopes were 
used from the imaging core facility of the Department of Biomedicine (DBM).  
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List of primary antibodies 
 
Antibody Cat. No Company Species/ 
Isotype 
IgG 
Epitope 
(mAb/pAb) 
Dilution Experiment 
anti-MFN1 sc-50330 Santacruz Rabbit  pAb 1:1000 WB 
anti-OPA1 612606 BD Lifescience Mouse 
 
mAb 1:1000 WB 
anti-Actin  Sc-1615 Santacruz Goat pAb 1:1000 WB 
anti-PIK3CA 20583-1-AP Protein tech Rabbit pAb 1:1000 WB 
anti-H3 Ab1791 Abcam Rabbit pAb  10μg ChIP 
anti-H2B Ab 1790 Abcam Rabbit  pAb 1:1000 WB 
anti-SOX2 Ab 59776 Abcam Rabbit pAb 10μg ChIP 
normal IgG 12-370 Millipore Rabbit pAb  10μg ChIP 
anti-SOX2 mAB4343 Millipore Mouse mAb 1:1000 IF/WB 
DAPI D9542 Sigma-Aldrich - - 1:10,000 IF 
Hoechst H1398 Thermofischer 
Scientific 
- - 10nM Live- Imaging  
Mitotracker 
green 
M7514 Thermofischer 
Scientific 
- - 10nM Live- Imaging 
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List of secondary antibodies 
 
Secondary 
Antibody 
Cat. No Company Fluorescent 
conjugate 
Dilution Experiment 
Goat  
anti- mouse 
926-32210 Odyssey IR-Dye* 800CW 1:10000 WB 
Donkey 
anti-goat 
925-32214 Odyssey IR-Dye* 800CW 1:10000 WB 
Goat 
anti-rabbit 
A21109 Invitrogen Alexa- 680 1:10000 WB 
Goat 
anti-mouse 
A21057 Invitrogen Alexa- 680 1:10000 WB 
Donkey 
anti-mouse 
A21057 Invitrogen Alexa- 555 1:10000 Confocal imaging 
Goat 
anti-mouse 
115-165-164 Jackson 
immunoresearch 
Cy3 1:10000 Confocal imaging 
 
Statistical Analyses 
 
All data are presented as mean ± SEM or mean ± SD as mentioned. Student's t test, 
Mann-Whitney test were used where appropriate using graph pad prism v6.  
 
3q26-29 genes promoter sequences 
 
Human and mouse promoter sequences upto 2000 bp upstream of transcription 
start site of 3q26-29 genes are aligned using CLUSTAL W (1.83) multiple sequence 
alignment. Potential SOX2 binding sites are highlighted in yellow (List of potential 
binding sites for SOX2 are shown in Result section Fig. 23 of Chapter I). 
 
1. SOX2 promoter region 
 
CLUSTAL W (1.83) multiple sequence alignment 
 
hSOX2           AAGAACTAAAACAAGCCATAACTTGAGAGAAAAAGGAGAACCTTCGGGGG 
mSOX2           A---------------------------------GGA----------GGG 
                *                                 ***          *** 
 
hSOX2           GCAGGAAGGTTGATTGGAAATAACTTAAGGAAAGTCTGCAGAATTCTTTT 
mSOX2           GCCGC------------------------GAGAG---------------- 
                ** *                         ** **                 
 
hSOX2           TTTTACAACTTTTCTGAGTTTCCAGTGGGTATATTTAGTGTGAGTTTGAC 
mSOX2           -----------------------------TA--TT------------G-- 
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                                             **  **            *   
 
hSOX2           AGTAACAGGCTAGGGAGGGCAGAGATTGGAGAAATTGGGGGTCGGGGGAG 
mSOX2           -----CA-----GG------------------------------------ 
                     **     **                                     
 
hSOX2           TGATTATGGGAAGAAGGTTAGTAAGGAACAAAACAATGCACCGTTTTGTA 
mSOX2           ---------GAAA----------------AA------------------A 
                         ***                 **                  * 
 
hSOX2           AAGATAATAAATGGAACGTGGCTGGTAGATACTATTCAGTACATTTTCTT 
mSOX2           AAGA---------------------------------------------- 
                ****                                               
 
hSOX2           AGGGTGAGTAAGGGTAGACCAGGGGAGGAGGGGGCGGAGAGAGTGTTACA 
mSOX2           ---------A-----------------------------AG--------- 
                         *                             **          
 
hSOX2           GAAGAAAGAAAATAAGTAACCCTGATGGTTTAAGCCCTTTAT-------- 
mSOX2           AAAGAAAGAAAATAAGTAACCCTGATGGTTTAAGCTCTTTATTTAAAAAA 
                 ********************************** ******         
 
hSOX2           AAAAAAGAAATGGCATCAGGTTTTTTTTTCTTTATTCCCCCCCACCCCAC 
mSOX2           AAAAAAAAAATGGCATCAGGACTTTCTTCCTTCTCT--------CCCC-T 
                ****** *************  *** ** ***   *        ****   
 
hSOX2           CCTTTGTAGTCAAGTGCATTTTAGCCACAAAGATCCCAACAAGAGAGTGG 
mSOX2           CTTTTGTACCCAAGTGCATTTTAGCCACAAAGGTTCCAACAAGAGAGTGG 
                * ******  ********************** * *************** 
 
hSOX2           AAGGAAACTTAGACGAGGCTTTGTTTGACTCCGTGTAGCGACAACAAGAG 
mSOX2           AAGGAAACTTAGACGGGGCTTTGTTTGACTCCGTGTAGCGACAACAAGAG 
                *************** ********************************** 
 
hSOX2           AAACAAAACTACCTATTTGTAACGGACGTGCTGCCATTGCCCTCCGCA-- 
mSOX2           AAACAAAACTACCTATTTGTAACGGACGTGGGGCTGTGGCTCTGGGCTTT 
                ******************************  **  * ** **  **    
 
hSOX2           TTGAGCGCCTACCTATTGAAATCTTTACGTCGGGACAATGGGAGAGCGGC 
mSOX2           TTGAGCGCCTGCCGATTGAAATCTTTACGTCTGGACAATGGGAGATCGGC 
                ********** ** ***************** ************* **** 
 
hSOX2           TAAAATTACCCTCTTGGGTCCTGGGCGGGCAAGATTCCTGAGCCCCTACC 
mSOX2           TAAAATTACCCTCTCGGGTCCTGGGCAGGCAAGATTCTTGAACCCCTACC 
                ************** *********** ********** *** ******** 
 
hSOX2           CCCGCCCCCATCTCATCCTCCTCTAACCCGGGCCTTGCTGGGCTCCCCCT 
mSOX2           CCCGCCCCCAGCCCATTCTCCCACAGCCTGGG-CTTGCTTGGTGCCGGCT 
                ********** * *** ****   * ** *** ****** **  **  ** 
 
hSOX2           TCCCCAGTCCCGGCCGCCTTCTCCCAGTGTGCGCTGCCTGCACCTGTGCC 
mSOX2           CCTCGGGTTCGGCGGGCCTTCTCTCC---------GCCTGCACCTGCACC 
                 * *  ** * *   ******** *          ***********  ** 
 
hSOX2           TGGAGAGCATCGACCCCGCCTCCCAGGCCTTGAGCCCCTTTGCGGCGCAG 
mSOX2           TCTGGACC-CCG--CGCGCTTCCCAGGCCC------------CGGCGC-- 
                *   ** *  **  * *** *********             ******   
 
hSOX2           CCCCAGCCTTGCGCGGCCTGGGCTTTGCGGCCACCACAATGGAAATCTAC 
mSOX2           -------CT--CTCGGCCGGGCCTTCGTGACTACCACCGTGCCTGTCAGC 
                       **  * ***** ** *** * * * *****  **    **  * 
 
hSOX2           GGGGAAAATGCCAGGGCTGGTTCTGCTGGAGTCCTGGGAACTCTGCGTGG 
mSOX2           AGGGGCAATGCC--GGCTG-CGCTGCCCCA-TCCTGAGAACGCTGCGTGG 
                 ***  ******  *****   ****   * ***** **** ******** 
 
hSOX2           GAGGGAGTTTGTGACTGCGGCCCAAAAGCCACCTCCATACAGTGCCGTGG 
mSOX2           GAGGGAGTTTGTGAGCGCAGCCCAAATGCCACCTCCGCGCCTCGCGGTGG 
                **************  ** ******* *********   *   ** **** 
 
hSOX2           GATGCCAGGAAGTTGAAATCACCCTCC-CCCATCGCCTGCACTTTTGAGC 
mSOX2           GATGCCAGGAAGTTGC-GTGACCCTCCCCCCATCCCCTGCACTCGGGAGC 
                ***************   * ******* ****** ********   **** 
 
hSOX2           GCCCTTCCGTCTGTGTCTT--T-CCCCAGCCCCCATTTGAAAGCCGCACG 
mSOX2           TTCTTTCCGTTGATGCTTTCGTCCCCAAGGTTTCCTCTGAAACTGCCACC 
                  * ******   **  **  * *** **    * * *****    ***  
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hSOX2           ACCGAAACCCTTCTTACGGGGAGGCATGGGA-TGGGAATGGGGAGTGGGG 
mSOX2           ACTAAAAATCCTCTTGTGT-CAGGGTTGGGAGTTAGAA---AGAGCGGGA 
                **  ***  * ****  *   ***  ***** *  ***    *** ***  
 
hSOX2           GCAGACAGTAGAAGCATCCCCTTTGCTACGGTTGAATGAAGACAGTCTAG 
mSOX2           GCAG--AGTTCCAGCTTTGCCTTTGCACCCTTTGGATGG-GGCAGGTTGG 
                ****  ***   *** *  *******  *  *** ***  * ***  * * 
 
hSOX2           TGGGAGATGTGGCT-GGGGCTAAGAGGAAGAGCTGCAGTTTCCTGGGCCA 
mSOX2           TGGAGTAGGGAATTAGGGGTTGAGGACACGTGCTGCGGTTCCTTGAGCCA 
                ***   * *    * **** * **   * * ***** *** * ** **** 
 
hSOX2           AAGAGCTGAGTTGGACAGGGAGATGGCAGCTTACCAAGGCCTGCTGGT-T 
mSOX2           C--ACCTGAGTCGGCCTAGGAAAAGGCTGGG-AACAAGGCCTGGTCCTAG 
                   * ****** ** *  *** * *** *   * ********* *  *   
 
hSOX2           CTCAGCTCTAGAGTCTGCCTTATGGTCCGAGCAGGATTTATTTTTAAGAA 
mSOX2           CTCTGCTCTACAGTCAGCTACATGGGCAGA---GGACTCGTGTTTGGGAA 
                *** ****** **** **   **** * **   *** *  * ***  *** 
 
hSOX2           CAGAGCAAGTTACGTGGAAGCAAGGAAGGTTTTGAGGACAGAGGTTTGGG 
mSOX2           CCGAGCCGATGACACGGAAGCCAGGAGGGCGCTGAGGCCCGAGGCTTGGG 
                * ****   * **  ****** **** **   ***** * **** ***** 
 
hSOX2           TCTCCTAACTTCTAGTCGGGACTGTGAGAAG--GGCGTGAGAGAGTGTTG 
mSOX2           TC---TAACTTCTCGTCTGTACGGTGAGAAGAGGGGGTGAGTGGGTGCTG 
                **   ******** *** * ** ********  ** ***** * *** ** 
 
hSOX2           GCACCTGTAAGGTAAGAGAGGAGAGCGGAAGAGCGCAGTACGGGAGCGGC 
mSOX2           GCGAC---AAGGT------------TGGAAGAG----------GGGCTGC 
                **  *   *****             *******          * ** ** 
 
hSOX2           ACCAGAGGGGCTGGAGTTGGGGGGGAGTGCTGTGGATGAGCGGGAGAACA 
mSOX2           GACAGAG---------------CGCAGTGCCGCGGATGAGCGCAGAAACA 
                  *****                * ***** * *********    **** 
 
hSOX2           ATGACACACCAACTCCTGCACTGGCTGTTTCCAGAAATACGAGTTGGACA 
mSOX2           ATGGCACACCACCTCCGGCTCTGCCAGCTTCCTGAAATACTAGTTGGACA 
                *** ******* **** ** *** * * **** ******* ********* 
 
hSOX2           GCCGCCCTGAGCCACCCACTGTGCCCTGCCCCACCCCCGCACCTTAGCTG 
mSOX2           GTCGCCCTGAACCACCCA-TGGGCCTTGCCCCACCCTGGCCCC--A---G 
                * ******** ******* ** *** **********  ** **  *   * 
 
hSOX2           CTTCCCGCGTCCCATCCTCATTTAAGTACCCTGCACCAAAAAGTAAATCA 
mSOX2           CTTCCCGCGCCCCATCCACCCTTATGTATCC-------AAGAGAGAGCCA 
                ********* ******* *  *** *** **       ** **  *  ** 
 
hSOX2           ATATTAAGTTTAAAGAAAA-AAAAACCCACGTAGTCTTAGTGCTGTTTAC 
mSOX2           ATATTCCGTAGCATGGGGGAAAGGAGC--TGTCGTCTTGGTGCTGTTTAC 
                *****  **   * *     **  * *   ** ***** *********** 
 
hSOX2           CCACTTCCTTCGAAAAGGCGTGTGGTGTGACCTGTTGCTGCG-------- 
mSOX2           CCACTTCCTTCGAACAGGCGTGCGCCGTGACCTGTTGCTGAAAACGGGGG 
                ************** ******* *  **************           
 
hSOX2           ------AGAGGGGATACAAAGGTTTCTCAGTGGCTGGCAGGCTGGCTCTG 
mSOX2           GCGGGGGGGGGGGATACAAAGGTTCCCCAGCGGCCGGCTG-CGGGC---- 
                       * *************** * *** *** *** * * ***     
 
hSOX2           GGAGCCTCCTCCCCCTCCTCGCCTGCCCCCTCCTCCCCCGGCCTCCCCCG 
mSOX2           ----CCGCCTCCCCCGCGCGGTTCG-GGGCA----CAGCGCTCTGCTGGG 
                    ** ******** *   *   *    *     *  **  ** *   * 
 
hSOX2           CGCGGC-CGGCGGCGCGGGAGGCCCCGCCCCCTTTCATGCAAAACCCGGC 
mSOX2           CTCGGCTCGGCGGCGCGGCAGGCCCCGCCCCCTTTCATGCAAAACCCTCT 
                * **** *********** ****************************    
 
hSOX2           AGCGAGGCTGGGCTCGAGTGGAGGAGCCGCCGCGCGCTGATTGGTCGCTA 
mSOX2           GGCGAGGCTGGGCTCGGGCGCAGGAGCCGGCGCTCGCTGATTGGCCGCCG 
                 *************** * * ******** *** ********** ***   
 
hSOX2           GAAACCCATTTATTCCCTGACAGCCCCCGTCACATATGGATGGTTGTCTA 
mSOX2           GAAACCCATTTATTCCCTGACAGCCCCCATCACA--TGGATGGTTGTCTA 
                **************************** *****  ************** 
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hSOX2           TTAACTTGTTCAAAAAAGTATCAGGAGTTGTCAAGGCA------------ 
mSOX2           TTAACTTGTTCAAAAAAGTATCAGGAGTTGTCAAGGCAGAGAAGAGAGTG 
                **************************************             
 
hSOX2           -------------------------------------------------- 
mSOX2           TTTGCAAAAAGGGAAAAGTACTTTGCTGCCTCTTTAAGACTAGGGCTGGG 
                                                                   
 
hSOX2           -------------------------------------------------- 
mSOX2           AGAAAGAAGAGGAGAGAGAAAGAAAGGAGAGAAGTTTGGAGCCCGAGGCT 
                                                                   
 
hSOX2           -------------------------------------------------- 
mSOX2           TAAGCCTTTCCAAAAACTAATCACAACAATCGCGGCGGCCCGAGGAGGAG 
                                                                   
 
hSOX2           -------------------------------------------------- 
mSOX2           AGCGCCTGTTTTTTCATCCCAATTGCACTTCGCCCGTCTCGAGCTCCGCT 
                                                                   
 
hSOX2           -------------------------------------------------- 
mSOX2           TCCCCCCAACTATTCTCCGCCAGATCTCCGCGCAGGGCCGTGCACGCCGA 
                                                                   
 
hSOX2           -------------------------------------------------- 
mSOX2           GGCCCCCGCCCGCGGCCCCTGCATCCCGGCCCCCGAGCGCGGCCCCCACA 
                                                                   
 
hSOX2           --------------G------------------------------AG 
mSOX2           GTCCCGGCCGGGCCGAGGGTTGGCGGCCGCCGGCGGGCCGCGCCCGC 
 
 
2. MFN1 promoter region  
 
CLUSTAL W (1.83) multiple sequence alignment 
 
hMFN1           CACACGCCTCATGATCCAA-ACTGCTGGGATTACAGGCGTGAGCCATCGC 
mMFN1           TAGGTAC----TGACCTGTCTTTGCTGTGCTTT---GCAT-AGTATGTGC 
                 *    *    *** *      ***** * **    ** * **     ** 
 
hMFN1           ACCCGGCAAGATTAATCTTTTCGTTAAACATGTAATAGAAAGTTACCCCG 
mMFN1           ACACG-TGTGAGTACATTAGCCGCTAGAGAT-CAACAGTGAGCAACGTTC 
                ** **    ** **   *   ** ** * **  ** **  **  **     
 
hMFN1           AAAATCA-TCTAGACCTGGCTAGTTTTGAATATGTGGGAAACTTAGCCTA 
mMFN1           ACTATCAGTCTCCACCT-------------TATTTTGGAAAC--AGTCTT 
                *  **** ***  ****             *** * ******  ** **  
 
hMFN1           TTCGAGTTTTCTATTTTTTCTCGGTCTAATTTTGGTATTTGATGTTTTCC 
mMFN1           T-C---TTTTTTGTTTTTTGTTTGTCAAGACAGGGTTTCT-CTGTGTA-G 
                * *   **** * ****** *  *** *     *** * *  *** *    
 
hMFN1           CAGATTTTATACTTCATCT-AAGCTTTTCAATTTGTTGGCATTTAT-ATA 
mMFN1           CACTGGCTGTCCTGGAATTCACTCTGTAGACCAGGCTGGCCTCGAACTCA 
                **     * * **  *  * *  ** *  *    * **** *  *    * 
 
hMFN1           TATATCTATAGTTATTCT-CCCCTTAATTTGTGTCCTTTCATTTTTTATG 
mMFN1           GAAATCCT-CCTGCCTCTGCCTCCCAAGTGCTGG--GTTCAAAG-GTGTG 
                 * ***     *   *** ** *  ** *  **    ****     * ** 
 
hMFN1           TTCTTGAACAGATTTGGCAGTGATACATCAAATTGATAATTTCTTTCAAA 
mMFN1           TGC--CACCATGCCTGGCAA--GTCTTTCAAAGAACTCAGCTCACTGA-- 
                * *   * **    *****    *   *****    * *  **  * *   
 
hMFN1           TAACGTTAGTTTTTGTTAATATCTATGTTGGTTTTAGCGTTTATATTTTA 
mMFN1           T-TTGCTAGCCTGGCCAGCCAGCTCCAGAGATTTCCCCACCCCCAGCATT 
                *   * ***  *        * **     * ***   *      *   *  
 
hMFN1           ATTCTTTTCCTTCTTTGTGTTTACTCTCCTGGCTTTTTGGTAATATGTGT 
mMFN1           ATTGTTTTCCCCATGAGTGGCTAGAGATCTGGATCC-AGGTC-TTTATG- 
                *** ******   *  ***  **     **** *    ***  * * **  
 
hMFN1           GTTCCA-CACACACACAAAAGCAATGGATTAAATTTCTTATTACTTACTA 
mMFN1           ---CCATCACAGCAAGAACTTTACTGCTTGAGCCTTCTCCCCAG----TC 
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                   *** ****   * **    * **  * *   ****    *     *  
 
hMFN1           TATTAAACATTTA--ATTACCGTGCTATAATTTATAGCCTGTAATATGTC 
mMFN1           TCTTAAGTACTGATCCTTATTG-GC-----TATATACCCTGGAAATAGGC 
                * ****  * * *   ***  * **     * **** **** **   * * 
 
hMFN1           ACTCTTGCTTTAAAATGCAGTAATTATATTAAATATAATTATTAAGTACA 
mMFN1           AGTTCAAGGCCAGCCTGG--TCTATGGAGTGAGTTCCAGGGCTACACAGA 
                * *        *   **   *   *  * * * *   *    **   * * 
 
hMFN1           GAA-------CTAATAAAAGGATACCATCATGATTTTTAAAATTCAAACA 
mMFN1           GAAACCCTGTCTCA-AAAAGAAAAA---AATCATTTTAAAAAATCTGGCC 
                ***       ** * ***** * *     ** ***** **** **   *  
 
hMFN1           GAGTAAATGTTCCCTTTGAGACTACCTATGCTCAGAACTGA--TGGATTA 
mMFN1           TGGGAGGCAAAGGCATTGGATCTCTGTGAGTCCAAGGCTAACTTGTTCTA 
                  * *        * ***   **   *  *  **   ** *  **   ** 
 
hMFN1           GCTGGCACGACCCAG-ACCGATAAACTGGCTCATCTGACCTAGTGTCCCC 
mMFN1           CATAGTGAGTTCCAGGACCCA-GGACTGTCT-ATATAA---AATGACACT 
                  * *   *  **** *** *   **** ** ** * *   * ** * *  
 
hMFN1           CAACCCAGGAACTGACTCGTGCAGAAAGACAGCTTCCACTCCCTGCGATT 
mMFN1           GTCTCCAAAAAACAACCCA---AAACAAAAATCTTCAAATTTAGGCAGAG 
                    ***  **   ** *    * * * * * **** * *    **     
 
hMFN1           TCATCCCTGACCAATCAGCACTCCTG-GCTCAGTGGCCTCCCCCAACCCA 
mMFN1           TGAGAGC--ACAGATCTGAATTCTAGCACTTGGGAGGCTGTGACAGCGGG 
                * *   *  **  *** * * **  *  **  *  * **    ** *    
 
hMFN1           CCAAATTGTCCTTAAAAATTCTG--CTCCCCAGTGCTGCTCGGGGAGACT 
mMFN1           TTTGTGAGTTCTTTTTGTTGTTGTTTTGTTTTGTTTTGTTTTTTGTTGTT 
                       ** ***     *  **   *     **  ** *    *    * 
 
hMFN1           GATTTCAGTAATAATAAAACTCCAGTCTCCCATACAGCC-GGCTTTGCGT 
mMFN1           GTT-TGTTTGTTTG-------TTTGTTTTTTTTGGAGACAGGGTTTCTCT 
                * * *   *  *            ** *    *  ** * ** ***   * 
 
hMFN1           GACTAAGTCT--TTAT-TTGCAATCCCCCTGTCTTGTATCAGTTCTGGCT 
mMFN1           GTATAGCTCTGGTTGTCTTGGAA-CTCACT---TTGT---AGATCAGGCT 
                *  **  ***  ** * *** ** * * **   ****   ** ** **** 
 
hMFN1           AGTCAGCGGGCAAGGTGAAGGCTTTCCTTGGGCGGTTACCATCCGA-AGC 
mMFN1           GGCC-----TCAAACTCAGAAATCTGCCTGT-C-TCTGCCTCTCGAGTGC 
                 * *      ***  * *    * * * **  *   * **   ***  ** 
 
hMFN1           TTTAATTTTAAGTATA--ATGGCAAGCTGTTGGAAAGCTTTTTTTTTTTT 
mMFN1           TGGGATTAAAGGTGTGTGCCACCACGCCCAGCTCATGCTTGTTTTTTTAA 
                *   ***  * ** *       ** **       * **** *******   
 
hMFN1           TTTTTTTTTTTTTTTTTTTTTTTTGAGATGGAGTCTGGCTCTGTC---GC 
mMFN1           CTCATCCATTTTAGCACTGTCCTTCCTATG-TGTCTTGGACAGTTTTTCT 
                 *  *   ****     * *  **   ***  **** *  * **       
 
hMFN1           CCAGGC---TGGAGT-GCAGTGGCGCGATCTCGGCTCACTGTAACCTCCG 
mMFN1           CCAGATATTCCCAGTAACAGTC--CTGAAATGACCTGA--GAAATGACAT 
                ****        ***  ****     **  *   ** *  * **   *   
 
hMFN1           CCTC-CCGGGTTCAAGCAATTCTCTGCCTC-AGGCTCCTGAGTAGCTGGA 
mMFN1           CCTTTCAGAAAACACATACCTCTTTGGCTCCACCTTGCTCATTTTTCTTC 
                ***  * *    **   *  *** ** *** *   * ** * *        
 
hMFN1           ACTACAGGCGCCCGCCACCACCACGCCCGGCTA--CTTCTTGTATTTTTA 
mMFN1           ACTCTATCCTCTTGTCCTGATCTCCCCCCCCCCCCATAATAGCAGTCATA 
                ***  *  * *  * *   * * * ***  *     *  * * * *  ** 
 
hMFN1           GT-AGAGACGG--GCGTTCACCGTGT-TAGCCAGGATG-CTCCCGATCTC 
mMFN1           GTCTGAAATGATCTCATTCACTGTATTTATCCAACTTTTTTATCCAACTT 
                **  ** * *    * ***** ** * ** ***   *   *  * * **  
 
hMFN1           CTGACCTTG-TGATCCGCCCGCCTCG---GCCTCCCAAAGTGCTGGG-A- 
mMFN1           TTATTTTTATTTATCCAACTTTTGCAGGTGCCCATCAATGTTTTAAGCAC 
                 *    **  * ****  *     *    ***   *** **  *  * *  
 
hMFN1           -TTACAGGCGTGAGCCACCCCGCCCGGCCTGGAAAGCTTTTTAAGTTCGG 
mMFN1           TTTACAC-CCTAACCCATTT-ACTT-TCCCA--CAATTCATGAAGTAGGC 
                 *****  * * * ***     *    **     *  *  * ****  *  
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hMFN1           AAA-GTAATACGATCTGGATTTCTTTTCTTTTATTTATTTAT------TT 
mMFN1           ATTTTTAGTATTTTATAGATGAGGTAGCTGCCATTCATATGGATAAAGGG 
                *    ** **   * * ***    *  **   *** ** *           
 
hMFN1           ATTTAT-TTGAAAAAATGTCTCGCTCTCTTGCCCAGGCTGGAGTG-CA-G 
mMFN1           GCTTCCCTGGCAAAAGCATCTCATTTGCTAACTCTGTAAAGAACCTCTCA 
                  **   * * ****   ****  *  **  * * *    **    *    
 
hMFN1           TGGCACGATAAATCACAGTTCGCT-GCAGCCCCGGGCCCAAACAATCCCC 
mMFN1           GGACACATGCTGTGAAACCTCTCTTGGAAGGTGGAACATGTAGAGTCCTT 
                 * ***      * * *  ** ** * *     *  *    * * ***   
 
hMFN1           CCGCCTCAGTCTCCGAAGTAGCTGGGACCACAGGTGTGTGCCACCACGCC 
mMFN1           GGGCTTCACCCTC-GATCAATC---AATCAATGGT--TTAACAAGATTCC 
                  ** ***  *** **   * *    * **  ***   *  **  *  ** 
 
hMFN1           TCGCTAAGTTTTTAAAATTTTTTTAATTTTTCATTTTTTAATTTTGTAGA 
mMFN1           CAGGTGATTCC-TAACAAAGTT-TAAATCATGAACAATTAATTTTCTTGA 
                  * * * *   *** *   ** *** *  * *    ******** * ** 
 
hMFN1           G----AC---GGGGAGGAGGAAGAGGGTCGGGGGCGGGGGGGGGGGCGCC 
mMFN1           GTAATACCTCTTACAGTAAGTAGACACACACAGCTCACTCCAGTAACCCC 
                *    **       ** * * ***    *   *         *   * ** 
 
hMFN1           ----TCCCTATGTTGCCCAGCCTAGTCTCGAACTCCTGGGCTTAAGAGAT 
mMFN1           AGAAAACCAATCAAGACCAGAGCAATTGGAAAAGTCAAAGTTTTGACGAC 
                      ** **   * ****   * *    **   *   * **    **  
 
hMFN1           A--TCCCACCCCTTCGGTCTCCCAAAGTGCT--GGGATTATAGG---CGT 
mMFN1           CCCCCCCCCCCCCCCCGCATGATAAACATCTATGTGGTTTTGGGGTACTT 
                    *** ****  * *  *   ***   **  * * ** * **   * * 
 
hMFN1           CAGCCA--CCACCATCAT-------TGGAAGCTAGCTAAGCCTAGGCTGG 
mMFN1           CTCCCCCTACACCCTCAGATAACCATGGACATCTTTTCACACTTGGCGCC 
                *  **    **** ***        ****       * *  ** ***    
 
hMFN1           GCAGATACTTGGACACTTTGAGGGGAGAAGGGAGGGGAAGAAGTTGGAAG 
mMFN1           TTTGAGCTTTGAAAACTCTGAAGGGAAAAACCAAGGGGAGGAGTTGGAAG 
                   **   *** * *** *** **** **   * *** ** ********* 
 
hMFN1           GGGGAACGGAAAACCACTCTCCTG---GTAGCAGTCTCTGCCCACAACAA 
mMFN1           GTGGAACAGAAAACAGCCCAGTGGTTAATAAGAACTCCTGCCCAAAACAA 
                * ***** ******  * *    *    **  *    ******* ***** 
 
hMFN1           ACCTTGCCTTCTGCCCTTAAGGAAAATGGCGCCTGGCATAGATGCGCTTC 
mMFN1           ACCTCGCCTTCAGCCCTGAAGGAAAATGGCGCCCGCAATATATGCAGTTC 
                **** ****** ***** *************** *  *** ****  *** 
 
hMFN1           CGGCCACGGAGCCAAACAGAACAGAGGAGGCAAGAGGCCGGAAGTGACCG 
mMFN1           TGGTCTCGAAGCGTCAGCCAATAGGAGATCCGAAGCGCCGGAAGTAGCCG 
                 ** * ** ***   *   ** **  **  * *   *********  *** 
 
hMFN1           CCCTTTGCCACTCCCCCTGCCTCCTCTCCGCCTTTAACTTCTCGGGAAGA 
mMFN1           CCCCTAGCC----------------------------------------- 
                *** * ***                                          
 
hMFN1           TGAGGCAGTTTGGCATCTGTGGCCGAGTTGCTGTTGCCGGGTGATAGTTG 
mMFN1           ------------------------------------C------------- 
                                                    *              
 
hMFN1           GAGCGGAGACT 
mMFN1           --------CTC 
 
3. OPA1 promoter region  
 
CLUSTAL W (1.83) multiple sequence alignment 
 
hOPA1           ACCTCTGCCTCCTGGGTTCAAGCAATTTTTCTGCCTCAGCCTCCGAGTAG 
mOPA1           AGCAAAA-GTCCAACATCATTTCACACTGTGTAGCC-AAACAAAAAAACT 
                * *      ***    *     **   * * *  *  *  *    *     
 
hOPA1           CTGGCTAATTTTTTTATTTTTAGTAGAGACAGGGTTTCACCATATTGGCC 
mOPA1           CTGGCCTGAATTTGAACTAGTGGTGGTGGTTTGATTTCATAA---CAGTC 
                *****     ***  * *  * ** * *    * *****  *     * * 
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hOPA1           AGGCTGGT-CTCAAACTCCTGACCTCGTGATCT-GCCTTCCTCGGCCTCC 
mOPA1           TAACTAATTTTCCTATTCAG--CATTATAAGTAGATGTTCCTCAATGTAC 
                   **  *  **  * **    * *  * *       ******    * * 
 
hOPA1           -CAAAGTGCTG-GGATTACAGGCATAAGCCGCCATGCCCAGCCCAAATGT 
mOPA1           ATAGCGTGAAGTGGATGTCAT--ATAAAC--CCATTA-TAACTTGAA--- 
                  *  ***  * ****  **   **** *  ****    * *   **    
 
hOPA1           AGTGTTATTTTTAAAACACTGCATAGGCCAA---------CACTGTCTAA 
mOPA1           AGTCTCACTTGAGGCACACC-CATATCCCAAACTTCCTACCTCAGTCTAG 
                *** * * **     ****  ****  ****         * * *****  
 
hOPA1           ACC--AAAC--AAAACAGGTCTGTG--GGCTGAATTTG--GTCCAATGGT 
mOPA1           CCCTCTAACCTTAAACATGCTTACAACAGATACATTAGCAGTCAAGTGGC 
                 **   ***   ***** *  *      * *  *** *  *** * ***  
 
hOPA1           TGCAGTTTAT----TATACAACAGTTTGCCCTTTTTTCATGGCAACACTA 
mOPA1           C-TATTTTATATGGGATTGAGTAAATCACCCTTATTAGATAAT-ATATTA 
                   * *****     **  *  *  *  ***** **  **    * * ** 
 
hOPA1           TGTATCTATGGGAGATCATTCCTTATTAGTAC-GGATGTA--------AT 
mOPA1           AATATAGAAAACAGGCTGGTTGAAACAAGTATTGGATGCATGGCTTCTAT 
                  ***  *    **     *    *  ****  ***** *        ** 
 
hOPA1           TTATGTGTCTAGTTCCTAT-ACATGGACATT--T---ATACTGATTCCAA 
mOPA1           TGAATTTTCTTCTTCACATTTCTTTGACAGCATTGTGAAGTTAAAACAAA 
                * *  * ***  ***  **  * * ****    *   *   * *  * ** 
 
hOPA1           TCTT-TTCCCATTT--CATACAGTGCAGAAATAAACATCATCATGCATAC 
mOPA1           ACAAAAACCTAGATTAAAGCCATTTCAAATTAGGGCAATCTATTTCAGAT 
                 *     ** *  *   *  ** * ** *      **   *  * ** *  
 
hOPA1           ATCTTTGCATACATGGGAA-T--GATTCCACAGGATAAATGCCTAGA--- 
mOPA1           ATTATTCTCTATTTGGATACTGAGAGCTCATAGGTTTTGTGACTAGTGTG 
                **  **   **  ***  * *  **   ** *** *   ** ****     
 
hOPA1           AGTAGAACT-GCAAAACAAG-GGCTTCATA-AAACAT--ATGATAACCAT 
mOPA1           AATGTAATTCACTTAATTAGCTACTATCTAGAGACTTTCATGCTAACTCT 
                * *  ** *  *  **  **   **   ** * ** *  *** ****  * 
 
hOPA1           ATATA------AATGGTGATGGTG---GTTAGTTTCTCCTTTTTTTATGG 
mOPA1           ATTTTGCTATCTAATACAATGGTAGACATAAGTTACACATAGTCCCAGCC 
                ** *        *     *****     * **** * * *  *   *    
 
hOPA1           TTAAAGTC---TTTTATCCC-----------------TAATTTTTCTTTT 
mOPA1           TAGAAGTGGAATTATAAAGCAAGGGCTTTGTAAACTGCAAAGACACATT- 
                *  ****    ** **   *                  **     * **  
 
hOPA1           TTGTTGTTGTTGTTAAAGTCTCTTGGTTTCTCTTATTTTATTTTCTAA-A 
mOPA1           -ACACATGGAAGCAGCCGTCACTTACTTCTCCCTTTTGTGTTTTCCAACA 
                      * *  *     *** ***  **   * * ** * ***** ** * 
 
hOPA1           ATAACAAGGAAGTAACGATTACAAAGACACTTTTTGTACAACCCTACAAT 
mOPA1           AGAATTAGGAAGCAACAATAACAAATGCATTTTTTATTCAATACTAGAAA 
                * **  ****** *** ** *****  ** ***** * ***  *** **  
 
hOPA1           --CCCAGG----AA---GATCTACAG-----TTTGCACAGGTTGG----T 
mOPA1           AAGTTGGGGTTTAAACTGGTTTCTAGTTTGGTTTATACTGGTTAGGCTTT 
                      **    **   * * *  **     ***  ** **** *    * 
 
hOPA1           ACAGCAAATTGCTCTCTGGACCTGCCATTGAAACAGTCACCACAATAAAT 
mOPA1           ATAGAAGGTTTCTATCTACAGCTATCATTGAGACAGTCATCACAGTAAAT 
                * ** *  ** ** ***  * **  ****** ******* **** ***** 
 
hOPA1           AAAGAAAATTCTAAGAGTCCTGCATTTGGGAAGTTTACTATCA-ATGGCT 
mOPA1           AT-----ATTCCTCAAGTCCTGCAATCAGAACGTTTACTGTCAGACAGTT 
                *      ****    ********* *  * * ******* *** *  * * 
 
hOPA1           AGGTCT--ACTCTTGGTGGTATTGTGAGTGCATGGGTCCAGACTTATGAT 
mOPA1           GCGTTTATATACTTGCCACTATTGTGACTAGATGGATTCTGATTTATGGT 
                  ** *  *  ****    ******** *  **** * * ** ***** * 
 
hOPA1           TCTGACAATTAAGGGAAAAGGAATTGTCTTT--ATGCT-------CTGTG 
mOPA1           TTTGATAATTAGATAAAAAGCAATTTATTTGGGGTGCTGGTGGTGGTGTG 
                * *** *****    ***** ****   **    ****        **** 
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hOPA1           TATTT-GTGTATGTGTGTGGCAT-GGGTGGGGGGCGGGTAGTGGGGA--G 
mOPA1           TATTTCATGTGCGTGTGTGAGAGAGAGAGACTGACAGAGACAGGGGAAGG 
                *****  ***  *******  *  * * *   * * *  *  *****  * 
 
hOPA1           GAG----GTGAAAGG------TCCCTGAAGTAAAGAGGATGCACAGGACC 
mOPA1           GAGACGAGTGAAAGGAATGTATCCTTGAAGTGAA-ATAAAGTACAAGACT 
                ***    ********      *** ****** ** *  * * *** ***  
 
hOPA1           CTTTTATTTTAGTC------CCTAAAAATTGGCTTCATAACCGTTCACAG 
mOPA1           ATCTGATTTTTTCCAATAACACCATTAATCGACTTCACAATCTTTCACTG 
                 * * *****   *       * *  *** * ***** ** * ***** * 
 
hOPA1           GCCACATCCCTTTTACGGGCCC-TGGTTTCCTTACAAAACATAAAAGGTT 
mOPA1           GCAATATTCCTGTTTTGAGTCCCTGTTCTCTTTA-AAAAAATACAAAAAT 
                ** * ** *** **  * * ** ** * ** *** **** *** **   * 
 
hOPA1           TGTGTTGGAAGGGGAAAGGAGTATTTAAAGTGATGGAGG-AGAGGAGCTC 
mOPA1           G--GTTGAAGATGGAGAAGA-TACTTGGATTGATACAAATAATTTAGATT 
                   **** *   *** * ** ** **  * ****  *   *    ** *  
 
hOPA1           AAGATGGCTGAGATCTGGGCCTGTCCAACATTGAGAAATTTGGGAGGGGA 
mOPA1           ATTAAGGAGAAAATGTA-GCCAGA--AAAAGGAAGGAACTCAAAAGGCCC 
                *  * **   * ** *  *** *   ** *   ** ** *    ***    
 
hOPA1           G--CCATCAAAGAAGCCTGGGAGCAGCAGTTCCAGGGAAAAAGGAGAATG 
mOPA1           AAAACCTAACTGGAACTTTTGAATATTAAATAA---TAGTTGGGAGAAGC 
                    * * *  * * * *  **  *  *  *      *    ******   
 
hOPA1           TGATGGCCAGAGAGCCAAAAGAAAAAGTA-GTTGAAGGAGTGCTCAGCAC 
mOPA1           AGGTAGCTAG-GAGACTAGACATCAACTACGTCCGAAGAGGGGTTGA--- 
                 * * ** ** *** * * * *  ** ** **   * *** * *       
 
hOPA1           TAGGCATCTGAACTGAATGCTGTGGCAGGCTCACTGGCCACAAACAATAG 
mOPA1           TAGGGA----------GGAGTG-GGGAGGG--ATAGGTTACAAGGAGAAG 
                **** *              ** ** ***   *  **  ****  *  ** 
 
hOPA1           GGAGCTGG---TGGAGGCCTTGACGAGGACCATTTCAACAAACTGGTGGG 
mOPA1           GAAGAATGAATCTGACGTCTTGAAAATCAAAA-GAAAACTAAGAAGAGAA 
                * **   *     ** * *****  *  *  *    *** **   * *   
 
hOPA1           CTTA------AAATCCGGAAGAAACAGTTGAACAAATCATTTTGACGCCT 
mOPA1           CTTAGGCAGATACTACT-AAGGAGCCATTACTGGAG--A-GATGGCGCTG 
                ****       * * *  *** * *  **     *   *   ** ***   
 
hOPA1           TTTATAAACCA-CACAAG-CTTATTCCAAACCCGTTACTGGCCTAACTGA 
mOPA1           TTAAGAGACTTTGACAAGGGCCATTTCAATAAAATGGGTGCCATTA-AAA 
                ** * * **    *****    *** ***     *   ** * * *   * 
 
hOPA1           TTTAAGTCCCTTTCCCATCTGATCCTCAGAGATTCTAAGGGACTTAGCCT 
mOPA1           TTCAGGTGA--AAGCCAACAAAG---GGGGGAATG-AAAAAACAAAACAA 
                ** * **       *** *  *      * ** *  **   **  * *   
 
hOPA1           ATCCATGACTCTT-CGTCCTGCTTCTCACCTCCCATGATTGCCCTAACGA 
mOPA1           AACAAAAACATTTGTGTCTTA-ATAAAACTGTATGTGTTTATCCCAAACC 
                * * *  **  **  *** *   *   **      ** **  ** **    
 
hOPA1           TGTGAAAGTGCTTTCAAACAAAGATGCC-CAAGAAAGAAGGTAGGCAAAT 
mOPA1           T---AC--AGCTTA--------AATGTCAGAAGTCACTTTCCAATCAGAT 
                *   *    ****          *** *  ***  *      *  ** ** 
 
hOPA1           GTGCAAGCATTAGTTTGTAGTACGCTATTACTGTAT-TTCACCTTGCACT 
mOPA1           CTCGGA-CTTTCTAAGGTGTCTCGC--ATACTCGATCTTCTGGCTATATG 
                 *   * * **     **    ***   ****  ** ***    *  *   
 
hOPA1           CTCTAGTTTCCTTCGTGCTCCCTCAATATCCAACTCTTAATAAATTCATG 
mOPA1           ATTCAGCTACGAAAATGATCTTTAAA-A--GA--TTTCCTTAAATTGGCT 
                 *  ** * *     ** **  * ** *   *  * *   ******     
 
hOPA1           GCTCCCGGTGAGCATTCATCAATTCTCATTCCACGCCTTTAGCCCTTCCC 
mOPA1           GCTCCTAATAAACATTCGTCCAGTG-GATTTCCTGCACCCAGCCCGCCCA 
                *****   * * ***** ** * *   *** *  **    *****  **  
 
hOPA1           GTTCCCGCCCAACTCTCGCTCCCTCCCCTGGCCAAATCTCTAACCTGCAA 
mOPA1           GTTCATTTTCAAAATTCCTACACTTTGAGGGCGGAGCCAAGAA---G-AG 
                ****     ***   **   * **     ***  *  *   **   * *  
 
hOPA1           GGCTAATTCCGAATTCCAAATCGGAAGCGGGCCCCGTGAGAGGCG-ATGG 
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mOPA1           GAGCACTACACAGGTCCCGCCCAGTGGC--TCCCCGCGCA-TGCGCATGT 
                *   * * *  *  ***    * *  **   ***** *    *** ***  
 
hOPA1           ATTGCTCCAGTCCGTTCCCGACGCACTGTGCGCATGCGCTGGTCCTCCGC 
mOPA1           C-ATCCGCGGCCCGTTTGT---GCAGCCTGCCTA-GCGT---TCCT--GT 
                    *  * * *****      ***   ***  * ***    ****  *  
 
hOPA1           GGACCGTTC 
mOPA1           G----GGTG 
                *    * * 
 
4. PIK3CA promoter region  
 
hPIK3CA         ACATTATCAACCGTGAATTGAATAGTAAATGCTACTCCTGTACCAATGAA 
mPIK3CA         GTTTTCTCGTTTTTAAGAGGAGCC----TTGGAAGGCATGTGTGTATGG- 
                   ** **     * *   **        **  *  * ***    ***   
 
hPIK3CA         TGGTGTCATGCATTCAAGTACCAGGTATGGCTTTTTCTGCTATG-ACACA 
mPIK3CA         --GGGCTGGGGACTTGAGCACT-GGTACA--TTGTCCAGATGTGGTCAGA 
                  * *    * * *  ** **  ****    ** * * * * **  ** * 
 
hPIK3CA         CAACTTCTTAGGGGCAGATAATCACATAACAAAAAACATATTATGTAATT 
mPIK3CA         GGACAGCTCTGGG--AACTGGTTCCCTGTGAGACCAGAGAT--TGAACTC 
                  **  **  ***  *  *  *  * *   * *  * * **  ** * *  
 
hPIK3CA         AGCATTTTCTTATTAAAAAATAAATTTTAGGCTGGGCATGTCGGCTGAAG 
mPIK3CA         AG-GTCATCTGATT-----------TCCATGGCAAGCACTTTTACCCATG 
                **  *  *** ***           *  * *    ***  *   *  * * 
 
hPIK3CA         TCTGTAATCCCAACACTTTGGGAGGCCGAGGTAGA-TGAATCTCTTGAGC 
mPIK3CA         --AGCCATCTCAACAACT-GT-AAGCGTGCATATTTTAAAGGTTTTAATG 
                   *  *** *****  * *  * **     **   * **  * ** *   
 
hPIK3CA         CCAGGAGTTGGAGACCAGTCTGGGCAACGAAGCAAGACC-CTGTCTTTAC 
mPIK3CA         GCAT--CTTCCAAATGAGTCC----------CCAAGACTGCTGTCATCT- 
                 **    **  * *  ****            ******  ***** *    
 
hPIK3CA         AAAAAATAAAACATTTTTAAAAATCACAAATAGGCCAGGTGCGGTGGCTT 
mPIK3CA         AAAATATTATAAGTATTTA---ATC---------CGAAGTGGGGTGACAC 
                **** ** * *  * ****   ***         * * *** **** *   
 
hPIK3CA         ACGCCTGTAATCCTAGCACTCTGGGAAGTCGAGGGGGGTGGATCACCTGA 
mPIK3CA         AGAGAGTTAGTCGTAGGTCCTTCAATA-TTTAAAACAGTCCATCTCAAGA 
                *      ** ** ***  *  *    * *  *     **  *** *  ** 
 
hPIK3CA         AGTCAGAAGTTTGAGACCAGCCTGACCAACATGGTGAAACCCCGTCTCTA 
mPIK3CA         ATATTAAGAATTGGC-ACAGCTTAATCACCATGCT--------------T 
                *     *   ***    **** * * ** **** *                
 
hPIK3CA         CTAAGAAATACAAAAATTAGCTGGCATGTTGGCTGGTGCCTGTAATCCCA 
mPIK3CA         C-AAGGAA---AATAATT-GATGATATTTTGTTATGTAACAATATACTTT 
                * *** **   ** **** * **  ** ***    **  *  **  *    
 
hPIK3CA         GCTACTCGGGAGGCTGAGGCAGAAGAATCGCTTGAACCCGGGAGGCAGAG 
mPIK3CA         AAAA---ACCAAATTGGGGGCTAAGAGTGGCACCAGCCTT-----TAGTC 
                   *      *   ** **   **** * **   * **        **   
 
hPIK3CA         GCTGCAGTGAGCCGAGACTGCACCGCTGAACTCCAGCCTGGGCTACAGAG 
mPIK3CA         CCAGCACTTGG--GAG---GCACAG------GCTAGCCTGATCTACAGAG 
                 * *** *  *  ***   **** *       * ******  ******** 
 
hPIK3CA         TGAGACTCTGGCTCAAAAAAATAATAATAATAAATAAATAATAAATTTTA 
mPIK3CA         TAAGTTCCAGG-GCATCCAG--GCTACCCAGAAAGAAGCCCTGTCCTGAA 
                * **   * **  **   *     **   * *** **    *    *  * 
 
hPIK3CA         TAAGGAAAAATATCCCTAGTATATTTTTCCCCACCAAGGTCTACCTATTA 
mPIK3CA         AAAGCAAAAA---CCAAAACAAATGA---GGCAGAGAGGTGGATTTGC-- 
                 *** *****   **  *  * **       **   ****  *  *     
 
hPIK3CA         ATATCTCATATAACTCTGTGCT--TGAAACACAATTTGGGATATATTGCC 
mPIK3CA         --AATTAAGAACACTTGGTGCTCTTGAA-GA--GGCCCAGAGTTCACGTC 
                  *  * * *  ***  *****  ****  *        **  *   * * 
 
hPIK3CA         TTAAAATTTACTTTGACTAGCAATTCAGTGTTCCTTTTTTAAAAAAATCT 
mPIK3CA         CTAGCATTCACAT---CAGGCAGTTCA--------------CAGGCATCT 
 148 
                 **  *** ** *   *  *** ****               *   **** 
 
hPIK3CA         GTACTCTGGAGTAACAGTGTTCTAAAACTGTTGAAGAACATTGGTTCGAG 
mPIK3CA         GTAAC-TTCAGCTATACCTGTGTGAAT---TTGATGCTCTTTGGCCTCTG 
                ***   *  **  * *    * * **    **** *  * ****     * 
 
hPIK3CA         AAAAACATTTAGAAACACAAACCCCTGGAATGTGAGATGAAAATCCGAGC 
mPIK3CA         -----CAGTTACATATGCACAC--ATGCAA-----AAATAGAATACC-TT 
                     ** *** * *  ** **   ** **      *  * *** *     
 
hPIK3CA         TAAAGGGAGAAAAAGGACGAAAGAAAGAAAACACAGAAAAGAAAGAAATA 
mPIK3CA         TAAAA------ACAGAATGGAAG-------CCACTTATAACCCCAACAGT 
                ****       * ** * * ***        ***  * **     * *   
 
hPIK3CA         CAGTCAAGTGAAACTACGACCACAAAGAGGAACAGATCCATCTCATTTA- 
mPIK3CA         CAG-CAGGTGGAATTAGAAGCAT----CGGAACA--TCAAGCAAGGCTAG 
                *** ** *** ** **  * **      ******  ** * *     **  
 
hPIK3CA         CCATTGGGGTATGGACGGACGTGCGGTGTTCGAGAAGACTGTTATTGGTC 
mPIK3CA         TCTTTGTTATAT---CGAAAATTCGAGGCCAGGCTGGACCGTCTT-AGAC 
                 * ***   ***   ** *  * **  *   *    *** **  *  * * 
 
hPIK3CA         AGAGTTTTGCTCTAGAGGACAAGTAGGACTGTAA-CATCTCTAGGATGGG 
mPIK3CA         CCTTTCTCAAACAAAACCCCAGAGTGGTCTAAAAGTATCACTTAGACAA- 
                    * *    * * *   **    ** **  **  *** **  **     
 
hPIK3CA         TCACTTCCCAAGCCCTCTATTACTTAAAAATTCAAGGAGGAACCGATGCT 
mPIK3CA         --ACAACCC-AGCCCCCTACCAACAGAA-----AGGAAGTGACAGGGACT 
                  **  *** ***** ***  *    **     * * **  ** *   ** 
 
hPIK3CA         GGAGTACTTGTATCTCAGACTTCTAATCACTGC-TCCTACGCTTTTCCAA 
mPIK3CA         AGAGAAATGG-CTTTCAGT----TAAG-AATGCATACTGCTCTTTCGGAG 
                 *** * * *  * ****     ***  * *** * ** * ****   *  
 
hPIK3CA         TATTACAACAAAAGACCAGTAGGGGGAGAAAAACGCACAGTACCGAACCC 
mPIK3CA         -----GAACAGAAT-TTATT------TCTATCACGCACATCAGGCACTCC 
                      **** **    * *         *  *******  *   *  ** 
 
hPIK3CA         TTATCAGTAGTAATCTCAAAAGTCAACAGATTGATTTACTCTCAAGCAAA 
mPIK3CA         CTGCTGCCTGTAACTCCAG--CTC--CAGGGAGATCTGTTCCC------T 
                 *       ****   **    **  ***   *** *  ** *        
 
hPIK3CA         CAGACTTCTAAGGTACGCAGCACCAAGACACTACCTTGAATCAAATCTAT 
mPIK3CA         CTGTCCTCTACAGGCGCCTGCACTCACA--------TGCACACATTCATT 
                * * * ****  *    * ****  * *        ** *   * **  * 
 
hPIK3CA         AGCCTATATGACATTTCTGAAGTCTCTGTTGGCATTACGCGAAAAATCCC 
mPIK3CA         AAGATTTAAGATAGAGCCGG---GCGTGGTGGCG-CACGCCTTTAATCCC 
                *   * ** ** *   * *       ** ****   ****    ****** 
 
hPIK3CA         CCACGTCTTCTGAATAGTTAGAATTGAATCCTACAAGCTGCTTCGAATCA 
mPIK3CA         --A-GTACTCGGG--AGGCAGAG---------GCAGGCGGATT----TCT 
                  * **  ** *   **  ***           ** ** * **    **  
 
hPIK3CA         GAATTCGATTTAAAAAAAAAAATGAGGGCATAGCAAAAGGTCTCCACGAA 
mPIK3CA         GAG-----------------TCTAAGGGCAGGCC---TGGTCT--ACAAA 
                **                    * ******   *    *****  ** ** 
 
hPIK3CA         GTGAGTCAAAGGACTGCAGAGGGCTGTGACAGTGCATTCCGCCTTCGGGA 
mPIK3CA         GTGAGTTCCAGGACAGC-CAGGGCTAC-ACAGAGAAACCCTGTCTCGAAA 
                ******   ***** **  ******   **** * *  **    ***  * 
 
hPIK3CA         -TGGTATACAACTTAAACCATGTCGGCAGAAGAACGCACAGCAACGCTTT 
mPIK3CA         AAAACAAACAAA-CAAACAAAGAT---TTAAGATGGAA-----AGACT-- 
                     * ****   **** * *       ****  * *     *  **   
 
hPIK3CA         GTAAAAAGCATTCTTTCTATTATAGAATCCATAACCACGCTGGTTAGCCA 
mPIK3CA         ----AAGCCATTTAATTTCACAT-GACTGCATA----TGCTGGGTGAAGA 
                    **  ****   * *   ** ** * ****     ***** *    * 
 
hPIK3CA         CTGACAGCGGCGGTTAGCCACCGCACCTCCTCTCACCCCCGAACTAATCT 
mPIK3CA         --GAAAGAAGGAG-GAGTATCTG-GGCTGTATTTACACTTAAATAAGTCA 
                  ** **  *  *  **   * *   **    * ** *   **  * **  
 
hPIK3CA         CGTTTCCTCTATGGGTGTAAAAGTGAAATAACCCACTTGCTCCCAATATT 
mPIK3CA         GGA-CCCGTTAC----CTAAAA--------------------------GA 
                 *   **  **      *****                             
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hPIK3CA         CCTTTCTATATCTCTACCCCAGCTCGCCTGCTGCTCGTAGAAACAAATAT 
mPIK3CA         TC-TGCCATGTCTGTGGCA-TCCTCAAATGATAGTAACAGTGGCAGAAGC 
                 * * * ** *** *  *    ***   ** *  *   **   ** *    
 
hPIK3CA         ACTACACGTACG-CTGTCCTAGGATGACACAACACCCTCACTACTGCAGA 
mPIK3CA         ----CATCTTCGTGTGTGCCAGG------CAA-GTGCTCACTACTCCAT- 
                    **  * **  *** * ***      ***    ********* **   
 
hPIK3CA         AGACGGATCATTAAACAAACGTCAGAAGAGCAGCCCCAACTGTACATAAA 
mPIK3CA         ---CCCATCCCTAACCT---GTT-----GGCTGCTGCTACTTGAGACATG 
                   *  ***  *** *    **       ** **  * ***  * * *   
 
hPIK3CA         CTTCGGGCGGAAAAGCAAGACGCAGGCGCAGTAGCACATATTGTTACCCT 
mPIK3CA         CTT---GC-TAAGTGTTCCAGGCAAGCCTTGAACC------TGCAAA--T 
                ***   **  **  *    * *** **   * * *      **  *   * 
 
hPIK3CA         ATTTGCCCACTCCCTGCTCCTCCTCGCCTCAATTTCGCTTCCGCTTCTTT 
mPIK3CA         AAAT-CCCCCTGCCTCAGCCAAA-----GGAGCTGAGGTTGCAGGCC--T 
                *  * *** ** ***   **          *  *  * ** *    *  * 
 
hPIK3CA         GCG-CATCTGCTTCCGGGGGATTGTAGGCTCTGCCCCTCC-TCAGCTCTT 
mPIK3CA         GCACCACCAAGCCTGGGGAGATGGTCATTTCTGGTTGAGTTACAGC--TT 
                **  ** *       *** *** **    ****         ****  ** 
 
hPIK3CA         ACCCTCTTCTGCCGGAGGAGGGGGGGGGCCGAGGGGGTGGGGAAGAGTTC 
mPIK3CA         GCTTT-TTCATTC-------------TTCCCAT------------TGCTT 
                 *  * ***   *               ** *              * *  
 
hPIK3CA         GTTGTTTGTTTACACGATGTGAGCGGAAAAAGAGACCAATAAAGTTTATT 
mPIK3CA         GTT-TTTGTG-AGACCCA--GCTTAGAAAACCTATTCAATATTTTTAAAT 
                *** *****  * **     *    *****      *****   ** * * 
 
hPIK3CA         CTGGAAACAAAAGGAAAAAAAAACAGGGGCGACGGAGAAAGGAGTCGGGG 
mPIK3CA         TTT-CATTAAATCTAATTAAATGCAGGTTATTTTTCTACTGTCTTCTGTA 
                 *   *  ***   **  ***  ****          *  *   ** *   
 
hPIK3CA         GCGGGGG-CGTGTGGCGGGGGCTAGCGAGGAG-AGGGAGCGAGAAGTAGA 
mPIK3CA         ATAAAATCTGTGTA-----GCCTAGTTTAGAGCAACCATCTAGA-TTAAA 
                         ****      * ****    *** *   * * ***  ** * 
 
hPIK3CA         AAGCGGCAGTTCCGGTGCCGCCGCTGCGGCCGCTGAGGTGTCGGGCTGCT 
mPIK3CA         ACACATAAGTT-----ATTACTGCT-------CTGATTAGTCAGACAACA 
                *  *   ****         * ***       ****   *** * *  *  
 
hPIK3CA         GCTGCCGCGGCCGCTGGGACTGGGGCTGGGGCCGCCGGCGAGGCAGGGCT 
mPIK3CA         A--GTTGTGACCATTTGCACTTC--TCAGTGCTGTCGTC-----AGTGT- 
                   *  * * **  * * ***       * ** * ** *     ** *   
 
hPIK3CA         CGGGCCCGGCC-GGGCAGCTCCGGAGCGGCGGGGGAGAGGGGCCGGGAGG 
mPIK3CA         -GTGATCAGCAATTGCTTCTCTCTA--------------------ACAGG 
                 * *  * **    **  ***   *                      *** 
 
hPIK3CA         CGGGGGCCGTGCCGCCCGCTCTCCTCTCCCTCGGCGCCGCCGCCGCCGCC 
mPIK3CA         TGG------T-------TTTCTTCTTTTGTTCA----------------- 
                 **      *         *** ** *   **                   
 
hPIK3CA         CGCGGGGCTGGGACCCGATGCGGTTAGAGCCGCGGAGCCTGGAA 
mPIK3CA         ----GGGC----AC-T-----GTTT--------GGAGACAGTCG 
                    ****    **       * **        **** * *    
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